cisapride motor Effects function patients syndrome irritable
cisapride motor Effects function patients syndrome bowel
cisapride motor Effects function patients syndrome
cisapride agent treatment symptoms bowel irritable
cisapride agent treatment symptoms bowel
cisapride agent treatment long syndrome
cisapride agent treatment long syndrome IBS
cisapride h underwent patients IBS constipation n diarrhoea
cisapride h underwent patients IBS
cisapride h underwent patients IBS constipation
cisapride groups observed patients RESULTS diarrhoea
cisapride / treated diarrhoea
cisapride / treated diarrhoea
cisapride sec 2 3 longer duration 6 cisapride / treated diarrhoea
cisapride 001 0 + + 2 lower frequency 6 cisapride / treated diarrhoea
cisapride constipation patients IBS
cisapride mm 14 patients IBS
cisapride lower scores relating severity constipation
cisapride constipation
cisapride mm 14 patients constipation cisapride lower scores relating severity constipation
cisapride mm 14 patients constipation
cisapride score had Diarrhoea
cisapride mm Diarrhoea
cisapride score had patients IBS
cisapride mm Diarrhoea had patients IBS
cisapride score had score pain
cisapride mm Diarrhoea had score pain
Cisapride affects characteristics symptoms IBS
pilocarpine effects evaluate designed models arrhythmia
pilocarpine delayed decreased course tachycardia ventricular
pilocarpine delayed decreased course tachycardia
pilocarpine delayed decreased course tachycardia and
pilocarpine delayed decreased course tachycardia fibrillation
pilocarpine delayed onset arrhythmias
pilocarpine delayed reduced score arrhythmia
pilocarpine delayed increased time rats arrhythmic
pilocarpine produced rat arrhythmic
cisplatin striking BACKGROUND rate effects neurotoxic
CDDP BACKGROUND rate effects neurotoxic
carboplatin advantages striking BACKGROUND rate effects neurotoxic
CBDCA advantages striking BACKGROUND rate effects neurotoxic
CBDCA higher schedules drugs neurotoxic
CDDP caused those similar neurotoxic
CDDP caused those similar probable induced neurotoxicity
CBDCA neurotoxic
CBDCA neurotoxic similar probable induced neurotoxicity
propranolol toxicity
propranolol toxicity result developed an Alzheimer
propranolol toxicity
propranolol toxicity result developed an Alzheimer dementia
warfarin model hemorrhage
Warfarin associated type stroke
PCC suggesting treatment ICH
glutamate subtype modulates models disease Parkinson
glutamate subtype modulates models disease Parkinson '
glutamate subtype modulates models disease s
glutamate subtype modulates models disease
glutamate receptors modulate represent treatment disease Parkinson
glutamate receptors modulate represent treatment disease Parkinson '
glutamate receptors modulate represent treatment disease s
glutamate receptors modulate represent treatment disease
glutamate receptors modulate represent treatment disease PD
N effects tested models PD
N dihydrochloride effects tested models PD
' N dihydrochloride effects tested models PD
dibenzhydrylethane dihydrochloride effects tested models PD
- dibenzhydrylethane dihydrochloride effects tested models PD
1 - dibenzhydrylethane dihydrochloride effects tested models PD
2 - dibenzhydrylethane dihydrochloride effects tested models PD
diamine dihydrochloride effects tested models PD
dihydrochloride effects tested models PD
AMN dihydrochloride effects tested models PD
082 AMN dihydrochloride effects tested models PD
AMN 0 administration oral reverses haloperidol induced catalepsy
082 AMN 0 administration oral reverses haloperidol induced catalepsy
AMN 082 reverses mg lesioned task used evaluate symptoms akinetic
082 reverses mg lesioned task used evaluate symptoms akinetic
6 cue respond reverses mg lesioned task used evaluate symptoms akinetic
OHDA cue respond reverses mg lesioned task used evaluate symptoms akinetic
AMN 082 reverses mg lesioned task used evaluate symptoms patients PD
082 reverses mg lesioned task used evaluate symptoms patients PD
6 cue respond reverses mg lesioned task used evaluate symptoms patients PD
OHDA cue respond reverses mg lesioned task used evaluate symptoms patients PD
AMN 082 reduces duration induced catalepsy
082 reduces duration induced catalepsy
AMN doses have effect models PD
082 AMN doses have effect models PD
isoflurane anesthesia hypertensive
2 determined extent injury neuronal
2 determined extent injury
3 5 2 determined extent injury neuronal
3 5 2 determined extent injury
5 2 determined extent injury neuronal
5 2 determined extent injury
triphenyltetrazolium 5 2 determined extent injury neuronal
triphenyltetrazolium 5 2 determined extent injury
phenylephrine indicate instituted aggravate edema
phenylephrine indicate instituted aggravate improves edema
phenylephrine indicate instituted aggravate core ischemic
phenylephrine indicate instituted aggravate improves periphery territory ischemic
phenylephrine indicate instituted aggravate reduces area dysfunction neuronal
phenylephrine indicate instituted aggravate reduces area dysfunction
phenylephrine indicate instituted aggravate MCAO
captopril sensitivity Contribution treated rats hypertensive
captopril treated rats hypertensive
captopril treated contributes importantly effect hypertensive
hexamethonium infusion resulted decline eliminated increase
hexamethonium infusion resulted decline eliminated MAP in
hexamethonium infusion resulted decline eliminated MAP
cyproterone women thromboembolism risk venous
cyproterone women thromboembolism
acetate cyproterone women thromboembolism risk venous
acetate cyproterone women thromboembolism
ethinylestradiol acetate cyproterone women thromboembolism risk venous
ethinylestradiol acetate cyproterone women thromboembolism
cyproterone ethinylestradiol women thromboembolism venous
cyproterone ethinylestradiol women thromboembolism
acetate ethinylestradiol women thromboembolism venous
acetate ethinylestradiol women thromboembolism
cyproterone ethinylestradiol women thromboembolism VTE
acetate ethinylestradiol women thromboembolism VTE
CPA EE ethinylestradiol women thromboembolism venous
CPA EE ethinylestradiol women thromboembolism
CPA EE ethinylestradiol women thromboembolism VTE
ethinylestradiol women thromboembolism venous
ethinylestradiol women thromboembolism
ethinylestradiol women thromboembolism VTE
EE ethinylestradiol women thromboembolism venous
EE ethinylestradiol women thromboembolism
EE ethinylestradiol women thromboembolism VTE
levonorgestrel women years COCs 1 women risk VTE
CPA EE women risk VTE
EE women risk VTE
CPA EE taking similar risk VTE
EE taking similar risk VTE
Haloperidol induced parkinsonian
AIDA doses 5 microg rigidity muscle
AIDA doses 5 microg rigidity
AZT induced anemia patients AIDS
AZT therapy induced anemia patients AIDS
morphine induced interval ischemia spinal
morphine induced interval ischemia cord
morphine induced interval ischemia
N activation contribute degeneration neurons induced interval ischemia spinal
N activation contribute degeneration neurons induced interval ischemia cord
N activation contribute degeneration neurons induced interval ischemia
methyl N activation contribute degeneration neurons induced interval ischemia spinal
methyl N activation contribute degeneration neurons induced interval ischemia cord
methyl N activation contribute degeneration neurons induced interval ischemia
D N activation contribute degeneration neurons induced interval ischemia spinal
D N activation contribute degeneration neurons induced interval ischemia cord
D N activation contribute degeneration neurons induced interval ischemia
aspartate receptors N activation contribute degeneration neurons induced interval ischemia spinal
aspartate receptors N activation contribute degeneration neurons induced interval ischemia cord
aspartate receptors N activation contribute degeneration neurons induced interval ischemia
morphine interval occlusion aortic
morphine interval occlusion
N receptors activation degeneration relationship investigated morphine interval occlusion aortic
N receptors activation degeneration relationship investigated morphine interval occlusion
methyl receptors activation degeneration relationship investigated morphine interval occlusion aortic
methyl receptors activation degeneration relationship investigated morphine interval occlusion
d methyl receptors activation degeneration relationship investigated morphine interval occlusion aortic
d methyl receptors activation degeneration relationship investigated morphine interval occlusion
aspartate receptors activation degeneration relationship investigated morphine interval occlusion aortic
aspartate receptors activation degeneration relationship investigated morphine interval occlusion
NMDA receptors activation degeneration relationship investigated morphine interval occlusion aortic
NMDA receptors activation degeneration relationship investigated morphine interval occlusion
MK induced paraparesis spastic
MK induced paraparesis
801 MK induced paraparesis spastic
801 MK induced paraparesis
MK reduced paraparesis spastic
MK reduced paraparesis
801 reduced paraparesis spastic
801 reduced paraparesis
NMDA activation involved glutamate increase induces paraparesis spastic
NMDA activation involved glutamate increase induces paraparesis
glutamate increase induces paraparesis spastic
glutamate increase induces paraparesis
NMDA activation ischemia setting neurotoxic
NMDA activation ischemia spinal
NMDA activation ischemia cord
NMDA activation ischemia
interferon therapy hemolysis
ribavirin reduction timing C chronic
ribavirin reduction timing C hepatitis
ribavirin reduction timing C
ribavirin interferon therapy hemolysis patients timing C chronic
ribavirin interferon therapy hemolysis patients timing C hepatitis
ribavirin interferon therapy hemolysis patients timing C
ribavirin reduction timing patients hemolysis
ribavirin interferon therapy hemolysis
interferon therapy hemolysis patients timing C chronic
interferon therapy hemolysis patients timing C hepatitis
interferon therapy hemolysis patients timing C
ribavirin reduction timing examined patients hemolysis
ribavirin reduction patients 10 continue < g values decreased anemia
rifampicin administration developed failure renal
rifampicin administration developed failure
Cocaine use associated vasoconstriction vasculitis
Cocaine use associated complications neurovascular
Cocaine use associated complications
cocaine use associated SAH underwent patients found evidence narrowing evidence narrowing vasculitis
fluorouracil therapy associated toxicity cardiac
fluorouracil therapy associated toxicity
5 therapy associated toxicity cardiac
5 therapy associated toxicity
FU 5 therapy associated toxicity cardiac
FU 5 therapy associated toxicity
5 infusion treatment tumors
FU infusion treatment tumors
5 infusion associated patients disease coronary
5 infusion associated patients disease artery
5 infusion associated patients disease
- infusion associated patients disease coronary
- infusion associated patients disease artery
- infusion associated patients disease
FU infusion associated patients disease coronary
FU infusion associated patients disease artery
FU infusion associated patients disease
captopril overdose due reversal hypotension
Naloxone reversal hypotension
Naloxone reversal due overdose
captopril overdose
captopril actions hypotensive
naloxone shown block actions hypotensive
captopril overdose manifested hypotension
naloxone administration resolved overdose manifested hypotension
naloxone administration resolved overdose
captopril overdose
captopril case hypotension
naloxone treated hypotension
captopril resulting hypotension
naloxone reversal hypotension
Amphotericin B induced AIDS
B induced AIDS
amphotericin infusion patent AIDS
B infusion patent AIDS
amphotericin B infusion experienced seizures grand
amphotericin B infusion experienced seizures mal
amphotericin B infusion experienced seizures
B infusion experienced seizures grand
B infusion experienced seizures mal
B infusion experienced seizures
lorazepam phenytoin administration persisted seizures
phenytoin administration persisted seizures
alcohol cause seizures
alcohol cause had history abuse alcohol
alcohol cause had history abuse
Didanosine has potential inducing seizures
amphotericin B cause seizures patient AIDS
B cause seizures patient AIDS
lamivudine monotherapy cirrhosis
lamivudine monotherapy cirrhosis improvement patient virus hepatitis
lamivudine monotherapy cirrhosis improvement patient virus B
lamivudine administration cirrhosis
ritanserin Microinjection improves scopolamine amnesia
ritanserin effect amnesia
ritanserin microinjection improves amnesia
aminoglycoside treatment effects Nephrotoxic
aminoglycosides act nephrotoxicants level inducing impairment
aminoglycosides act nephrotoxicants level inducing impairment reabsorption of
aminoglycosides act nephrotoxicants level inducing impairment reabsorption renal
aminoglycosides act nephrotoxicants level inducing impairment reabsorption
D developed patients arthritis rheumatoid
D developed patients arthritis
penicillamine D developed patients arthritis rheumatoid
penicillamine D developed patients arthritis
glyceryl trinitrate Effect sphincter
glyceryl trinitrate Effect spasm of
glyceryl trinitrate Effect spasm Oddi
glyceryl trinitrate Effect spasm
trinitrate Effect sphincter
trinitrate Effect spasm of
trinitrate Effect spasm Oddi
trinitrate Effect spasm
morphine Effect sphincter
morphine Effect spasm of
morphine Effect spasm Oddi
morphine Effect spasm
prostigmine evoked spasm Effect sphincter
prostigmine evoked spasm of
prostigmine evoked spasm Oddi
prostigmine evoked spasm
glyceryl trinitrate effect induced evaluated sphincter
glyceryl trinitrate effect induced evaluated sphincter spasm of
glyceryl trinitrate effect induced evaluated sphincter spasm Oddi
glyceryl trinitrate effect induced evaluated sphincter spasm
trinitrate effect induced evaluated sphincter
trinitrate effect induced evaluated sphincter spasm of
trinitrate effect induced evaluated sphincter spasm Oddi
trinitrate effect induced evaluated sphincter spasm
morphine trinitrate effect induced evaluated sphincter
morphine trinitrate effect induced evaluated sphincter spasm of
morphine trinitrate effect induced evaluated sphincter spasm Oddi
morphine trinitrate effect induced evaluated sphincter spasm
glyceryl trinitrate effect induced evaluated patients sphincter
glyceryl trinitrate effect induced evaluated patients sphincter dyskinesia of
glyceryl trinitrate effect induced evaluated patients sphincter dyskinesia Oddi
glyceryl trinitrate effect induced evaluated patients sphincter dyskinesia
trinitrate effect induced evaluated patients sphincter
trinitrate effect induced evaluated patients sphincter dyskinesia of
trinitrate effect induced evaluated patients sphincter dyskinesia Oddi
trinitrate effect induced evaluated patients sphincter dyskinesia
prostigmine morphine trinitrate effect induced evaluated sphincter
prostigmine morphine trinitrate effect induced evaluated sphincter spasm of
prostigmine morphine trinitrate effect induced evaluated sphincter spasm Oddi
prostigmine morphine trinitrate effect induced evaluated sphincter spasm
morphine administration prostigmine induced Sphincter
morphine administration prostigmine induced Sphincter spasm of
morphine administration prostigmine induced Sphincter spasm Oddi
morphine administration prostigmine induced Sphincter spasm
morphine subcutaneously intramuscularly 0 prostigmine induced Sphincter
morphine subcutaneously intramuscularly 0 prostigmine induced Sphincter spasm of
morphine subcutaneously intramuscularly 0 prostigmine induced Sphincter spasm Oddi
morphine subcutaneously intramuscularly 0 prostigmine induced Sphincter spasm
prostigmine induced Sphincter
prostigmine induced Sphincter spasm of
prostigmine induced Sphincter spasm Oddi
prostigmine induced Sphincter spasm
prostigmine intramuscularly 0 prostigmine induced Sphincter
prostigmine intramuscularly 0 prostigmine induced Sphincter spasm of
prostigmine intramuscularly 0 prostigmine induced Sphincter spasm Oddi
prostigmine intramuscularly 0 prostigmine induced Sphincter spasm
glyceryl trinitrate effectiveness evidence sphincter
glyceryl trinitrate effectiveness evidence sphincter spasm of
glyceryl trinitrate effectiveness evidence sphincter spasm Oddi
glyceryl trinitrate effectiveness evidence sphincter spasm
trinitrate effectiveness evidence sphincter
trinitrate effectiveness evidence sphincter spasm of
trinitrate effectiveness evidence sphincter spasm Oddi
trinitrate effectiveness evidence sphincter spasm
morphine trinitrate effectiveness evidence sphincter
morphine trinitrate effectiveness evidence sphincter spasm of
morphine trinitrate effectiveness evidence sphincter spasm Oddi
morphine trinitrate effectiveness evidence sphincter spasm
glyceryl trinitrate able relevance treatment sphincter
glyceryl trinitrate able relevance treatment sphincter dyskinesia of
glyceryl trinitrate able relevance treatment sphincter dyskinesia Oddi
glyceryl trinitrate able relevance treatment sphincter dyskinesia
trinitrate able relevance treatment sphincter
trinitrate able relevance treatment sphincter dyskinesia of
trinitrate able relevance treatment sphincter dyskinesia Oddi
trinitrate able relevance treatment sphincter dyskinesia
Ethambutol used treatment tuberculosis
dobutamine stress spasm due ischemia Myocardial
dobutamine stress spasm due ischemia
Dobutamine echocardiography test ischemia myocardial
Dobutamine echocardiography test ischemia
dobutamine induced ischemia myocardial
dobutamine induced ischemia
acetylcholine injection induced documented stenosis coronary
acetylcholine injection induced documented stenosis artery
acetylcholine injection induced documented stenosis
milrinone treatment Vasopressin hypotension failure heart
milrinone treatment Vasopressin hypotension failure
Vasopressin hypotension failure heart
Vasopressin hypotension failure
milrinone treatment failure heart
milrinone treatment failure
milrinone treatment hypotension failure heart
milrinone treatment hypotension failure
milrinone effect inhibiting restored patients failure heart
milrinone effect inhibiting restored patients failure
vasopressin doses restored patients failure heart
vasopressin doses restored patients failure
amphetamine reflects rotation lesion substantia
amphetamine reflects rotation lesion nigra
amphetamine reflects rotation lesion
6 reported period rotation contralateral
6 reported period rotation
OHDA SN 6 reported period rotation contralateral
OHDA SN 6 reported period rotation
6 reported precede circling ipsilateral
6 reported precede circling
OHDA SN 6 reported precede circling ipsilateral
OHDA SN 6 reported precede circling
6 SN
6 SN lesion
OHDA SN
OHDA SN lesion
macrolides experience recorded function side established gastroenteritis
erythromycin administration demonstrated Cardiotoxicity
macrolides reported demonstrated Cardiotoxicity
clarithromycin doses occurred case dysrhythmias ventricular
clarithromycin doses occurred case dysrhythmias
Phenobarbital dyskinesia neurologically
Phenobarbital child impaired
phenobarbital therapy starting seizures
phenobarbital therapy starting developed impairment neurologic
phenobarbital therapy starting developed impairment
Phenobarbital added list cause disorders movement
Phenobarbital added list cause disorders
CB synthase mediated cytotoxicity
3717 CB synthase mediated cytotoxicity
N CB synthase mediated cytotoxicity
10 N CB synthase mediated cytotoxicity
propargyl N CB synthase mediated cytotoxicity
- propargyl N CB synthase mediated cytotoxicity
5 - propargyl N CB synthase mediated cytotoxicity
8 - propargyl N CB synthase mediated cytotoxicity
dideazafolic acid N CB synthase mediated cytotoxicity
acid N CB synthase mediated cytotoxicity
CB fold determinant cytotoxicity
3717 CB fold determinant cytotoxicity
CB cytotoxicity
3717 cytotoxicity
CB studies seen cancer cancer ovarian
CB studies seen cancer cancer
3717 CB studies seen cancer cancer ovarian
3717 CB studies seen cancer cancer
CB studies seen cancer mesothelioma
3717 CB studies seen cancer mesothelioma
CB studies seen cancer breast
CB studies seen cancer
3717 CB studies seen cancer breast
3717 CB studies seen cancer
CB studies seen cancer hepatoma
3717 CB studies seen cancer hepatoma
sodium density subunits dependence inactivation susceptibility seizures
sodium beta lacking mice seizures
NAD diet Influence precursors hepatotoxicity
poly polymerase inhibitor amide effects demonstrated mice suffering acetaminophen hepatitis
ADP polymerase inhibitor amide effects demonstrated mice suffering acetaminophen hepatitis
ribose ADP polymerase inhibitor amide effects demonstrated mice suffering acetaminophen hepatitis
poly polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury liver
poly polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury
ADP polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury liver
ADP polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury
ribose ADP polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury liver
ribose ADP polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury
nicotinic amide effects demonstrated mice suffering acetaminophen hepatitis
acid amide effects demonstrated mice suffering acetaminophen hepatitis
amide effects demonstrated mice suffering acetaminophen hepatitis
nicotinic amide effects demonstrated mice suffering suggesting involves injury liver
nicotinic amide effects demonstrated mice suffering suggesting involves injury
acid amide effects demonstrated mice suffering suggesting involves injury liver
acid amide effects demonstrated mice suffering suggesting involves injury
amide effects demonstrated mice suffering suggesting involves injury liver
amide effects demonstrated mice suffering suggesting involves injury
NAD precursors diet substrate acts hepatitis
oxaloacetate transaminase transaminase quantified injuries Liver
oxaloacetate transaminase transaminase quantified injuries
pyruvate transaminase quantified injuries Liver
pyruvate transaminase quantified injuries
glutamate activities quantified injuries Liver
glutamate activities quantified injuries
glutamate transaminase transaminase quantified injuries Liver
glutamate transaminase transaminase quantified injuries
NAA given observed reduction hepatitis
NAD depletion reduced reduced AAP hepatitis
NAA reduced AAP hepatitis
NAA application see avoid damage hepatic
NAA application see avoid damage
aryl induced catalepsy
piperazine Reversal induced catalepsy
buspirone drug reverses induced catalepsy
buspirone analogues series tested ability reverse catalepsy
aryl series tested ability reverse catalepsy
piperazine analogues series tested ability reverse catalepsy
5 buspirone analogues series tested ability reverse catalepsy
hydroxytryptaminergic agonists tested ability reverse catalepsy
agonists tested ability reverse catalepsy
5 affinity drugs hydroxytryptamine able reverse catalepsy
hydroxytryptamine able reverse catalepsy
5 inhibition receptors reversal catalepsy
HT receptors reversal catalepsy
Cyclophosphamide induced behavioral model pain visceral
Cyclophosphamide induced behavioral model pain
acrolein produce known agent Cyclophosphamide used induce cystitis
Morphine dose reversed disorders behavioral
Morphine dose reversed disorders
morphine administration time observed modifications edema
CP model induced model pain visceral
CP model induced model pain
iodine induced cardiomyopathy
125 iodine induced cardiomyopathy
metaiodobenzylguanidine Detection induced cardiomyopathy
adriamycin treatment duration analyzed degree degeneration vacuolar
adriamycin treatment duration analyzed degree degeneration
adriamycin treatment duration analyzed degree degeneration cells of
adriamycin treatment duration analyzed degree degeneration cells myocardial
adriamycin treatment duration analyzed degree degeneration cells
adriamycin detection method indicates appearance presence impairment scattered degeneration vacuolar
adriamycin detection method indicates appearance presence impairment scattered degeneration
MIBG method indicates appearance presence impairment myocardial
MIBG method indicates appearance presence impairment
MIBG method detection adriamycin induced cardiomyopathy
MIBG method indicates appearance presence impairment scattered degeneration vacuolar
MIBG method indicates appearance presence impairment scattered degeneration
ergot history discussion includes discovery epidemics gangrene
ergot preparations continue play persists fire danger Anthony St
ergot preparations continue play persists fire danger Anthony
ergot preparations continue play persists fire danger '
ergot preparations continue play persists fire s
ergot preparations continue play persists fire
calcium blockers advent continue play therapy migraine
calcium blockers advent continue play persists fire danger Anthony St
calcium blockers advent continue play persists fire danger Anthony
calcium blockers advent continue play persists fire danger '
calcium blockers advent continue play persists fire s
calcium blockers advent continue play persists fire
carbamazepine therapy institution atonic Myoclonic
carbamazepine therapy institution atonic
carbamazepine therapy institution atonic and
carbamazepine therapy institution atonic seizures absence
carbamazepine therapy institution atonic seizures
carbamazepine treated years aged children had reaction characterized onset absence atypical myoclonic
carbamazepine treated years aged children had reaction characterized onset absence atypical
carbamazepine treated years aged children had reaction characterized onset absence
carbamazepine treated years aged children had reaction characterized onset absence and
carbamazepine treated years aged children had reaction characterized onset absence /
carbamazepine treated years aged children had reaction characterized onset absence or
carbamazepine treated years aged children had reaction characterized onset absence seizures atonic
carbamazepine treated years aged children had reaction characterized onset absence seizures motor minor
carbamazepine treated years aged children had reaction characterized onset absence seizures motor
carbamazepine treated years aged children had reaction characterized onset absence seizures
carbamazepine epilepsy
carbamazepine discontinued returned had resolve seizures
carbamazepine discontinued returned had persist seizures
propranolol bendrofluazide reactions treatment hypertension
bendrofluazide reactions treatment hypertension
propranolol bendrofluazide one allocated Participants trial hypertension
bendrofluazide one allocated Participants trial hypertension
propranolol taking phenomenon include tolerance gout
bendrofluazide treatment associated men gout tolerance include phenomenon Raynaud
bendrofluazide treatment associated men gout tolerance include phenomenon Raynaud '
bendrofluazide treatment associated men gout tolerance include phenomenon s
bendrofluazide treatment associated men gout tolerance include phenomenon
bendrofluazide treatment associated men gout tolerance include phenomenon dyspnoea
propranolol taking phenomenon include tolerance impaired
propranolol taking phenomenon include tolerance glucose
propranolol taking phenomenon include tolerance
propranolol group occurred known disease corneal
propranolol group occurred known disease
Dexmedetomidine associated mortality OR infarction myocardial
Dexmedetomidine associated mortality OR infarction
Dexmedetomidine associated mortality OR ischaemia myocardial
Dexmedetomidine associated mortality OR ischaemia
Clarithromycin associated failure chronic
Clarithromycin associated failure renal
Clarithromycin associated failure
macrolide antibiotic occurring hallucinations visual
macrolide antibiotic occurring hallucinations
clarithromycin face failure chronic
clarithromycin face failure renal
clarithromycin face failure
aluminum intoxication combination dose clarithromycin face failure chronic
aluminum intoxication combination dose clarithromycin face failure renal
aluminum intoxication combination dose clarithromycin face failure
aluminum intoxication combination facilitated appearance effect neurotoxic
clarithromycin dose combination facilitated appearance effect neurotoxic
Warfarin induced vasculitis leukocytoclastic
Warfarin induced vasculitis
warfarin LV
warfarin receiving developed eruptions skin
warfarin receiving developed eruptions
warfarin discontinued available results biopsies skin
warfarin discontinued available results biopsies lesion
warfarin therapy associated reaction late LV
paracetamol survivors transplant induced injury acute
paracetamol survivors transplant induced injury liver
paracetamol survivors transplant induced injury
paracetamol caused induced injury liver
paracetamol caused induced injury
paracetamol caused higher age age died disease liver
paracetamol caused higher age age died disease
heparin induced aggregation platelet
heparin induced aggregation
heparin require aggregation platelet
heparin require aggregation
chlorpropamide treated diabetes 65 year woman adult
chlorpropamide treated diabetes onset
chlorpropamide treated diabetes
Diabenese diabetes 65 year woman adult
Diabenese diabetes onset
Diabenese diabetes
chlorpropamide therapy discontinuation resolved neuropathy had diabetes 65 year woman adult
chlorpropamide therapy discontinuation resolved neuropathy had diabetes onset
chlorpropamide therapy discontinuation resolved neuropathy had diabetes
dexamethasone saline pretreated patients determined myalgia
dexamethasone group patients complained differ Incidence myalgia
dexamethasone group patients complained myalgia
dexamethasone group patients complained reported myalgia
dexamethasone Administration IMPLICATIONS induced myalgia postoperative
dexamethasone Administration IMPLICATIONS induced myalgia
dexamethasone Pretreatment justified prevent myalgia postoperative
dexamethasone Pretreatment justified prevent myalgia
estrogens exogenous had disease Hodgkin
estrogens exogenous had disease
estrogens exogenous had failure ovarian
estrogens exogenous had failure
estrogens failure ovarian
estrogens failure
estrogens failure therapy cancer
pilocarpine model characterized period epilepticus status
pilocarpine model characterized period epilepticus
PILO model characterized period epilepticus status
PILO model characterized period epilepticus
pilocarpine model characterized period epilepticus followed seizures
PILO model characterized period epilepticus followed seizures
pilocarpine model epilepsy
PILO model epilepsy
pilocarpine model characterized period epilepticus followed seizures damage brain
pilocarpine model characterized period epilepticus followed seizures damage
PILO model characterized period epilepticus followed seizures damage brain
PILO model characterized period epilepticus followed seizures damage
hydrogen production superoxide failure acute
hydrogen production superoxide failure liver
hydrogen production superoxide failure
peroxide production superoxide failure acute
peroxide production superoxide failure liver
peroxide production superoxide failure
superoxide failure acute
superoxide failure liver
superoxide failure
hydrogen superoxide production Defects implicated incidence infections bacterial
hydrogen superoxide production Defects implicated incidence infections
peroxide production Defects implicated incidence infections bacterial
peroxide production Defects implicated incidence infections
hydrogen superoxide production Defects implicated patients failure acute
hydrogen superoxide production Defects implicated patients failure liver
hydrogen superoxide production Defects implicated patients failure
peroxide production Defects implicated patients failure acute
peroxide production Defects implicated patients failure liver
peroxide production Defects implicated patients failure
hydrogen superoxide production Defects implicated patients failure ALF
peroxide production Defects implicated patients failure ALF
superoxide production Defects implicated incidence infections bacterial
superoxide production Defects implicated incidence infections
superoxide production Defects implicated patients failure acute
superoxide production Defects implicated patients failure liver
superoxide production Defects implicated patients failure
superoxide production Defects implicated patients failure ALF
oxygen production patients ALF
oxygen production patients ALF due overdose
paracetamol overdose
hydrogen Superoxide production neutrophils ALF
peroxide production neutrophils ALF
hydrogen Superoxide production neutrophils stimulated zymosan opsonized serum ALF
peroxide production neutrophils stimulated zymosan opsonized serum ALF
Superoxide production neutrophils ALF
Superoxide production neutrophils stimulated zymosan opsonized serum ALF
hydrogen Superoxide production neutrophils stimulated patients ALF
peroxide production neutrophils stimulated patients ALF
formyl phenylalanine stimulated patients ALF
methionyl phenylalanine stimulated patients ALF
leucyl methionyl phenylalanine stimulated patients ALF
phenylalanine stimulated patients ALF
fMLP phenylalanine stimulated patients ALF
Superoxide production neutrophils stimulated patients ALF
paracetamol overdose
dopamine agonist hyperprolactinemia
cabergoline induced hyperprolactinemia
cabergoline treated hyperprolactinemia
risperidone males Manual bipolar
risperidone males disorder
risperidone males Manual bipolar Mental
risperidone males Manual bipolar Disorders
cabergoline treated RESULTS males disorder psychoses
cabergoline treated RESULTS males Manual bipolar Mental
cabergoline treated RESULTS males Manual bipolar Disorders
cabergoline treated RESULTS males Manual bipolar
cabergoline treated RESULTS males disorder
risperidone males disorder psychoses
Cabergoline useful treatment hyperprolactinemia
tacrine treated showed outcome CNS onset epileptic
tacrine induced processes severity model epilepsy
lithium model epilepsy
penicillin analysis activity epileptiform
penicillin analysis activity
Penicillin model model research epilepsy
penicillin analysis activity epileptiform
penicillin analysis activity
penicillin activity analyzed periods epileptiform
penicillin activity analyzed periods activity
diclofenac tolerability results tolerability etoricoxib patients rheumatoid
diclofenac tolerability results tolerability etoricoxib patients arthritis
sodium tolerability results tolerability etoricoxib patients rheumatoid
sodium tolerability results tolerability etoricoxib patients arthritis
etoricoxib patients rheumatoid
etoricoxib patients arthritis
etoricoxib tolerability results tolerability etoricoxib patients rheumatoid
etoricoxib tolerability results tolerability etoricoxib patients arthritis
diclofenac etoricoxib compare patients arthritis rheumatoid
diclofenac etoricoxib compare patients arthritis
diclofenac etoricoxib compare patients arthritis RA
etoricoxib compare patients arthritis rheumatoid
etoricoxib compare patients arthritis
etoricoxib compare patients arthritis RA
diclofenac mg daily received diagnosed enrolled RA
etoricoxib daily received diagnosed enrolled RA
etoricoxib lower rate due AEs GI
etoricoxib lower rate due AEs
diclofenac etoricoxib higher incidence discontinuations related oedema
diclofenac etoricoxib % 0 001 01 oedema
diclofenac etoricoxib higher incidence discontinuations hypertension
diclofenac etoricoxib % 0 001 hypertension
Etoricoxib mg demonstrated discontinuing treatment higher AEs GI
Etoricoxib mg demonstrated discontinuing treatment higher AEs
Etoricoxib mg demonstrated discontinuing treatment higher common discontinuations AEs GI
Etoricoxib mg demonstrated discontinuing treatment higher common discontinuations AEs
etoricoxib higher AEs GI
etoricoxib higher AEs
etoricoxib higher common discontinuations AEs GI
etoricoxib higher common discontinuations AEs
hepatitis vaccine injections injections globulin hepatitis
hepatitis vaccine injections injections globulin B
B vaccine injections injections globulin hepatitis
B vaccine injections injections globulin B
vaccine injections injections globulin hepatitis
vaccine injections injections globulin B
Metformin hydrochloride discontinued resolved jaundice
hydrochloride discontinued resolved jaundice
metformin initiation wk jaundice
metformin example represents believe onset wk jaundice
metformin initiation wk onset believe reported associated hepatotoxicity
metformin example represents believe reported associated hepatotoxicity
Amiodarone toxicity pulmonary
Amiodarone toxicity
amiodarone toxicity thought result injury related accumulation pneumonitis hypersensitivity
amiodarone toxicity thought result injury related accumulation pneumonitis
amiodarone toxicity pulmonary
amiodarone toxicity
amiodarone induced toxicity pulmonary
amiodarone induced toxicity
etoposide enhancing protects myelosuppression
daunorubicin etoposide enhancing protects myelosuppression
doxorubicin etoposide enhancing protects myelosuppression
Dexrazoxane protects myelosuppression
daunorubicin cleavage limit myelosuppression toxicity cardiac
daunorubicin cleavage limit myelosuppression toxicity
etoposide daunorubicin cleavage limit myelosuppression
etoposide daunorubicin cleavage limit myelosuppression toxicity cardiac
etoposide daunorubicin cleavage limit myelosuppression toxicity
daunorubicin cleavage limit myelosuppression
epipodophyllotoxin etoposide daunorubicin cleavage limit myelosuppression
doxorubicin daunorubicin cleavage limit myelosuppression toxicity cardiac
doxorubicin daunorubicin cleavage limit myelosuppression toxicity
epipodophyllotoxin etoposide daunorubicin cleavage limit myelosuppression toxicity cardiac
epipodophyllotoxin etoposide daunorubicin cleavage limit myelosuppression toxicity
doxorubicin daunorubicin cleavage limit myelosuppression
anthracyclines daunorubicin cleavage limit myelosuppression
anthracyclines daunorubicin cleavage limit myelosuppression toxicity cardiac
anthracyclines daunorubicin cleavage limit myelosuppression toxicity
anthracycline induced cardiotoxicity
Dexrazoxane recommended anthracycline induced cardiotoxicity
ICRF Dexrazoxane recommended anthracycline induced cardiotoxicity
187 ICRF Dexrazoxane recommended anthracycline induced cardiotoxicity
dexrazoxane coadministration toxicity hematologic
dexrazoxane coadministration toxicity
dexrazoxane determined investigated toxicity hematologic
dexrazoxane determined investigated toxicity
etoposide daunorubicin reduced antagonized dexrazoxane myelosuppression cytotoxicity
etoposide daunorubicin reduced loss myelosuppression
etoposide daunorubicin reduced antagonized dexrazoxane myelosuppression
dexrazoxane doses reduced loss myelosuppression weight
dexrazoxane doses reduced loss
dexrazoxane doses reduced antagonized dexrazoxane myelosuppression loss weight
dexrazoxane doses reduced antagonized dexrazoxane myelosuppression loss
dexrazoxane antagonized reduced loss myelosuppression weight
dexrazoxane antagonized reduced loss
dexrazoxane myelosuppression loss weight
dexrazoxane myelosuppression loss
daunorubicin reduced loss myelosuppression
daunorubicin reduced antagonized dexrazoxane myelosuppression
doxorubicin cytotoxicity
doxorubicin cytotoxicity myelosuppression dexrazoxane antagonized reduced loss myelosuppression
doxorubicin cytotoxicity myelosuppression
dexrazoxane doses reduced antagonized dexrazoxane myelosuppression cytotoxicity
dexrazoxane myelosuppression cytotoxicity
daunorubicin reduced antagonized dexrazoxane myelosuppression cytotoxicity
dexrazoxane doses reduced loss myelosuppression
dexrazoxane doses reduced antagonized dexrazoxane myelosuppression
dexrazoxane antagonized reduced loss myelosuppression
dexrazoxane myelosuppression
etoposide doses combining metastases
dexrazoxane doses combining metastases patients trials ongoing aim improving toxicity hematologic
dexrazoxane doses combining metastases patients trials ongoing aim improving toxicity
dexrazoxane doses combining metastases
amiodarone presenting coma myxedemic
amiodarone presenting coma
amiodarone patient congestive
amiodarone patient heart
amiodarone patient failure
amiodarone secondary report coma myxedema
amiodarone secondary report coma
amiodarone secondary hypothyroidism failure patient heart congestive
amiodarone secondary hypothyroidism failure patient heart
amiodarone secondary hypothyroidism failure
amiodarone secondary hypothyroidism failure CHF
amiodarone therapy coma myxedema
amiodarone therapy coma
amiodarone CHF
amiodarone usage given patients CHF
magnesium supplementation importance furosemide Tetany rhabdomyolysis
magnesium supplementation importance furosemide Tetany
calcium potassium supplementation corrected cannot spasms associated hypomagnesemia
potassium supplementation corrected cannot spasms associated hypomagnesemia
calcium potassium supplementation corrected cannot spasms associated cause hypokalemia
calcium potassium supplementation corrected cannot spasms muscle
calcium potassium supplementation corrected cannot spasms
calcium potassium supplementation corrected cannot spasms associated cause weakness muscle
calcium potassium supplementation corrected cannot spasms associated cause weakness
calcium potassium supplementation corrected cannot spasms tetany
potassium supplementation corrected cannot spasms tetany
potassium supplementation corrected cannot spasms associated cause hypokalemia
potassium supplementation corrected cannot spasms muscle
potassium supplementation corrected cannot spasms
potassium supplementation corrected cannot spasms associated cause weakness muscle
potassium supplementation corrected cannot spasms associated cause weakness
magnesium depletion effects noted reported observed hypocalcemia
magnesium depletion effects noted reported hypokalemia
ribavirin strategies anemia treatment C hepatitis
ribavirin strategies anemia treatment C
interferon published OBJECTIVES alpha treatment C chronic
interferon published OBJECTIVES alpha treatment C hepatitis
interferon published OBJECTIVES alpha treatment C
alpha treatment C chronic
alpha treatment C hepatitis
alpha treatment C
interferon published OBJECTIVES alpha treatment C CHC
alpha treatment C CHC
ribavirin therapy effectiveness efficacy demonstrated published OBJECTIVES alpha treatment C chronic
ribavirin therapy effectiveness efficacy demonstrated published OBJECTIVES alpha treatment C hepatitis
ribavirin therapy effectiveness efficacy demonstrated published OBJECTIVES alpha treatment C
ribavirin therapy effectiveness efficacy demonstrated published OBJECTIVES alpha treatment C CHC
phenobarbital action carcinogenic
diethylnitrosamine given phenobarbital action carcinogenic
phenobarbital carcinogenesis
PB phenobarbital carcinogenesis
diethylnitrosamine administered carcinogenesis
DEN phenobarbital carcinogenesis
PB or weeks treated schedule hepatocarcinogenesis
DEN weeks treated schedule hepatocarcinogenesis
DEN PB or weeks treated schedule hepatocarcinogenesis
PB given reduced number size foci preneoplastic
PB given reduced number size foci
DEN PB prolonged decreased incidence tumor
DEN obtained results decreased incidence tumor
PB prolonged decreased incidence tumor
PB promotes carcinogenesis
DEN treatment administered promotes carcinogenesis
DEN given reduces PB promotes carcinogenesis
androgens role favored pathogenesis apnea sleep
androgens role favored pathogenesis apnea
Valproate mg month improved subthalamotomy developed had hemianopsia homonymous
Valproate mg month improved subthalamotomy developed had hemianopsia
serotonin blockers induced treatment effects sexual
serotonin blockers induced treatment effects side
serotonin blockers induced treatment effects
Yohimbine treatment effects sexual
Yohimbine treatment effects side
Yohimbine treatment effects
yohimbine facilitates helpful treatment impotence male
yohimbine facilitates helpful treatment impotence
yohimbine used treat effects sexual
yohimbine used treat effects side
yohimbine used treat effects
serotonin blockers caused study evaluated treatment effects sexual
serotonin blockers caused study evaluated treatment effects side
serotonin blockers caused study evaluated treatment effects
yohimbine evaluated treatment effects sexual
yohimbine evaluated treatment effects side
yohimbine evaluated treatment effects
yohimbine given suffered patients disorder obsessive
yohimbine given suffered patients disorder compulsive
yohimbine given suffered patients disorder
yohimbine given suffered patients disorder disorders affective
yohimbine given suffered patients disorder disorders
serotonin blockers treatment given suffered patients disorder obsessive
serotonin blockers treatment given suffered patients disorder compulsive
serotonin blockers treatment given suffered patients disorder
yohimbine given suffered patients disorder anxiety
serotonin blockers treatment given suffered patients disorder anxiety
serotonin blockers treatment given suffered effects sexual
serotonin blockers treatment given suffered effects side
serotonin blockers treatment given suffered effects
yohimbine given suffered patients disorder trichotillomania
serotonin blockers treatment given suffered patients disorder trichotillomania
yohimbine given suffered effects sexual
yohimbine given suffered effects side
yohimbine given suffered effects
serotonin blockers treatment given suffered patients disorder disorders affective
serotonin blockers treatment given suffered patients disorder disorders
yohimbine effects included sweating anxiety
serotonin blockers caused effects sexual
serotonin blockers caused effects side
serotonin blockers caused effects
yohimbine treatment effects sexual
yohimbine treatment effects side
yohimbine treatment effects
folic acid activity induces SLE acid epilepsy
acid activity induces SLE acid epilepsy
folic acid epilepsy
acid epilepsy
folic acid effect study containing determine rate defects birth
folic acid effect study containing determine rate defects
acid effect study containing determine rate defects birth
acid effect study containing determine rate defects
folic acid effect study containing supplementation women epileptic
acid effect study containing supplementation women epileptic
folic acid effect study containing determine rate defects epilepsy
acid effect study containing determine rate defects epilepsy
folic acid women epileptic
acid women epileptic
folic acid women developed epilepsy
acid women developed epilepsy
carbamazepine treated woman epileptic
folic acid carbamazepine treated woman epileptic
acid carbamazepine treated woman epileptic
folic acid dose barrier triggered disease autoimmune
folic acid dose barrier triggered disease
acid dose barrier triggered disease autoimmune
acid dose barrier triggered disease
folic acid dose barrier triggered disease CONCLUSIONS patient epileptic
acid dose barrier triggered disease CONCLUSIONS patient epileptic
folic acid dose all disease autoimmune
folic acid dose all disease
acid dose all disease autoimmune
acid dose all disease
folic acid healthy women epileptic
acid healthy women epileptic
folic acid dose increase risk seizures epileptic
folic acid dose increase risk seizures
acid dose increase risk seizures epileptic
acid dose increase risk seizures
epsilon due treatment necrotizing case patient haemorrhage subarachnoid
epsilon due treatment necrotizing case patient haemorrhage
aminocaproic acid epsilon due treatment necrotizing case patient haemorrhage subarachnoid
aminocaproic acid epsilon due treatment necrotizing case patient haemorrhage
acid epsilon due treatment necrotizing case patient haemorrhage subarachnoid
acid epsilon due treatment necrotizing case patient haemorrhage
epsilon due treatment necrotizing case SAH
aminocaproic acid epsilon due treatment necrotizing case SAH
acid epsilon due treatment necrotizing case SAH
EACA acid epsilon due treatment necrotizing case patient haemorrhage subarachnoid
EACA acid epsilon due treatment necrotizing case patient haemorrhage
EACA acid epsilon due treatment necrotizing case SAH
epsilon due treatment necrotizing
epsilon due myopathy
aminocaproic acid epsilon due treatment necrotizing
aminocaproic acid epsilon due myopathy
acid epsilon due treatment necrotizing
acid epsilon due myopathy
EACA acid epsilon due treatment necrotizing
EACA acid epsilon due myopathy
Valproate induced hyperglycinemia nonketotic
Valproate induced hyperglycinemia
glycine system defect leads disorder
glycine system defect leads disorder metabolism of
glycine system defect leads disorder metabolism amino
glycine system defect leads disorder metabolism acid
glycine system defect leads disorder metabolism
glycine accumulation leads disorder
glycine accumulation leads disorder metabolism of
glycine accumulation leads disorder metabolism amino
glycine accumulation leads disorder metabolism acid
glycine accumulation leads disorder metabolism
glycine system defect leads disorder hyperglycinemia Nonketotic
glycine system defect leads disorder hyperglycinemia
glycine accumulation leads disorder hyperglycinemia Nonketotic
glycine accumulation leads disorder hyperglycinemia
valproate therapy initiation have found delay retardation mental
valproate therapy initiation have found delay retardation
valproate therapy initiation have hyperglycinemia nonketotic
valproate therapy initiation have hyperglycinemia
valproate therapy initiation have found delay language
valproate therapy initiation have found delay
nimesulide Tolerability urticaria
paracetamol nimesulide Tolerability urticaria
NSAID Tolerability urticaria
nimesulide paracetamol number history induced urticaria
paracetamol number history induced urticaria
NSAID history induced urticaria
nimesulide procedure applied patients history angioedema urticaria
paracetamol nimesulide procedure applied patients history angioedema urticaria
NSAID angioedema urticaria
NSAID history subjects % urticaria
NSAID history subjects % induced angioedema urticaria
NSAID history subjects % induced alone with urticaria
nimesulide tolerability confirm patients experienced angioedema urticaria
paracetamol nimesulide tolerability confirm patients experienced angioedema urticaria
NSAIDs caused angioedema urticaria
NSAID history increased increased history urticaria
carboplatin rhabdomyosarcoma embryonal
carboplatin rhabdomyosarcoma
amphotericin B prevention drug it hypokalemia patients cancer
B prevention drug it hypokalemia patients cancer
Spironolactone it hypokalemia patients cancer
Spironolactone it hypokalemia
amphotericin B effect Nephrotoxicity
B effect Nephrotoxicity
AmB B effect Nephrotoxicity
potassium wasting responsible seems toxicity
AmB treatment effect wasting responsible seems toxicity
Potassium depletion potentiates toxicity
AmB toxicity
AmB treatment patients neutropenic
spironolactone ability assess reduce prevent patients neutropenic
spironolactone ability assess reduce prevent hypokalemia
potassium requirements reduce prevent hypokalemia
potassium requirements reduce prevent patients neutropenic
AmB receive randomized patients disorders hematological
AmB receive randomized patients disorders
AmB mg randomized patients disorders hematological
AmB mg randomized patients disorders
spironolactone AmB mg daily developing proven infection fungal
spironolactone AmB mg daily developing proven infection
AmB receive randomized mg daily developing proven infection fungal
AmB receive randomized mg daily developing proven infection
AmB mg daily developing proven infection fungal
AmB mg daily developing proven infection
spironolactone AmB mg randomized patients disorders hematological
spironolactone AmB mg randomized patients disorders
AmB treatment patients neutropenic
spironolactone reduce prevent reducing patients neutropenic
spironolactone reduce prevent hypokalemia
potassium requirements reduce prevent hypokalemia
potassium loss reducing prevent hypokalemia
potassium requirements reduce prevent reducing patients neutropenic
potassium loss reducing patients neutropenic
enflurane delineated foci Epileptic
enflurane prove activator foci epileptic
sulfasalazine arthritis
benztropine Ethopropazine parkinsonism
Ethopropazine parkinsonism
fluphenazine enanthate outpatients schizophrenic
enanthate outpatients schizophrenic
ethopropazine compared benztropine treatment parkinsonism induced enanthate outpatients schizophrenic
benztropine treatment parkinsonism induced enanthate outpatients schizophrenic
benztropine treatment parkinsonism
ethopropazine compared benztropine treatment parkinsonism
procyclidine efficacious found effective symptoms parkinsonian
procyclidine efficacious found effective symptoms
benztropine Ethopropazine found effective symptoms parkinsonian
benztropine Ethopropazine found effective symptoms
Ethopropazine found effective symptoms parkinsonian
Ethopropazine found effective symptoms
procyclindine treatment condition had increase dyskinesia tardive
procyclindine treatment condition had increase dyskinesia
ethopropazine patients anxiety
procyclindine treatment condition anxiety depression
ethopropazine patients anxiety depression
ethopropazine patients anxiety condition had increase dyskinesia tardive
ethopropazine patients anxiety condition had increase dyskinesia
procyclindine treatment condition anxiety
benztropine drug choice treatment neuroleptic symptoms parkinsonian
benztropine drug choice treatment neuroleptic symptoms
Doxorubicin induces self nephropathy
Doxorubicin induces self nephropathy characterized glomerular
Doxorubicin induces self nephropathy characterized and
Doxorubicin induces self nephropathy characterized lesions late
Doxorubicin induces self nephropathy characterized lesions onset
Doxorubicin induces self nephropathy characterized lesions tubular
Doxorubicin induces self nephropathy characterized lesions
citrate activity glomerular
citrate activity glomerular and
citrate activity glomerular lesions tubular
citrate activity glomerular lesions
superoxide function encoded reduction induced lesions renal
superoxide function encoded reduction induced lesions
doxorubicin encoded reduction induced lesions renal
doxorubicin encoded reduction induced lesions
oxprenolol mediated hypokalemia
oxprenolol efficacy investigated antagonizing hypokalemia
oxprenolol pretreatment concentrations spite antagonized hypokalemia
thalidomide study carcinoma renal
thalidomide study carcinoma cell
thalidomide study carcinoma
thalidomide toxicity
thalidomide toxicity evaluate patients cancer renal
thalidomide toxicity evaluate patients cancer cell
thalidomide toxicity evaluate patients cancer
thalidomide carcinoma renal
thalidomide carcinoma cell
thalidomide carcinoma
thalidomide carcinoma renal
thalidomide carcinoma cell
thalidomide carcinoma
amlodipine telmisartan combination hypertension
amlodipine hypertension
telmisartan combination hypertension
amlodipine mg monotherapy patients hypertension
amlodipine 5 mg monotherapy patients hypertension
telmisartan + efficacy amlodipine mg monotherapy patients hypertension
warfarin juice haemopericardium
warfarin dosage maintaining consumed man report case haemorrhage
ketamine induced analgesia
morphine ketamine induced analgesia
morphine ketamine predominance reflected Latency loss righting reflex rigidity
ketamine predominance reflected Latency loss righting reflex rigidity
Naloxone inhibited effects cataleptic
naloxone ID asymmetry latency rigidity
naloxone ID asymmetry latency differences argue suggest mechanisms catalepsy
carboplatin cancer ovarian
carboplatin cancer
Paclitaxel combined carboplatin cancer ovarian
Paclitaxel combined carboplatin cancer
carboplatin administered women cancer ovarian
carboplatin administered women cancer
paclitaxel dose determine study phase infusion combination carboplatin administered women cancer ovarian
paclitaxel dose determine study phase infusion combination carboplatin administered women cancer
Taxol Bristol paclitaxel dose determine study phase infusion combination carboplatin administered women cancer ovarian
Taxol Bristol paclitaxel dose determine study phase infusion combination carboplatin administered women cancer
paclitaxel doses escalated phase infusion combination carboplatin administered women cancer ovarian
paclitaxel doses escalated phase infusion combination carboplatin administered women cancer
interferon therapy treatment infection HCV
interferon therapy treatment infection
ribavirin interferon therapy treatment infection HCV
ribavirin interferon therapy treatment infection
ribavirin result decrease problematic patients those comorbid disorders renal
ribavirin result decrease problematic patients those comorbid disorders renal or
ribavirin result decrease problematic patients those comorbid disorders renal cardiovascular
ribavirin result decrease problematic patients those comorbid disorders
ribavirin result hemolysis
ribavirin result decrease problematic patients infection HCV
ribavirin result decrease problematic patients infection
ribavirin result decrease problematic anemia
ribavirin anemia
ribavirin associated anemia
Viramidine has potential maintain decreasing risk anemia hemolytic
Viramidine has potential maintain decreasing risk anemia
Viramidine has potential maintain decreasing patients C chronic
Viramidine has potential maintain decreasing patients C hepatitis
Viramidine has potential maintain decreasing patients C
ribavirin prodrug liver has potential maintain decreasing patients C chronic
ribavirin prodrug liver has potential maintain decreasing patients C hepatitis
ribavirin prodrug liver has potential maintain decreasing patients C
ribavirin efficacy maintain decreasing patients C chronic
ribavirin efficacy maintain decreasing patients C hepatitis
ribavirin efficacy maintain decreasing patients C
vancomycin course osteomyelitis
tenofovir AIDS patients failure Acute
tenofovir AIDS patients failure renal
tenofovir AIDS patients failure
tenofovir AIDS
vancomycin course receiving Acute failure patients AIDS
tenofovir AIDS patients failure Acute receiving course osteomyelitis
tenofovir fumarate receiving patients developed failure Renal
tenofovir fumarate receiving patients developed failure
disoproxil fumarate receiving patients developed failure Renal
disoproxil fumarate receiving patients developed failure
fumarate receiving patients developed failure Renal
fumarate receiving patients developed failure
vancomycin therapy course developed failure Renal
vancomycin therapy course developed failure
Tenofovir implicated development syndrome Fanconi
Tenofovir implicated development syndrome
Tenofovir implicated development insufficiency renal
Tenofovir implicated development insufficiency
Vancomycin infrequent nephrotoxicity
Vancomycin infrequent result agent nephrotoxic
vancomycin administration raise risk failure renal
vancomycin administration raise risk failure
tenofovir raise risk failure renal
tenofovir raise risk failure
CC received presented pain chest
CC received presented pain
CC complication Thrombosis
Thorazine receiving developed tachycardia Supraventricular
Thorazine receiving developed tachycardia
chlorpromazine Thorazine receiving developed tachycardia Supraventricular
chlorpromazine Thorazine receiving developed tachycardia
lidocaine administration responded arrhythmias ventricular
lidocaine administration responded arrhythmias
propranolol instances required responded arrhythmias ventricular
propranolol instances required responded arrhythmias
phenothiazines drugs receiving patients quantify risk complications cardiac
phenothiazines drugs receiving patients quantify risk complications
Tramadol opioid used treat pain
Tramadol opioid used treat pain pain
Tramadol opioid used treat pain cancer
paroxetine hydrochloride patient tetraparetic
dosulepine paroxetine hydrochloride patient pain chronic
dosulepine paroxetine hydrochloride patient pain
hydrochloride patient pain chronic
hydrochloride patient pain
dosulepine paroxetine hydrochloride patient tetraparetic
hydrochloride patient tetraparetic
paroxetine hydrochloride patient pain chronic
paroxetine hydrochloride patient pain
anthracycline derivative induced cardiomyopathy
SM derivative induced cardiomyopathy
5887 SM derivative induced cardiomyopathy
SM potential cardiotoxic
5887 potential cardiotoxic
SM potential pre cardiotoxicity
5887 potential pre cardiotoxicity
SM effect 5887 potential cardiotoxic
5887 potential cardiotoxic
SM effect 5887 potential pre cardiotoxicity
5887 potential pre cardiotoxicity
doxorubicin induced potential cardiotoxic
doxorubicin induced potential pre cardiotoxicity
SM sacrificed animals cardiomyopathy
5887 administration show demonstrated changes decrease cardiomyopathy
SM effect cardiotoxic
5887 effect cardiotoxic
SM effect examine cardiomyopathy
5887 effect examine cardiomyopathy
doxorubicin cardiomyopathy examine effect cardiotoxic
doxorubicin treatment enhanced changes cardiotoxic
SM progress grade cardiomyopathy
5887 treatment SM progress grade cardiomyopathy
SM have potential cardiotoxicity
5887 have potential cardiotoxicity
SM induced cardiotoxicity
5887 have SM induced cardiotoxicity
doxorubicin effect potential cardiotoxicity
doxorubicin effect potential have SM induced cardiotoxicity
metoprolol antagonism hypokalemia
diphenylhydantoin toxicity
DPH toxicity
DPH toxicity manifest liable patients damage cerebral
DPH toxicity manifest liable patients damage
iopentol lower Frequencies fibrillation ventricular
iopentol lower Frequencies fibrillation
iohexol iopentol lower Frequencies fibrillation ventricular
iohexol iopentol lower Frequencies fibrillation
levobupivacaine bupivacaine rats toxicity
bupivacaine rats toxicity
ropivacaine bupivacaine rats toxicity
levobupivacaine bupivacaine toxicity
bupivacaine toxicity
ropivacaine bupivacaine toxicity
bupivacaine those larger similar doses seizures
bupivacaine those larger smaller doses levobupivacaine produced dysrhythmias asystole
bupivacaine those larger smaller doses levobupivacaine produced dysrhythmias
levobupivacaine toxicity
levobupivacaine bupivacaine induced that treatment susceptible appears conclude intermediate toxicity
bupivacaine ropivacaine that intermediate conclude appears arrest cardiac
bupivacaine ropivacaine that intermediate conclude appears arrest
bupivacaine induced that treatment susceptible appears arrest cardiac
bupivacaine induced that treatment susceptible appears arrest
bupivacaine ropivacaine that intermediate toxicity
bupivacaine induced that treatment susceptible appears conclude intermediate toxicity
ropivacaine that intermediate toxicity
ropivacaine rate administered intermediate toxicity
tacrolimus treatment associated dermatitis
tacrolimus describe eruptions
tacrolimus ointment dermatitis facial
tacrolimus ointment dermatitis
tacrolimus describe herein patients developed rosacea
tacrolimus describe eruptions dermatitis
tacrolimus immunomodulators use regarded cause dermatitis
Heparin induced thrombocytopenia thrombosis
heparin resistance count a
heparin resistance count falling
heparin resistance count platelet
heparin resistance count
heparin added plasma revealed count a
heparin added plasma revealed count falling
heparin added plasma revealed count platelet
heparin added plasma revealed count
heparin receiving indicated testing platelet
heparin receiving indicated testing aggregation
calcium chloride injected mydriasis tremor
chloride injected mydriasis tremor
calcium chloride injected mydriasis clonic
calcium chloride injected mydriasis produced convulsions tonic
calcium chloride injected mydriasis produced convulsions
chloride injected mydriasis clonic
chloride injected mydriasis produced convulsions tonic
chloride injected mydriasis produced convulsions
calcium chloride injected mydriasis
chloride injected mydriasis
calcium chloride changed hand tremor
chloride changed hand tremor
calcium chloride changed hand clonic
calcium chloride changed convulsions tonic
calcium chloride changed convulsions
chloride changed hand clonic
chloride changed convulsions tonic
chloride changed convulsions
calcium chloride changed hand mydriasis
chloride changed hand mydriasis
calcium chloride dissociate phenomena mydriasis tremor
chloride dissociate phenomena mydriasis tremor
calcium chloride dissociate phenomena mydriasis clonic
calcium chloride dissociate phenomena convulsions tonic
calcium chloride dissociate phenomena convulsions
chloride dissociate phenomena mydriasis clonic
chloride dissociate phenomena convulsions tonic
chloride dissociate phenomena convulsions
calcium chloride dissociate phenomena mydriasis
chloride dissociate phenomena mydriasis
dexamethasone myeloma
cyclophosphamide definition XI dexamethasone myeloma
bortezomib definition XI dexamethasone myeloma
dexamethasone transplantation patients myeloma multiple
dexamethasone transplantation patients myeloma
dexamethasone transplantation patients myeloma MM
cyclophosphamide dose evaluate dexamethasone transplantation patients myeloma multiple
cyclophosphamide dose evaluate dexamethasone transplantation patients myeloma
cyclophosphamide dose evaluate dexamethasone transplantation patients myeloma MM
bortezomib evaluate dexamethasone transplantation patients myeloma multiple
bortezomib evaluate dexamethasone transplantation patients myeloma
bortezomib evaluate dexamethasone transplantation patients myeloma MM
dexamethasone combination bortezomib treatment patients MM
cyclophosphamide m combination bortezomib treatment patients MM
bortezomib treatment patients MM
metoprolol treatment SR block shock cardiogenic
metoprolol treatment SR block shock
verapamil SR block shock cardiogenic
verapamil SR block shock
atropine doses uses block heart
atropine doses uses block
dopamine agents doses uses block heart
dopamine agents doses uses block
dopamine agents doses uses block remain hypotensive
dobutamine dopamine agents doses uses block heart
dobutamine dopamine agents doses uses block
atropine doses uses block remain hypotensive
dobutamine dopamine agents doses uses block remain hypotensive
calcium chloride use resolved hypotension
chloride use resolved hypotension
calcium chloride use resolved hypotension block heart
calcium chloride use resolved hypotension block
chloride use resolved hypotension block heart
chloride use resolved hypotension block
paclitaxel cancer Chemotherapy non
paclitaxel cancer small
paclitaxel cancer cell
paclitaxel cancer lung
paclitaxel cancer
Paclitaxel demonstrated types ovarian
Paclitaxel demonstrated types and
Paclitaxel demonstrated types carcinoma breast
Paclitaxel demonstrated types carcinoma
Taxol Bristol Paclitaxel demonstrated types ovarian
Taxol Bristol Paclitaxel demonstrated types and
Taxol Bristol Paclitaxel demonstrated types carcinoma breast
Taxol Bristol Paclitaxel demonstrated types carcinoma
Paclitaxel demonstrated types tumor
Taxol Bristol Paclitaxel demonstrated types tumor
paclitaxel infusions trials patients IIIB non
paclitaxel infusions trials cell small
paclitaxel infusions trials cell
paclitaxel infusions trials cell cancer lung
paclitaxel infusions trials cell cancer
paclitaxel infusions trials NSCLC
paclitaxel infusion efficacy investigated IIIB NSCLC
paclitaxel infusion efficacy toxicity
Paclitaxel agent 3 infusion proving effective superior terms incidence toxicity
paclitaxel combined drugs active NSCLC
paclitaxel comparing studies remain indicated studies paclitaxel combined drugs active NSCLC
Cyclosporin A caused reduction hypertrophy
A caused reduction hypertrophy
CsA A caused reduction hypertrophy
macrolide rapamycin A caused reduction hypertrophy
rapamycin A caused reduction hypertrophy
Fujimycine A caused reduction hypertrophy
FK Fujimycine A caused reduction hypertrophy
506 FK Fujimycine A caused reduction hypertrophy
FK CsA toxicity
506 toxicity
CsA toxicity
timolol Comparison response patients treatment glaucoma
timolol trial DESIGN rate patients treated glaucoma
timolol solution timolol trial DESIGN rate patients treated glaucoma
timolol suspension trial DESIGN rate patients treated glaucoma
timolol gellan conjunctiva forms suspension trial DESIGN rate patients treated glaucoma
timolol solution placebo masked Forty randomized patients years open
timolol solution placebo masked Forty randomized patients years open glaucoma angle
timolol solution placebo masked Forty randomized patients years open glaucoma
timolol gellan placebo masked Forty randomized patients years open
timolol gellan placebo masked Forty randomized patients years open glaucoma angle
timolol gellan placebo masked Forty randomized patients years open glaucoma
timolol solution placebo masked Forty randomized patients years open glaucoma hypertension ocular
timolol solution placebo masked Forty randomized patients years open glaucoma hypertension
timolol gellan placebo masked Forty randomized patients years open glaucoma hypertension ocular
timolol gellan placebo masked Forty randomized patients years open glaucoma hypertension
HCBD produced damage discriminated both damage glomerular
HCBD produced damage discriminated both damage
BEA HCBD produced damage discriminated both damage glomerular
BEA HCBD produced damage discriminated both damage
PAN produced damage glomerular
PAN produced damage
droperidol dose administration minutes developed protrusion year man allergies drug
droperidol dose administration minutes developed protrusion year man allergies
droperidol dose administration minutes developed protrusion year man allergies angioedema tongue
droperidol dose administration minutes developed protrusion year man allergies angioedema tongue swelling
ethambutol map pattern degeneration axonal
ethambutol map pattern degeneration
Ethambutol agent used treat tuberculosis
EMB management terms important manage patients impairment renal
EMB management terms important manage patients impairment
ethambutol dosing manage patients impairment renal
ethambutol dosing manage patients impairment
Metformin prevents pathway induced nephropathy
gentamicin pathway induced nephropathy
metformin diminish prevent dysfunction vascular
metformin diminish prevent dysfunction
gentamicin toxicity
Metformin treatment blocked gentamicin failure acute
Metformin treatment blocked gentamicin failure renal
Metformin treatment blocked gentamicin failure
metformin correction markers dysfunction kidney
metformin correction markers dysfunction
metformin effects lessen nephrotoxicity
gentamicin lessen nephrotoxicity
sodium administration toxicity Treatment sulphonate patients cancer lung
sodium administration toxicity Treatment sulphonate patients cancer
2 sodium administration toxicity Treatment sulphonate patients cancer lung
2 sodium administration toxicity Treatment sulphonate patients cancer
mercaptoethane sulphonate patients cancer lung
mercaptoethane sulphonate patients cancer
sulphonate patients cancer lung
sulphonate patients cancer
MESNA sulphonate patients cancer lung
MESNA sulphonate patients cancer
sodium administration toxicity urothelial
sodium administration toxicity
2 sodium administration toxicity urothelial
2 sodium administration toxicity
mercaptoethane sulphonate Treatment toxicity urothelial
mercaptoethane sulphonate Treatment toxicity
sulphonate Treatment toxicity urothelial
sulphonate Treatment toxicity
MESNA sulphonate Treatment toxicity urothelial
MESNA sulphonate Treatment toxicity
ifosfamide Treatment sulphonate patients cancer lung
ifosfamide Treatment sulphonate patients cancer
sodium effect tested group patients cancer lung
sodium effect tested group patients cancer
2 sodium effect tested group patients cancer lung
2 sodium effect tested group patients cancer
mercaptoethane sulphonate sodium effect tested group patients cancer lung
mercaptoethane sulphonate sodium effect tested group patients cancer
sulphonate sodium effect tested group patients cancer lung
sulphonate sodium effect tested group patients cancer
MESNA sulphonate sodium effect tested group patients cancer lung
MESNA sulphonate sodium effect tested group patients cancer
thiol compound administration effect tested group patients cancer lung
thiol compound administration effect tested group patients cancer
sodium sulphonate toxicity urothelial
sodium sulphonate toxicity
2 sodium sulphonate toxicity urothelial
2 sodium sulphonate toxicity
mercaptoethane sulphonate toxicity urothelial
mercaptoethane sulphonate toxicity
sulphonate toxicity urothelial
sulphonate toxicity
MESNA sulphonate toxicity urothelial
MESNA sulphonate toxicity
ifosfamide induced toxicity sulphonate sodium effect tested group patients cancer lung
ifosfamide induced toxicity sulphonate sodium effect tested group patients cancer
IF effect tested group patients cancer lung
IF effect tested group patients cancer
IF treatment tested group patients cancer lung
IF treatment tested group patients cancer
thiol compound administration effect sodium sulphonate toxicity urothelial
thiol compound administration effect sodium sulphonate toxicity
MESNA series differences were toxicity
methylprednisolone do injury spinal
methylprednisolone do injury cord
methylprednisolone do injury
methylprednisolone became Studies Spinal
methylprednisolone became Studies Cord
methylprednisolone became Studies Injury
methylprednisolone became injury spinal
methylprednisolone became injury cord
methylprednisolone became injury
corticosteroid myopathy
steroid myopathy recovers recording protection offers injury spinal
steroid myopathy recovers recording protection offers injury cord
steroid myopathy recovers recording protection offers injury
steroid myopathy recovery recording protection offers injury spinal
steroid myopathy recovery recording protection offers injury cord
steroid myopathy recovery recording protection offers injury
steroid myopathy
steroid myopathy recovers recording recovery myopathy
steroid myopathy recovery recording recovers myopathy
steroid myopathy
methylprednisolone offers injury spinal
methylprednisolone offers injury cord
methylprednisolone offers injury
corticosteroid myopathy
tamoxifen use tumors
tamoxifen treated year 52 CASE breast
tamoxifen treated year 52 CASE breast carcinoma
estrogen receptor tamoxifen treated year 52 CASE breast
estrogen receptor tamoxifen treated year 52 CASE breast carcinoma
tamoxifen Patients CONCLUSION induced risk tumors granulosa
tamoxifen Patients CONCLUSION induced risk tumors cell
tamoxifen Patients CONCLUSION induced risk tumors
tamoxifen metabolism alterations tumors granulosa
tamoxifen metabolism alterations tumors cell
tamoxifen metabolism alterations tumors
quetiapine symptoms extrapyramidal
quetiapine symptoms
quetiapine symptoms EPS
quetiapine studies patients mania bipolar
quetiapine studies patients mania
quetiapine evaluate symptoms akathisia
quetiapine evaluate symptoms extrapyramidal
quetiapine evaluate symptoms
quetiapine evaluate symptoms EPS
quetiapine patients mania bipolar
quetiapine patients mania
quetiapine different monotherapy events akathisia
quetiapine different monotherapy related RESULTS incidence EPS
QTP Li events DVP EPS
DVP EPS
DVP different DVP EPS
DVP low low incidence akathisia
DVP DVP low low incidence akathisia
quetiapine monotherapy low incidence akathisia
QTP DVP low low incidence akathisia
Li DVP low low incidence akathisia
Li DVP DVP low low incidence akathisia
quetiapine associated incidence tremor
quetiapine associated contributed tremor
quetiapine associated contributed rate tremor
quetiapine induced incidence akathisia
quetiapine induced incidence akathisia syndrome extrapyramidal
quetiapine induced incidence akathisia syndrome
quetiapine induced incidence akathisia tremor
quetiapine therapy incidence EPS akathisia
quetiapine therapy incidence EPS
quetiapine therapy incidence similar mania bipolar
quetiapine therapy incidence similar mania
Steroid treatment meshwork similar those reported glaucoma glaucoma open
Steroid treatment meshwork similar those reported glaucoma glaucoma angle
Steroid treatment meshwork similar those reported glaucoma glaucoma
Steroid treatment meshwork similar those reported glaucoma corticosteroid
Steroid treatment meshwork similar those reported glaucoma
Remifentanil pretreatment reduces myoclonus
remifentanil kg pretreatment effect compare incidence myoclonus
remifentanil group lower incidence myoclonus
remifentanil microg Pretreatment CONCLUSION reduced effects sedation apnea
etomidate induction reduced effects sedation nausea
remifentanil microg Pretreatment CONCLUSION reduced myoclonus
etomidate induction reduced effects sedation pruritus
remifentanil microg Pretreatment CONCLUSION reduced effects sedation pruritus
etomidate induction reduced effects sedation apnea
remifentanil microg Pretreatment CONCLUSION reduced effects sedation nausea
nitric production Association model nephropathy
oxide production Association model nephropathy
NO association role studied apoptosis model syndrome nephrotic
NO association role studied apoptosis model syndrome
ADR groups groups nephropathy
ADR revealed areas proliferation mesangial
ADR revealed areas proliferation
ADR revealed areas proliferation inflammation tubulointerstitial
ADR revealed areas proliferation inflammation
ADR increased group nephropathy
nitrite levels increased group nephropathy
acetylcholine phenylephrine responses impaired group nephropathy
ADR group nephropathy
phenylephrine responses impaired group nephropathy
ADR group nephropathy
ADR pathogenesis important nephrosis
NO interactions important nephrosis
paracetamol overdose
paracetamol overdose survived increased patients failure due hepatitis viral
paracetamol overdose survived increased patients failure due hepatitis
PPA abuse linked involved overdose
PPA abuse linked injury myocardial
PPA abuse linked injury
Dexatrim case injury myocardial
Dexatrim case injury
PPA Dexatrim case injury myocardial
PPA Dexatrim case injury
PPA injury myocardial
PPA injury
Reserpine produced dyskinesia orofacial
Reserpine produced dyskinesia
Reserpine produced tremor suggestive disease Parkinson
Reserpine produced tremor suggestive disease Parkinson '
Reserpine produced tremor suggestive disease s
Reserpine produced tremor suggestive disease
MK 801 administered induced catalepsy
801 administered induced catalepsy
MK injection produced increase tremor
801 injection produced increase tremor
apomophine injection followed administered Reserpine produce dyskinesia oral
apomophine injection followed administered Reserpine produce dyskinesia
Reserpine produce dyskinesia oral
Reserpine produce dyskinesia
MK 801 attenuated catalepsy
801 attenuated catalepsy
MK 801 attenuated catalepsy tremor
801 attenuated catalepsy tremor
MK increases tremor catalepsy
801 increases tremor catalepsy
MK increases tremor
801 increases tremor
reserpine produces considered parkinsonian
NMDA produced blockage restore signs vacuous chewing movements catalepsy
NMDA produced blockage restore signs vacuous chewing movements tremor
magnesium toxicity
nifedipine potentiate toxicity
apomorphine dose administration dyskinesia study included patients had disease Parkinson
apomorphine dose administration dyskinesia study included patients had disease Parkinson '
apomorphine dose administration dyskinesia study included patients had disease s
apomorphine dose administration dyskinesia study included patients had disease
poly polymerase Activation contributes development failure heart
poly polymerase Activation contributes development failure
ADP polymerase Activation contributes development failure heart
ADP polymerase Activation contributes development failure
ribose ADP polymerase Activation contributes development failure heart
ribose ADP polymerase Activation contributes development failure
anthracycline antibiotic factor implicated cardiotoxicity
doxorubicin cardiotoxicity
DOX doxorubicin cardiotoxicity
DOX induced cardiotoxicity
DOX induced dysfunction cardiac
DOX induced dysfunction
PJ deletion Using demonstrate development dysfunction cardiac
PJ deletion Using demonstrate development dysfunction
34 PJ deletion Using demonstrate development dysfunction cardiac
34 PJ deletion Using demonstrate development dysfunction
PJ Treatment improved dysfunction cardiac
PJ Treatment improved dysfunction
34 PJ Treatment improved dysfunction cardiac
34 PJ Treatment improved dysfunction
DOX cardiotoxicity
DOX treatment associated complications cardiac
DOX treatment associated complications
fentanyl dose received period case rigidity leading respiratory
fentanyl dose received period case rigidity leading respiratory described failure
oxytocin administration associated intoxication abortion
oxytocin administration intoxication described abortions
Oxytocin administration advocated carried report asthenia
Oxytocin administration advocated carried report asthenia irritability
Oxytocin administration advocated abortions
Oxytocin administration advocated carried report asthenia headaches
Dopamine essential development methamphetamine induced neurotoxicity
dopamine mediates methamphetamine toxicity
dopamine mediates drugs interfere toxicity
dopamine mediates drugs interfere enhance toxicity
DA dopamine mediates methamphetamine toxicity
DA dopamine mediates drugs interfere toxicity
DA dopamine mediates drugs interfere enhance toxicity
DA toxicity interfere drugs mediates methamphetamine toxicity
DA toxicity
DA toxicity interfere enhance toxicity
DA neurotransmission increase drugs enhance interfere drugs mediates methamphetamine toxicity
DA neurotransmission increase drugs enhance interfere toxicity
DA neurotransmission increase drugs enhance toxicity
methamphetamine toxicity
methamphetamine mediates drugs interfere toxicity
methamphetamine mediates drugs interfere enhance toxicity
METH methamphetamine toxicity
METH methamphetamine mediates drugs interfere toxicity
METH methamphetamine mediates drugs interfere enhance toxicity
DA confounded neurotoxicity
L ability dihydroxyphenylalanine show confounded neurotoxicity
dihydroxyphenylalanine show confounded neurotoxicity
alpha tyrosine effect reverse dihydroxyphenylalanine show confounded neurotoxicity
methyl tyrosine effect reverse dihydroxyphenylalanine show confounded neurotoxicity
para methyl tyrosine effect reverse dihydroxyphenylalanine show confounded neurotoxicity
tyrosine effect reverse dihydroxyphenylalanine show confounded neurotoxicity
DA deficient engineered mice develop METH neurotoxicity
METH deficits dopaminergic
METH deficits
DA deficits develop METH deficits dopaminergic
DA deficits develop METH deficits
DA essential neurotoxicity
DA mechanisms warrant suggest demonstrate essential neurotoxicity
morphine doubled increased incoordination
NH 4 Ac blocked reversed depression
4 Ac blocked reversed depression
Ac blocked reversed depression
catecholamine release blocked reversed depression
acetaldehyde release blocked reversed depression
calcium Addition reversed depression
calcium reversed depression
NH 4 activity analgesia
4 activity analgesia
Ac activity analgesia
NH verapamil mg activity analgesia
4 Ac verapamil mg activity analgesia
Ac verapamil mg activity analgesia
verapamil mg activity analgesia diazepam incoordination
verapamil mg activity analgesia diazepam incoordination
diazepam analgesia
amphetamine analgesia diazepam incoordination
verapamil mg activity analgesia
verapamil mg activity analgesia
morphine analgesia diazepam incoordination
amphetamine analgesia
metrazol action affected verapamil mg activity analgesia diazepam incoordination
metrazol action affected verapamil mg activity analgesia
morphine analgesia
calcium channel exerts hyperammonemia
salicylates calcium treated arthritis rheumatoid
salicylates calcium treated arthritis
naproxen therapy institution developed year man arthritis rheumatoid
naproxen therapy institution developed year man arthritis
fenoprofen calcium treated arthritis man year developed necrosis renal
fenoprofen calcium treated arthritis man year developed necrosis papillary
fenoprofen calcium treated arthritis man year developed necrosis
calcium treated arthritis man year developed necrosis renal
calcium treated arthritis man year developed necrosis papillary
calcium treated arthritis man year developed necrosis
fenoprofen calcium treated arthritis man year developed necrosis RPN
calcium treated arthritis man year developed necrosis RPN
sulindac calcium treated arthritis rheumatoid
sulindac calcium treated arthritis
salicylates calcium treated arthritis man year developed necrosis renal
salicylates calcium treated arthritis man year developed necrosis papillary
salicylates calcium treated arthritis man year developed necrosis
salicylates calcium treated arthritis man year developed necrosis RPN
fenoprofen calcium treated arthritis rheumatoid
fenoprofen calcium treated arthritis
calcium treated arthritis rheumatoid
calcium treated arthritis
sulindac calcium treated arthritis man year developed necrosis renal
sulindac calcium treated arthritis man year developed necrosis papillary
sulindac calcium treated arthritis man year developed necrosis
sulindac calcium treated arthritis man year developed necrosis RPN
gold salts calcium treated arthritis man year developed necrosis renal
gold salts calcium treated arthritis man year developed necrosis papillary
gold salts calcium treated arthritis man year developed necrosis
gold salts calcium treated arthritis man year developed necrosis RPN
gold salts calcium treated arthritis rheumatoid
gold salts calcium treated arthritis
sulindac advantages discuss antiinflammatory linking RPN
sulindac advantages discuss patients experienced toxicity renal
sulindac advantages discuss patients experienced toxicity
All induced leukemia acute
All induced leukemia promyelocytic
All induced leukemia
trans All induced leukemia acute
trans All induced leukemia promyelocytic
trans All induced leukemia
retinoic acid trans All induced leukemia acute
retinoic acid trans All induced leukemia promyelocytic
retinoic acid trans All induced leukemia
acid trans All induced leukemia acute
acid trans All induced leukemia promyelocytic
acid trans All induced leukemia
all acid associated leukemia acute
all acid associated leukemia promyelocytic
all acid associated leukemia
trans acid associated leukemia acute
trans acid associated leukemia promyelocytic
trans acid associated leukemia
retinoic acid associated leukemia acute
retinoic acid associated leukemia promyelocytic
retinoic acid associated leukemia
acid associated leukemia acute
acid associated leukemia promyelocytic
acid associated leukemia
all acid associated nodosum APL
trans acid associated nodosum APL
retinoic acid associated nodosum APL
acid associated nodosum APL
ATRA acid associated leukemia acute
ATRA acid associated leukemia promyelocytic
ATRA acid associated leukemia
ATRA acid associated nodosum APL
ATRA therapy developed patients APL
ATRA therapy developed nodules painful
steroid use effective induced nodosum erythema
steroid use effective induced nodosum
ziprasidone dose developed history schizophrenia
hydrocortisone rise associated output increased
hydrocortisone rise associated output cardiac
hydrocortisone rise associated output
alcohol intake admitted Five patients pain
alcohol intake admitted Five patients seven patients pain
tamoxifen used treatment breast
tamoxifen used treatment cancer
tamoxifen used proposed prevention cancer breast
tamoxifen used proposed prevention cancer
tamoxifen use investigated women treated cancer breast
tamoxifen use investigated women treated cancer
tamoxifen received had Women had disease advanced
tamoxifen received had Women had disease
tamoxifen role suggest used proposed prevention breast
tamoxifen role suggest used proposed prevention cancer
tamoxifen cancer breast
tamoxifen cancer
tamoxifen treatment cancer breast
tamoxifen treatment cancer
Nitric expression hypertension
oxide expression hypertension
oxygen species reduced hypertension
nitrotyrosine sequestration increased reduced hypertension
NO metabolites excretion reduced hypertension
NO sequestration increased reduced hypertension
NO expression depressed due reduction NOx hypertension
MDA concentration lowered ameliorated hypertension
Vitamin supplementation ameliorated hypertension
E supplementation ameliorated hypertension
NO inactivation actions stress associated hypertension
CYP observed increased mice inflammation bladder
CYP observed increased mice inflammation
RAPA conversion effects evaluate patients undergoing cyclosporine toxicity
tacrolimus cyclosporine toxicity
Tac tacrolimus cyclosporine toxicity
cyclosporine toxicity
CsA cyclosporine toxicity
CsA CsA hepatotoxicity
CsA hepatotoxicity
Tac nephrotoxicity CsA CsA disorder posttransplant
Tac nephrotoxicity CsA CsA disorder lymphoproliferative
Tac nephrotoxicity CsA CsA disorder
Tac nephrotoxicity CsA CsA disorder PTLD
Tac toxicity CsA disorder posttransplant
Tac toxicity CsA disorder lymphoproliferative
Tac toxicity CsA disorder
Tac toxicity CsA disorder PTLD
CsA CsA dysmorphism facial
CsA CsA dysmorphism
CsA dysmorphism facial
CsA dysmorphism
Tac nephrotoxicity CsA CsA hepatotoxicity
Tac toxicity CsA hepatotoxicity
Tac nephrotoxicity CsA CsA dysmorphism facial
Tac nephrotoxicity CsA CsA dysmorphism
Tac toxicity CsA dysmorphism facial
Tac toxicity CsA dysmorphism
Tac nephrotoxicity CsA CsA toxicity
Tac toxicity
CsA CsA toxicity
CsA toxicity
CsA CsA disorder posttransplant
CsA CsA disorder lymphoproliferative
CsA CsA disorder
CsA CsA disorder PTLD
CsA disorder posttransplant
CsA disorder lymphoproliferative
CsA disorder
CsA disorder PTLD
creatinine + decrease was nephrotoxicity
RAPA discontinued patients pneumonia ulcers aphtous
RAPA discontinued patients pneumonia ulcers
RAPA discontinued patients pneumonia PTLD
RAPA discontinued patients pneumonia
RAPA levels converting monitored However given immunosuppression antiviral prophylaxis Pneumocystis
RAPA levels converting monitored However given immunosuppression antiviral prophylaxis carinii
RAPA levels converting monitored However given immunosuppression antiviral prophylaxis pneumonia
heroin dependence methadone treated patients prolongation Syncope
heroin dependence methadone treated patients prolongation Syncope QT
heroin dependence methadone treated patients prolongation
methadone users reported Prolongation interval ECG patients pointes torsade
methadone users reported Prolongation interval ECG patients pointes de
methadone users reported Prolongation interval ECG patients pointes
methadone users reported Prolongation TdP
heroin addicts faint attribute underestimate incidence TdP
methadone effect caused attribute underestimate incidence TdP
heroin addicts faint attribute episodes syncope
heroin addicts population associated prolongation reporting syncope
heroin addicts population associated prolongation QT
heroin addicts population associated prolongation
acetylcholine expression caused dysfunction muscle
acetylcholine expression caused dysfunction
Prednisolone induced caused more atrophy
acetylcholine expression caused more atrophy
d curves fatigability nerve tensions tensions tetanic
tubocurarine fatigability nerve tensions tensions tetanic
prednisolone dysfunction neuromuscular
prednisolone dysfunction
acetylcholine expression changes dose dose atrophy muscle
acetylcholine expression changes dose dose atrophy
uric acid dL buffer compared effects nephrotoxic
acid dL buffer compared effects nephrotoxic
suprofen mg dose effects nephrotoxic
uric acid distribution altering causes declines acute
uric acid distribution altering causes declines
uric acid distribution altering causes declines function in
uric acid distribution altering causes declines function renal
uric acid distribution altering causes declines function
acid distribution altering causes declines acute
acid distribution altering causes declines
acid distribution altering causes declines function in
acid distribution altering causes declines function renal
acid distribution altering causes declines function
Atorvastatin prevented dexamethasone induced hypertension
atorvastatin effects assess hypertension
atorva atorvastatin effects assess hypertension
atorva kg treated day hypertension
Atorva reversed dex hypertension
atorva 441 < 0001 392 + superoxide hypertension
superoxide hypertension
atorvastatin prevented dexamethasone induced hypertension
captopril Effect proteinuria rats hypertensive
captopril Effect proteinuria
aminonucleoside existing captopril Effect proteinuria rats hypertensive
captopril treatment patients hypertensive
captopril treatment effect Proteinuria
captopril reproducing abnormality renal
captopril reproducing abnormality
captopril administration failed aggravate pre proteinuria
captopril treatment failed potentiate development proteinuria
Glyceryl trinitrate induces aura sufferers migraine
Glyceryl trinitrate induces aura sufferers migraine aura with
Glyceryl trinitrate induces aura sufferers migraine aura
trinitrate induces aura sufferers migraine
trinitrate induces aura sufferers migraine aura with
trinitrate induces aura sufferers migraine aura
nitric oxide involved mechanisms pain
oxide involved mechanisms pain
NO oxide involved mechanisms pain
glyceryl trinitrate infusion examined response headache
trinitrate infusion examined response headache
GTN trinitrate infusion examined response headache
glyceryl trinitrate infusion examined clarify true migraine
glyceryl trinitrate infusion examined clarify true migraine aura with
glyceryl trinitrate infusion examined clarify true migraine aura
trinitrate infusion examined clarify true migraine
trinitrate infusion examined clarify true migraine aura with
trinitrate infusion examined clarify true migraine aura
glyceryl trinitrate infusion examined sufferers migraine
glyceryl trinitrate infusion examined sufferers migraine aura with
glyceryl trinitrate infusion examined sufferers migraine aura
trinitrate infusion examined sufferers migraine
trinitrate infusion examined sufferers migraine aura with
trinitrate infusion examined sufferers migraine aura
GTN trinitrate infusion examined clarify true migraine
GTN trinitrate infusion examined clarify true migraine aura with
GTN trinitrate infusion examined clarify true migraine aura
GTN trinitrate infusion examined sufferers migraine
GTN trinitrate infusion examined sufferers migraine aura with
GTN trinitrate infusion examined sufferers migraine aura
GTN infusion during controls severe migraineurs
GTN infusion during controls severe Headache
GTN induced headache disappeared occurred migraineurs
GTN induced headache
GTN induced headache disappeared occurred intensity headache
NO involved mechanisms migraine
NO involved aura with
NO involved aura
NO involved mechanisms pain
NO liberate shown cortical spreading depression
NO liberate shown help spreading depression
NO liberate shown help spreading migraine
NO liberate shown help spreading migraine aura with
NO liberate shown help spreading migraine aura
NO liberate shown help spreading depression headache
timolol hypokalemia
timolol drug tended correct hypokalemia
alpha induced Peroxisomes lesions liver
alpha induced Peroxisomes lesions
benzene hexachloride examined induced Peroxisomes lesions liver
benzene hexachloride examined induced Peroxisomes lesions
hexachloride examined induced Peroxisomes lesions liver
hexachloride examined induced Peroxisomes lesions
ethyl p respond were most hepatomas
alpha p respond were most hepatomas
p respond were most hepatomas
chlorophenoxyisobutyrate p respond were most hepatomas
ethyl p respond were differentiated tumors
alpha p respond were differentiated tumors
p respond were differentiated tumors
chlorophenoxyisobutyrate p respond were differentiated tumors
ethyl p respond cells tumor
alpha p respond cells tumor
p respond cells tumor
chlorophenoxyisobutyrate p respond cells tumor
Morphine alter hyperalgesia
sertraline effect Absence sensitization impairment cognitive
sertraline effect Absence sensitization impairment
sertraline administration worsened profile impairment cognitive
sertraline administration worsened profile impairment
adriamycin mitochondria impairment cardiomyopathy
adriamycin cancer
ADR adriamycin cancer
adriamycin use limited due toxicity cardiovascular
adriamycin use limited due toxicity
ADR adriamycin use limited due toxicity cardiovascular
ADR adriamycin use limited due toxicity
ADR treatment caused arrhythmias cardiovascular
ADR treatment caused arrhythmias
ADR treatment caused indicated underwent swelling
estradiol progesterone use left forty year woman developed headache vomiting
estradiol progesterone use left forty year woman developed headache nausea
progesterone use left hemiparesis seizure
estradiol progesterone use left forty year woman developed headache
progesterone use left hemiparesis
progesterone use left forty year woman developed headache
estradiol progesterone use left hemiparesis
estradiol progesterone use left hemiparesis seizure
progesterone use left forty year woman developed headache vomiting
progesterone use left forty year woman developed headache nausea
estradiol use increased thrombogenicity provided thrombosis
estradiol use increased thrombogenicity provided thrombosis ICA of
estradiol use increased thrombogenicity provided thrombosis ICA both
estradiol use increased thrombogenicity provided thrombosis ICA the
estradiol use increased thrombogenicity provided thrombosis ICA
estradiol use increased thrombogenicity provided thrombosis ICA and
estradiol use increased thrombogenicity provided thrombosis ICA sinus the
estradiol use increased thrombogenicity provided thrombosis ICA sinus venous
estradiol use increased thrombogenicity provided thrombosis ICA sinus
progesterone estradiol DM
estradiol DM
progesterone estradiol use increased thrombogenicity provided thrombosis
progesterone estradiol use increased thrombogenicity provided thrombosis ICA of
progesterone estradiol use increased thrombogenicity provided thrombosis ICA both
progesterone estradiol use increased thrombogenicity provided thrombosis ICA the
progesterone estradiol use increased thrombogenicity provided thrombosis ICA
progesterone estradiol use increased thrombogenicity provided thrombosis ICA and
progesterone estradiol use increased thrombogenicity provided thrombosis ICA sinus the
progesterone estradiol use increased thrombogenicity provided thrombosis ICA sinus venous
progesterone estradiol use increased thrombogenicity provided thrombosis ICA sinus
tamoxifen trial participating Patients group women cancer breast
tamoxifen trial participating Patients group women cancer
anastrozole trial participating Patients group women cancer breast
anastrozole trial participating Patients group women cancer
metoclopramide induced preexisting block left
metoclopramide induced preexisting block bundle
metoclopramide induced preexisting block branch
metoclopramide induced preexisting block
metoclopramide administration developed block left
metoclopramide administration developed block bundle
metoclopramide administration developed block branch
metoclopramide administration developed block
ifosfamide patient breast
ifosfamide patient cancer
ifosfamide sixty developed cancer breast
ifosfamide sixty developed cancer
cisplatin treated cancer developed anuria
ifosfamide sixty developed failure renal
ifosfamide sixty developed failure
cisplatin treated cancer developed failure renal
cisplatin treated cancer developed failure
cisplatin treated cancer breast
cisplatin treated cancer
cisplatin received perfusion occurring due anuria
ifosfamide due occurring perfusion due hypotension
cisplatin received perfusion due hypotension
glycopyrronium Use kg induced bradycardias
cephalosporins receiving patients described anemia hemolytic
cephalosporins receiving patients described anemia
penicillins cephalosporins receiving patients described anemia hemolytic
penicillins cephalosporins receiving patients described anemia
cefotetan receiving developed anemia
4 chloride Effect therapy toxicity
aminopyridine therapy toxicity
desipramine toxicity
calcium chloride Effect therapy toxicity
chloride Effect therapy toxicity
calcium blockade role hypotension
calcium overdose
NaHCO RESULTS reversed prolongation hypotension
3 NaHCO RESULTS reversed prolongation hypotension
CaCl group incidence arrhythmias seizures
2 group incidence arrhythmias seizures
4 CaCl administration CONCLUSION reverse antidepressant hypotension
aminopyridine reverse antidepressant hypotension
CaCl administration CONCLUSION reverse antidepressant hypotension
2 CaCl administration CONCLUSION reverse antidepressant hypotension
CaCl therapy worsen cardiovascular
CaCl therapy worsen cardiovascular and
CaCl therapy worsen cardiovascular toxicity central
CaCl therapy worsen cardiovascular toxicity nervous
CaCl therapy worsen cardiovascular toxicity system
CaCl therapy worsen cardiovascular toxicity
2 therapy worsen cardiovascular
2 therapy worsen cardiovascular and
2 therapy worsen cardiovascular toxicity central
2 therapy worsen cardiovascular toxicity nervous
2 therapy worsen cardiovascular toxicity system
2 therapy worsen cardiovascular toxicity
calcium inhibition role hypotension
ouabain Effects supply patients disease coronary
ouabain Effects supply patients disease artery
ouabain Effects supply patients disease
oxygen ouabain Effects supply patients disease coronary
oxygen ouabain Effects supply patients disease artery
oxygen ouabain Effects supply patients disease
digitalis glycosides effects interest presence disease coronary
digitalis glycosides effects interest presence disease artery
digitalis glycosides effects interest presence disease
glycosides effects interest presence disease coronary
glycosides effects interest presence disease artery
glycosides effects interest presence disease
oxygen supply glycosides effects interest presence disease coronary
oxygen supply glycosides effects interest presence disease artery
oxygen supply glycosides effects interest presence disease
ouabain effects assessed patients disease coronary
ouabain effects assessed patients disease artery
ouabain effects assessed patients disease
ouabain effects assessed failure congestive
ouabain effects assessed failure heart
ouabain effects assessed failure
ouabain administration falls conclude disease coronary
ouabain administration falls conclude disease artery
ouabain administration falls conclude disease
ouabain administration falls conclude disease failure congestive
ouabain administration falls conclude disease failure heart
ouabain administration falls conclude disease failure
Oxytocin attributed loss blood
Oxytocin attributed loss
oxytocin response Hypotension associated decrease increase volume stroke
pentamidine tachycardia ventricular
pentamidine tachycardia
Pentamidine isethionate associated tachyarrhythmias ventricular
Pentamidine isethionate associated tachyarrhythmias
isethionate associated tachyarrhythmias ventricular
isethionate associated tachyarrhythmias
magnesium levels serum related induce hypomagnesemia
Pentamidine induced related induce hypomagnesemia
magnesium levels serum related pointes torsade
magnesium levels serum related pointes de
magnesium levels serum related pointes
magnesium supplementation advocated observed prolongation QTc
magnesium supplementation advocated observed prolongation interval
magnesium supplementation advocated observed prolongation
calcium chloride induced tetany
chloride induced tetany
diltiazem infusion developed arrest respiratory
diltiazem infusion developed arrest
calcium chloride administration resolved tetany
chloride administration resolved tetany
calcium chloride remedy accompany life tetany
chloride remedy accompany life tetany
remifentanil propofol controlled Reduction pain
remifentanil infusing prevented pain
remifentanil prevent pain
Remifentanil assessed evaluated pain
remifentanil infusion assessed evaluated pain
remifentanil propofol TCI anaesthesia induction achieved reduction pain
remifentanil ml administration achieved reduction pain
anthracyclines cyclophosphamide used example patients systemic
anthracyclines cyclophosphamide used example patients sclerosis
cyclophosphamide used example patients systemic
cyclophosphamide used example patients sclerosis
mitoxantrone cyclophosphamide used example patients systemic
mitoxantrone cyclophosphamide used example patients sclerosis
anthracyclines cyclophosphamide used damage heart
anthracyclines cyclophosphamide used damage
bupropion release associated deprivation sleep
bupropion release associated deprivation
bupropion use sleep
bupropion use deprivation
bupropion risk add deprivation sleep
bupropion risk add deprivation
methadone responses Pain
methadone stabilized addicts opioid
methadone stabilized addicts
methadone stabilized addicts sample tolerance pain
ketorolac agents pressor examined pain
hydromorphone doses administration examined pain
choline acetyltransferase activates MC induced amnesia
Daidzein activates MC induced amnesia
acetylcholine production augmentation transmission enhances activator factor treatment disease Alzheimer
acetylcholine production augmentation transmission enhances activator factor treatment disease Alzheimer '
acetylcholine production augmentation transmission enhances activator factor treatment disease s
acetylcholine production augmentation transmission enhances activator factor treatment disease
acetylcholine production augmentation transmission enhances activator factor treatment disease AD
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease Alzheimer
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease Alzheimer '
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease s
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease AD
choline acetyltransferase activator factor treatment disease Alzheimer
choline acetyltransferase activator factor treatment disease Alzheimer '
choline acetyltransferase activator factor treatment disease s
choline acetyltransferase activator factor treatment disease
choline acetyltransferase activator factor treatment disease AD
scopolamine thunbergiana impairments
scopolamine thunbergiana impairments learning of
scopolamine thunbergiana impairments learning
scopolamine thunbergiana impairments learning and
scopolamine thunbergiana impairments learning memory
daidzein effects investigate thunbergiana impairments
daidzein effects investigate thunbergiana impairments learning of
daidzein effects investigate thunbergiana impairments learning
daidzein effects investigate thunbergiana impairments learning and
daidzein effects investigate thunbergiana impairments learning memory
daidzein Administration shown reverse test scopolamine induced amnesia
acetylcholine biosynthesis role play ameliorates scopolamine amnesia
daidzein play ameliorates scopolamine amnesia
phenobarbital therapy term Hepatonecrosis
PB treated epilepsy
PB one consequence arrest cardiac
PB one consequence arrest
PB other bronchopneumonia
PB diagnosis dysfunction chronic
PB diagnosis dysfunction hepatic
PB diagnosis dysfunction enzyme
PB diagnosis dysfunction
sirolimus mofetil mycophenolate have nephrotoxicity
rapamycin mofetil mycophenolate have nephrotoxicity
mycophenolate have nephrotoxicity
mofetil mycophenolate have nephrotoxicity
adenosine characterization antagonist disease Parkinson
adenosine characterization antagonist disease Parkinson '
adenosine characterization antagonist disease s
adenosine characterization antagonist disease
A A adenosine characterization antagonist disease Parkinson
A A adenosine characterization antagonist disease Parkinson '
A A adenosine characterization antagonist disease s
A A adenosine characterization antagonist disease
2 A adenosine characterization antagonist disease Parkinson
2 A adenosine characterization antagonist disease Parkinson '
2 A adenosine characterization antagonist disease s
2 A adenosine characterization antagonist disease
A adenosine characterization antagonist disease Parkinson
A adenosine characterization antagonist disease Parkinson '
A adenosine characterization antagonist disease s
A adenosine characterization antagonist disease
A antagonist disease Parkinson
A antagonist disease Parkinson '
A antagonist disease s
A antagonist disease
1 antagonist disease Parkinson
1 antagonist disease Parkinson '
1 antagonist disease s
1 antagonist disease
receptor antagonist disease Parkinson
receptor antagonist disease Parkinson '
receptor antagonist disease s
receptor antagonist disease
antagonist disease Parkinson
antagonist disease Parkinson '
antagonist disease s
antagonist disease
adenosine A characterization described antagonist models disease Parkinson
adenosine A characterization described antagonist models disease Parkinson '
adenosine A characterization described antagonist models disease s
adenosine A characterization described antagonist models disease
A characterization described antagonist models disease Parkinson
A characterization described antagonist models disease Parkinson '
A characterization described antagonist models disease s
A characterization described antagonist models disease
2 A A characterization described antagonist models disease Parkinson
2 A A characterization described antagonist models disease Parkinson '
2 A A characterization described antagonist models disease s
2 A A characterization described antagonist models disease
A A characterization described antagonist models disease Parkinson
A A characterization described antagonist models disease Parkinson '
A A characterization described antagonist models disease s
A A characterization described antagonist models disease
A antagonist models disease Parkinson
A antagonist models disease Parkinson '
A antagonist models disease s
A antagonist models disease
1 antagonist models disease Parkinson
1 antagonist models disease Parkinson '
1 antagonist models disease s
1 antagonist models disease
receptor antagonist models disease Parkinson
receptor antagonist models disease Parkinson '
receptor antagonist models disease s
receptor antagonist models disease
antagonist models disease Parkinson
antagonist models disease Parkinson '
antagonist models disease s
antagonist models disease
haloperidol models akinesia
MPTP rotation models akinesia
MPTP rotation models catalepsy
reserpine model catalepsy
6 rat akinesia models catalepsy
hydroxydopamine model models catalepsy
6 hydroxydopamine model models catalepsy
OHDA 6 hydroxydopamine model models catalepsy
reserpine model catalepsy models mouse = 17 has number models disease Parkinson
reserpine model catalepsy models mouse = 17 has number models disease Parkinson '
reserpine model catalepsy models mouse = 17 has number models disease s
reserpine model catalepsy models mouse = 17 has number models disease
MPTP rotation models mouse = 17 has number models disease Parkinson
MPTP rotation models mouse = 17 has number models disease Parkinson '
MPTP rotation models mouse = 17 has number models disease s
MPTP rotation models mouse = 17 has number models disease
haloperidol models mouse = 17 has number models disease Parkinson
haloperidol models mouse = 17 has number models disease Parkinson '
haloperidol models mouse = 17 has number models disease s
haloperidol models mouse = 17 has number models disease
6 rat akinesia models mouse = 17 has number models disease Parkinson
6 rat akinesia models mouse = 17 has number models disease Parkinson '
6 rat akinesia models mouse = 17 has number models disease s
6 rat akinesia models mouse = 17 has number models disease
hydroxydopamine model models mouse = 17 has number models disease Parkinson
hydroxydopamine model models mouse = 17 has number models disease Parkinson '
hydroxydopamine model models mouse = 17 has number models disease s
hydroxydopamine model models mouse = 17 has number models disease
6 hydroxydopamine model models mouse = 17 has number models disease Parkinson
6 hydroxydopamine model models mouse = 17 has number models disease Parkinson '
6 hydroxydopamine model models mouse = 17 has number models disease s
6 hydroxydopamine model models mouse = 17 has number models disease
OHDA 6 hydroxydopamine model models mouse = 17 has number models disease Parkinson
OHDA 6 hydroxydopamine model models mouse = 17 has number models disease Parkinson '
OHDA 6 hydroxydopamine model models mouse = 17 has number models disease s
OHDA 6 hydroxydopamine model models mouse = 17 has number models disease
6 rat akinesia
hydroxydopamine model models akinesia
6 hydroxydopamine model models akinesia
OHDA 6 hydroxydopamine model models akinesia
Gentamicin nephropathy
penicillin gentamicin died failure acute
penicillin gentamicin died failure renal
penicillin gentamicin died failure
gentamicin concentration reached developed anuria
caffeine administration developed patient history disease arrhythmia
caffeine administration developed patient history disease cardiac
caffeine administration developed patient history disease
caffeine tolerated aware potential arrhythmias ventricular
caffeine tolerated aware potential arrhythmias
Carbamazepine induced dysfunction cardiac
Carbamazepine induced dysfunction
carbamazepine associated dysfunction cardiac
carbamazepine associated dysfunction
carbamazepine overdose
carbamazepine used treatment neurologic conditions psychiatric
cyclophosphamide therapy complication cystitis Hemorrhagic
cyclophosphamide therapy complication cystitis
mesna neutralizes metabolite causes cystitis hemorrhagic
mesna neutralizes metabolite causes cystitis
cyclophosphamide metabolite causes cystitis hemorrhagic
cyclophosphamide metabolite causes cystitis
mesna uroprophylaxis received patients two had cystitis hemorrhagic
mesna uroprophylaxis received patients two had cystitis
vitamin C increase women diabetes
C increase women diabetes
vitamin C persons diabetic
C persons diabetic
vitamin C intake promote atherosclerosis
C intake promote atherosclerosis
vitamin intake relation studied women reported diabetic
C intake relation studied women reported diabetic
vitamin intake relation stroke
C intake relation stroke
vitamin intake relation artery coronary
vitamin intake relation artery
vitamin intake relation artery disease
C intake relation artery coronary
C intake relation artery
C intake relation artery disease
vitamin E folate intakes medication type 1 adjustment factors cardiovascular
vitamin E folate intakes medication type 1 adjustment factors disease
E folate intakes medication type 1 adjustment factors cardiovascular
E folate intakes medication type 1 adjustment factors disease
vitamin E folate intakes carotene mortality adjusted risks disease cardiovascular
vitamin E folate intakes carotene mortality adjusted risks disease
E folate intakes carotene mortality adjusted risks disease cardiovascular
E folate intakes carotene mortality adjusted risks disease
beta folate intakes medication type 1 adjustment factors cardiovascular
beta folate intakes medication type 1 adjustment factors disease
carotene intakes medication type 1 adjustment factors cardiovascular
carotene intakes medication type 1 adjustment factors disease
beta folate intakes carotene mortality adjusted risks disease cardiovascular
beta folate intakes carotene mortality adjusted risks disease
carotene mortality adjusted risks disease cardiovascular
carotene mortality adjusted risks disease
vitamin intake quintiles 0 < trend P 1 type medication diabetes
C intake quintiles 0 < trend P 1 type medication diabetes
vitamin intake quintiles 0 < trend P 1 type medication duration diabetes
C intake quintiles 0 < trend P 1 type medication duration diabetes
vitamin E folate intakes medication diabetes
E folate intakes medication diabetes
vitamin E folate intakes medication duration diabetes
E folate intakes medication duration diabetes
folate intakes medication diabetes
folate intakes medication duration diabetes
beta folate intakes medication diabetes
carotene intakes medication diabetes
beta folate intakes medication duration diabetes
carotene intakes medication duration diabetes
folate intakes medication type 1 adjustment factors cardiovascular
folate intakes medication type 1 adjustment factors disease
folate intakes carotene mortality adjusted risks disease cardiovascular
folate intakes carotene mortality adjusted risks disease
vitamin intake associated risk mortality women diabetes
C intake associated risk mortality women diabetes
trihexyphenidyl hydrochloride drug treated patient schizophrenic
hydrochloride drug treated patient schizophrenic
heparin therapy receiving patients thromboembolism
heparin associated complication thromboembolism
heparin therapy complication thromboembolism
heparin therapy initiation days occurring ischemia
heparin therapy initiation days occurring ischemia thrombi
heparin induced aggregation platelet
heparin induced aggregation
heparin factor relating thromboembolism
tachykinins involvement E hyperactivity bladder
tachykinins involvement E hyperactivity
tachykinins release contribute hyperactivity urge bladder
tachykinins release contribute hyperactivity
Prostanoids contribute hyperactivity urge bladder
Prostanoids contribute hyperactivity
flumazenil group nausea pain
azathioprine therapy initiation developed patient polymyositis
azathioprine therapy initiation developed patient patient evidence disease liver
azathioprine therapy initiation developed patient patient evidence disease
cephalosporins associated anemia hemolytic
cephalosporins associated anemia
deferoxamine tocopherol Effect induced neurotoxicity
methamphetamine tocopherol Effect induced neurotoxicity
alpha Effect induced neurotoxicity
tocopherol Effect induced neurotoxicity
Methamphetamine neurotoxicity
MA Methamphetamine neurotoxicity
iron chelator scavenger tocopherol induced neurotoxicity
oxygen species scavenger tocopherol induced neurotoxicity
deferoxamine species scavenger tocopherol induced neurotoxicity
DFO species scavenger tocopherol induced neurotoxicity
MA scavenger tocopherol induced neurotoxicity
alpha effect examined induced neurotoxicity
tocopherol induced neurotoxicity
alpha tocopherol induced neurotoxicity
TC alpha tocopherol induced neurotoxicity
alpha TC attenuated induced hyperthermia
TC attenuated induced hyperthermia
DFO TC attenuated induced hyperthermia
DFO TC ameliorate induced damage neuronal
DFO TC ameliorate induced damage
alpha induced damage neuronal
alpha induced damage
TC ameliorate induced damage neuronal
TC ameliorate induced damage
METH secondary induced hyperactivity
Chloroquine block heart
Chloroquine block
chloroquine ingestion presented deterioration
chloroquine ingestion presented deterioration vision of
chloroquine ingestion presented deterioration vision
chloroquine retinopathy features revealed revealed features failure block heart
chloroquine retinopathy features revealed revealed features failure block
chloroquine discontinuation resolved failure insertion treated block heart
chloroquine discontinuation resolved failure insertion treated block
iohexol iopromide incidence determined compared type presence cyanosis
contrast media CIN incidence determined compared type presence cyanosis
media CIN incidence determined compared type presence cyanosis
CM media CIN incidence determined compared type presence cyanosis
CM type presence cyanosis
iopromide incidence determined compared type presence cyanosis
CM type depends depends presence cyanosis
hepatitis antigen born infants done following screening B rubella
B antigen born infants done following screening B rubella
surface antigen born infants done following screening B rubella
antigen born infants done following screening B rubella
hepatitis antigen immunity rubella
B antigen immunity rubella
surface antigen immunity rubella
antigen immunity rubella
hepatitis antigen administration vaccine rubella
B antigen administration vaccine rubella
surface antigen administration vaccine rubella
antigen administration vaccine rubella
hepatitis antigen born women rubella
B antigen born women rubella
surface antigen born women rubella
antigen born women rubella
Doxorubicin anti agent tumor
Disulfiram induced optic
Disulfiram induced optic and
Disulfiram induced optic neuropathy peripheral
Disulfiram induced optic neuropathy
disulfiram use report management alcohol
disulfiram use report management dependence
disulfiram use report case neuropathy optic
disulfiram use report case neuropathy optic and
disulfiram use report case neuropathy optic peripheral
disulfiram use report case neuropathy
disulfiram taking dependence alcohol
disulfiram taking dependence
trifluoroacetyl adduct protein response detected patients hepatitis
enflurane reactivity cross determine hypersensitivity
halothane induced hypersensitivity
isoflurane enflurane reactivity cross determine hypersensitivity
enflurane produce condition hypersensitivity
halothane hepatitis that similar produce condition hypersensitivity
halothane administration subsequent produce condition hypersensitivity
isoflurane / enflurane produce condition hypersensitivity
cyclophosphamide doxorubicin encapsulated efficacy preserved cardiotoxicity
cyclophosphamide encapsulated efficacy preserved cardiotoxicity
doxorubicin encapsulated efficacy preserved cardiotoxicity
doxorubicin encapsulated efficacy preserved cardiotoxicity
cyclophosphamide doxorubicin encapsulated cyclophosphamide trial cancer breast
cyclophosphamide doxorubicin encapsulated cyclophosphamide trial cancer
cyclophosphamide trial cancer breast
cyclophosphamide trial cancer
doxorubicin encapsulated cyclophosphamide trial cancer breast
doxorubicin encapsulated cyclophosphamide trial cancer
doxorubicin encapsulated cyclophosphamide trial cancer breast
doxorubicin encapsulated cyclophosphamide trial cancer
cyclophosphamide combination Myocet reduces cardiotoxicity
Myocet reduces cardiotoxicity
doxorubicin Myocet reduces cardiotoxicity
doxorubicin cardiotoxicity
cyclophosphamide combination Myocet reduces determine treatment cancer breast
cyclophosphamide combination Myocet reduces determine treatment cancer
cyclophosphamide combination Myocet reduces determine treatment cancer MBC
Myocet reduces determine treatment cancer breast
Myocet reduces determine treatment cancer
Myocet reduces determine treatment cancer MBC
doxorubicin Myocet reduces determine treatment cancer breast
doxorubicin Myocet reduces determine treatment cancer
doxorubicin Myocet reduces determine treatment cancer MBC
doxorubicin cardiotoxicity reduces determine treatment cancer breast
doxorubicin cardiotoxicity reduces determine treatment cancer
doxorubicin cardiotoxicity reduces determine treatment cancer MBC
Myocet m mg m cyclophosphamide toxicity
doxorubicin Myocet m mg m cyclophosphamide toxicity
cyclophosphamide toxicity
cyclophosphamide m receive randomized Two patients MBC
Myocet m mg m receive randomized Two patients MBC
doxorubicin Myocet m mg m receive randomized Two patients MBC
cyclophosphamide used provides improves index doxorubicin reducing neutropenia cardiotoxicity
Myocet improves index doxorubicin reducing neutropenia cardiotoxicity
doxorubicin reducing neutropenia cardiotoxicity
cyclophosphamide used first therapy MBC
Myocet improves provides used first therapy MBC
doxorubicin index improves provides used first therapy MBC
puromycin aminonucleoside rats nephrosis model syndrome nephrotic
puromycin aminonucleoside rats nephrosis model syndrome
aminonucleoside rats nephrosis model syndrome nephrotic
aminonucleoside rats nephrosis model syndrome
puromycin aminonucleoside induced abnormalities hematological
puromycin aminonucleoside induced abnormalities
aminonucleoside induced abnormalities hematological
aminonucleoside induced abnormalities
Puromycin aminonucleoside induced dysfunction hyperlipidemia
aminonucleoside induced dysfunction hyperlipidemia
Puromycin aminonucleoside induced dysfunction renal
Puromycin aminonucleoside induced dysfunction
aminonucleoside induced dysfunction renal
aminonucleoside induced dysfunction
puromycin aminonucleoside induced syndrome nephrotic
puromycin aminonucleoside induced syndrome
aminonucleoside induced syndrome nephrotic
aminonucleoside induced syndrome
LSD abuse history patients schizophrenic
LSD abuse history patients disturbances visual
LSD abuse history patients disturbances
Risperidone disturbances patients schizophrenic
risperidone treated patients had developed EPS
LSD abuse history had patients schizophrenic
LSD abuse history had developed EPS
risperidone treated patients schizophrenic
LSD consumption related flashbacks experienced disturbances visual
LSD consumption related flashbacks experienced disturbances
lometrexol has activity tumours
methotrexate drugs refractory tumours
lometrexol development curtailed toxicities
folic administration prevented toxicity
acid administration prevented toxicity
lometrexol toxicity
folic supplementation confirmed reduced toxicity
acid supplementation confirmed reduced toxicity
folic supplementation reduced toxicity
acid supplementation reduced toxicity
lometrexol study prompted supplementation confirmed reduced toxicity
lometrexol toxicity
folate elevation extent relationship toxicity
folic administration altered indicating unlikely reduce toxicity
acid administration altered indicating unlikely reduce toxicity
lometrexol pharmacokinetics altered indicating unlikely reduce toxicity
lometrexol clearance enhancing reduce toxicity
calcium resuscitation arrest asystolic
calcium resuscitation arrest cardiac
calcium resuscitation arrest
calcium resuscitation arrest overdose
aspirin nitrate g 8 overdose
paracetamol nitrate g 8 overdose
nitrate g 8 overdose
alcohol overdose
isosorbide nitrate g 8 overdose
calcium therapy overdose onset asystole
calcium therapy overdose
Ca L decreases promotes occurrence fibrillation atrial
Ca L decreases promotes occurrence fibrillation
Ca L decreases promotes occurrence fibrillation AF
Ca L decreases promotes BACKGROUND tachycardia Atrial
Ca L decreases promotes BACKGROUND tachycardia
Ca channel promote AF
Ca channel promote AF consistent AF
Ca inhibition effect promoting AF
Ca inhibition effect promoting AF consistent AF
chloralose dogs morphine verapamil administered evaluate mechanisms promotion AF
Ca blockers evaluate mechanisms promotion AF
morphine verapamil administered evaluate mechanisms promotion AF
Diltiazem affect ERP length AF
Diltiazem affect ERP duration AF
diltiazem shared promoting dogs AF
UMB pretreatment - SM convulsions
24 UMB pretreatment - SM convulsions
SM convulsions
21 SM convulsions
13 trial cis acid children neuroblastoma
cis acid children neuroblastoma
retinoic acid children neuroblastoma
acid children neuroblastoma
13 lines neuroblastoma
cis PURPOSE Treatment lines neuroblastoma
retinoic acid cause PURPOSE Treatment lines neuroblastoma
acid cause PURPOSE Treatment lines neuroblastoma
cis acid cause PURPOSE Treatment lines neuroblastoma
RA cis acid cause PURPOSE Treatment lines neuroblastoma
cis effective demonstrated patients neuroblastoma
RA demonstrated patients neuroblastoma
cis pharmacokinetics maximal toxicities
RA pharmacokinetics maximal toxicities
cis pharmacokinetics RA administered neuroblastoma
RA administered neuroblastoma
cis resolved toxicities
RA discontinued resolved toxicities
mitomycin treatment associated failure anemia hemolytic
mitomycin treatment associated failure anemia
C treatment associated failure anemia hemolytic
C treatment associated failure anemia
mitomycin treatment associated failure anemia thrombocytopenia
C treatment associated failure anemia thrombocytopenia
mitomycin treatment start mth 8 develops % failure edema pulmonary
mitomycin treatment start mth 8 develops % failure edema
C treatment start mth 8 develops % failure edema pulmonary
C treatment start mth 8 develops % failure edema
mitomycin C developed died edema pulmonary
mitomycin C developed died edema
C developed died edema pulmonary
C developed died edema
mitomycin C developed failure while thrombocytopenia
C developed failure while thrombocytopenia
mitomycin C developed man adenocarcinoma gastric
mitomycin C developed man adenocarcinoma
C developed man adenocarcinoma gastric
C developed man adenocarcinoma
Ciprofloxacin induced patients cancer
Ciprofloxacin induced nephrotoxicity
ciprofloxacin associated Nephrotoxicity
ciprofloxacin treatment described followed failure developed cancer
echothiophate eye instillation resulting toxicity
iodide eye instillation resulting toxicity
echothiophate drops use developed given diagnosis gravis myasthenia
echothiophate drops use developed given diagnosis gravis
iodide drops use developed given diagnosis gravis myasthenia
iodide drops use developed given diagnosis gravis
levodopa pallidotomy signs parkinsonian
levodopa responsiveness outcome signs parkinsonian
levodopa responsiveness outcome correlations volume dyskinesias signs parkinsonian
levodopa responsiveness value indicate responsible generation signs parkinsonian
ifosfamide prevention mesna dexamethasone Use cystitis hemorrhagic
ifosfamide prevention mesna dexamethasone Use cystitis
dexamethasone Use cystitis hemorrhagic
dexamethasone Use cystitis
mesna dexamethasone Use cystitis hemorrhagic
mesna dexamethasone Use cystitis
ifosfamide chemotherapy effect AIM cystitis Hemorrhagic
ifosfamide chemotherapy effect AIM cystitis
ifosfamide chemotherapy effect AIM cystitis HC
IFS ifosfamide chemotherapy effect AIM cystitis Hemorrhagic
IFS ifosfamide chemotherapy effect AIM cystitis
IFS ifosfamide chemotherapy effect AIM cystitis HC
IFS prevention HC
dexamethasone use investigated mesna prevention HC
mesna prevention HC
IFS HC
Dexamethasone efficient blocking IFS HC
mesna combination Dexamethasone efficient blocking IFS HC
dexamethasone doses all mesna replacement prevent HC
mesna replacement prevent HC
mesna doses all mesna replacement prevent HC
chloride channels blocks rats pretreatment antagonized enhancement adrenaline induced bradycardia
chloride macromolecular benzodiazepine associated sites binding complex blocks rats pretreatment antagonized enhancement adrenaline induced bradycardia
benzodiazepine associated sites binding complex blocks rats pretreatment antagonized enhancement adrenaline induced bradycardia
GABA benzodiazepine associated sites binding complex blocks rats pretreatment antagonized enhancement adrenaline induced bradycardia
picrotoxin dose rats pretreatment antagonized enhancement adrenaline induced bradycardia
chloride complex acts facilitate bradycardia
benzodiazepine chloride complex acts facilitate bradycardia
GABA chloride complex acts facilitate bradycardia
D penicillamine treatment scleroderma localized
D penicillamine treatment scleroderma
penicillamine treatment scleroderma localized
penicillamine treatment scleroderma
D treated reports patients scleroderma localized
D treated reports patients scleroderma
penicillamine summarized reports patients scleroderma localized
penicillamine summarized reports patients scleroderma
D caused developed insufficiency renal
D caused developed insufficiency
Penicillamine caused developed insufficiency renal
Penicillamine caused developed insufficiency
D effective cases scleroderma localized
D effective cases scleroderma
penicillamine D effective cases scleroderma localized
penicillamine D effective cases scleroderma
serotonin inhibitor hydrochloride induced hyperprolactinemia effects model adenomyosis
serotonin inhibitor hydrochloride induced induction adenomyosis
serotonin inhibitor hydrochloride induced hyperprolactinemia
serotonin inhibitor Fluoxetine given produce hyperprolactinemia
methimazole had jaundice
propranolol methimazole had treatment hyperthyroidism
propranolol methimazole had jaundice
methimazole had treatment hyperthyroidism
propranolol methimazole had jaundice itching
Methimazole diagnosed cholestasis
propranolol therapy resumed diagnosed cholestasis
dipivalyl epinephrine glaucoma
epinephrine glaucoma
amphetamine cocaine screening prevalence determine patients seizure
cocaine screening prevalence determine patients seizure
alcohol drug underlying history time seizure
alcohol drug underlying history time seizure
alcohol drug underlying history history abuse cocaine
alcohol drug underlying history history abuse cocaine or
alcohol drug underlying history history abuse cocaine amphetamine
alcohol drug underlying history history abuse
amphetamines cocaine screening patients seizure
cocaine screening patients seizure
verapamil therapy hypotension adrenergic failure developed patients disease ischaemic
verapamil therapy hypotension adrenergic failure developed patients disease heart
verapamil therapy hypotension adrenergic failure developed patients disease
beta verapamil therapy hypotension adrenergic failure developed patients disease ischaemic
beta verapamil therapy hypotension adrenergic failure developed patients disease heart
beta verapamil therapy hypotension adrenergic failure developed patients disease
adrenergic failure developed patients disease ischaemic
adrenergic failure developed patients disease heart
adrenergic failure developed patients disease
blocking developed patients disease ischaemic
blocking developed patients disease heart
blocking developed patients disease
drugs blocking developed patients disease ischaemic
drugs blocking developed patients disease heart
drugs blocking developed patients disease
Thiazide diuretics hypokalemia arrhythmias cardiac
Thiazide diuretics hypokalemia arrhythmias
Thiazide diuretics hypokalemia
thiazide therapy consequence Hypokalemia
hydrochlorothiazide treated patients hypertension diastolic
hydrochlorothiazide treated patients hypertension
HCTC hydrochlorothiazide treated patients hypertension diastolic
HCTC hydrochlorothiazide treated patients hypertension
thiazide diuretics cause hypokalemia
potassium hypokalemia
prazosin blockade 2 rats hypertensive
prazosin treatment alters function control pressure rats hypertensive
rauwolscine treated SHR treated treated hypotension orthostatic
rauwolscine treated SHR treated treated hypotension
prazosin pretreatment determined responses bradycardia
prazosin abolished pressor effects bradycardia
prazosin treatment greater bradycardia
prazosin treatment similar bradycardia
methylprednisolone Value syndrome myalgia
iron dextran infusion associated syndrome myalgia
dextran infusion associated syndrome myalgia
methylprednisolone prevention arthralgia
MP administration demonstrate reduces frequency syndrome myalgia
MP administration demonstrate reduces frequency syndrome arthralgia
Levodopa alleviated dyskinesia choreic dystonic
Levodopa alleviated dyskinesia limbs cases Parkinsonism
levodopa induced lesions course treatment Parkinsonism
levodopa induced lesions thalamic
levodopa induced lesions
bupivacaine antagonist effect impairments cardiovascular
bupivacaine antagonist effect impairments
BN antagonist effect impairments cardiovascular
BN antagonist effect impairments
52021 BN antagonist effect impairments cardiovascular
52021 BN antagonist effect impairments
bupivacaine Administration elicited decrease
bupivacaine Administration elicited decrease pressure of
bupivacaine Administration elicited decrease pressure mean
bupivacaine Administration elicited decrease pressure arterial
bupivacaine Administration elicited decrease pressure blood
bupivacaine Administration elicited decrease pressure
bupivacaine Administration elicited decrease pressure MBP
bupivacaine Administration elicited decrease pressure and
bupivacaine Administration elicited decrease pressure rate heart
bupivacaine Administration elicited decrease pressure rate
bupivacaine Administration elicited decrease pressure HR
bupivacaine administration min suppressed decrease
bupivacaine administration min suppressed decrease MBP of
bupivacaine administration min suppressed decrease MBP
bupivacaine administration min suppressed decrease MBP and
bupivacaine administration min suppressed decrease MBP HR
BN 52021 activating suppressed decrease
BN 52021 activating suppressed decrease MBP of
BN 52021 activating suppressed decrease MBP
BN 52021 activating suppressed decrease MBP and
BN 52021 activating suppressed decrease MBP HR
52021 activating suppressed decrease
52021 activating suppressed decrease MBP of
52021 activating suppressed decrease MBP
52021 activating suppressed decrease MBP and
52021 activating suppressed decrease MBP HR
bupivacaine injected observed reversion decrease
bupivacaine injected observed reversion decrease MBP of
bupivacaine injected observed reversion decrease MBP
bupivacaine injected observed reversion decrease MBP and
bupivacaine injected observed reversion decrease MBP HR
BN injected observed reversion decrease
BN injected observed reversion decrease MBP of
BN injected observed reversion decrease MBP
BN injected observed reversion decrease MBP and
BN injected observed reversion decrease MBP HR
52021 BN injected observed reversion decrease
52021 BN injected observed reversion decrease MBP of
52021 BN injected observed reversion decrease MBP
52021 BN injected observed reversion decrease MBP and
52021 BN injected observed reversion decrease MBP HR
bupivacaine induced toxicity cardiovascular
bupivacaine induced toxicity
BN administration alter demonstrate action bupivacaine induced toxicity cardiovascular
BN administration alter demonstrate action bupivacaine induced toxicity
52021 BN administration alter demonstrate action bupivacaine induced toxicity cardiovascular
52021 BN administration alter demonstrate action bupivacaine induced toxicity
BN action bupivacaine induced toxicity cardiovascular
BN action bupivacaine induced toxicity
52021 BN action bupivacaine induced toxicity cardiovascular
52021 BN action bupivacaine induced toxicity
bupivacaine implicated appears induced alterations cardiovascular
bupivacaine implicated appears induced alterations
benzodiazepine antagonist used reverse depression sedation respiratory
benzodiazepine antagonist used reverse depression
benzodiazepines induced depression sedation respiratory
benzodiazepines induced depression
Flumazenil antagonist used reverse depression sedation respiratory
Flumazenil antagonist used reverse depression
levodopa improving seems improves bradykinesia rigidity
levodopa improving seems improves bradykinesia
propofol sedation underwent dementia
propofol sedation underwent repair hip
propofol sedation underwent repair fracture
propofol sedation use decreased prevalence delirium postoperative
propofol sedation use decreased prevalence delirium
aminoglycoside commonly used provide gram treatment neutropenia febrile
aminoglycoside commonly used provide gram treatment neutropenia
Amikacin used provide gram treatment neutropenia febrile
Amikacin used provide gram treatment neutropenia
aminoglycoside commonly used provide gram treatment neutropenia infections
Amikacin used provide gram treatment neutropenia infections
amikacin conventional randomized patients diagnosis consistent disorder hematologic
amikacin conventional randomized patients diagnosis consistent disorder /
amikacin conventional randomized patients diagnosis consistent disorder oncologic
amikacin conventional randomized patients diagnosis consistent disorder
aminoglycoside required disorder hematologic
aminoglycoside required disorder /
aminoglycoside required disorder oncologic
aminoglycoside required disorder
creatinine increase means nephrotoxicity
catecholamines severity hyperkinesia
catecholamines severity relationship levels psychosis
amphetamine diagnosis service psychiatric
catecholamines relationship patients service psychiatric
catecholamine levels drug assays collected examine relationship patients service psychiatric
cocaine relationship patients service psychiatric
catecholamines symptoms psychotic
catecholamines symptoms
catecholamines relationship examine interviewed psychosis
catecholamine levels drug assays collected examine relationship catecholamines symptoms psychotic
catecholamine levels drug assays collected examine relationship catecholamines symptoms
catecholamine levels drug assays collected examine interviewed psychosis
morphine premedicated patients kg found lasted occurred apnoea
nitrazepam + morphine premedicated patients kg found lasted occurred apnoea
scopolamine morphine premedicated patients kg found lasted occurred apnoea
oxypurines nucleosides ischemia cerebral
oxypurines nucleosides ischemia
nucleosides ischemia cerebral
nucleosides ischemia
oxypurines time observed ischemia
nucleosides oxypurines time observed ischemia
malondialdehyde increased min ischemia
nitroprusside mg w ischemia
nitroprusside mg receiving one model subjected animals groups recorded min ischemia
acetylsalicylate intravenously w mg nitroprusside hypotensive
malondialdehyde recorded groups animals subjected model one receiving mg nitroprusside hypotensive
malondialdehyde higher ischemia min recorded groups animals subjected model one receiving mg nitroprusside hypotensive
acetylsalicylate intravenously w ischemia
acetylsalicylate intravenously w mg receiving one model subjected animals groups recorded min ischemia
malondialdehyde recorded groups animals subjected model one receiving mg w ischemia
malondialdehyde recorded min ischemia
malondialdehyde higher ischemia min recorded groups animals subjected model one receiving mg w ischemia
malondialdehyde higher ischemia
nitroprusside hypotensive
oxypurines malondialdehyde determination used monitor alterations tissues occurring phenomena ischemic
nucleosides malondialdehyde determination used monitor alterations tissues occurring phenomena ischemic
malondialdehyde determination used monitor alterations tissues occurring phenomena ischemic
corticosteroids agents blocking neuromuscular paralysis
nondepolarizing paralysis
neuromuscular paralysis
blocking neuromuscular paralysis
agents blocking neuromuscular paralysis
ND discontinuation weakness developed insufficiency respiratory
ND discontinuation weakness developed insufficiency
NMBAs patients insufficiency respiratory
NMBAs patients insufficiency
corticosteroids due junction pathology due weakness
corticosteroids due junction pathology
corticosteroids due junction at
corticosteroids due junction both
corticosteroids due junction the
corticosteroids due junction neuromuscular
corticosteroids due junction
doxorubicin cycle fibrillation association form dystrophy muscular
doxorubicin cycle fibrillation association form dystrophy
doxorubicin cycle fibrillation association lymphoma gastric
doxorubicin cycle fibrillation association lymphoma
doxorubicin cycle fibrillation association lymphoma dystrophy myotonic
doxorubicin cycle fibrillation association lymphoma dystrophy
ranitidine replaced disappeared developed impotence
cimetidine doses Treatment associated toxicity hepatic
cimetidine doses Treatment associated toxicity hepatic or
cimetidine doses Treatment associated toxicity hepatic hematologic
cimetidine doses Treatment associated toxicity
cimetidine therapy seen level associated associated toxicity hepatic
cimetidine therapy seen level associated associated toxicity hepatic or
cimetidine therapy seen level associated associated toxicity hepatic hematologic
cimetidine therapy seen level associated associated toxicity
creatinine level associated associated toxicity hepatic
creatinine level associated associated toxicity hepatic or
creatinine level associated associated toxicity hepatic hematologic
creatinine level associated associated toxicity
ranitidine cimetidine doses Treatment associated toxicity hepatic
ranitidine cimetidine doses Treatment associated toxicity hepatic or
ranitidine cimetidine doses Treatment associated toxicity hepatic hematologic
ranitidine cimetidine doses Treatment associated toxicity
ranitidine therapy associated associated toxicity hepatic
ranitidine therapy associated associated toxicity hepatic or
ranitidine therapy associated associated toxicity hepatic hematologic
ranitidine therapy associated associated toxicity
corticosteroids respond % cases uveitis
chloroquine used found case drugs attributable chorioretinopathy
corticosteroids used found number cataracts
cibenzoline effects arrhythmias ventricular
cibenzoline effects arrhythmias
cibenzoline + effects examined using models ventricular
cibenzoline + effects examined using models arrhythmia
cibenzoline examined using models ventricular
cibenzoline examined using models arrhythmia
pentobarbital ouabain injection intermittent induced arrhythmia
Na blockers suppressed arrhythmia
Digitalis arrhythmia
Ca blockers suppressed arrhythmia Adrenaline
Ca blockers suppressed arrhythmia
halothane infusion induced arrhythmia Adrenaline
halothane infusion induced arrhythmia
cibenzoline arrhythmias
digitalis cibenzoline arrhythmias
cibenzoline 1 arrhythmias
digitalis arrhythmias
cibenzoline suppressed induced v arrhythmia
cibenzoline - dose needed suppress adrenaline arrhythmias
digitalis induced v arrhythmia
digitalis induced suppressed cibenzoline - dose needed suppress adrenaline arrhythmias
cibenzoline 0 arrhythmia
digitalis arrhythmia
naloxone reversal paralysis respiratory
naloxone reversal paralysis
GABA involvement reversal paralysis respiratory
GABA involvement reversal paralysis
naloxone reversed paralysis respiratory
naloxone reversed paralysis
amino acids any affecting stem produced arrest respiratory
amino acids any affecting stem produced arrest
acids any affecting stem produced arrest respiratory
acids any affecting stem produced arrest
glutamate decrease stem produced arrest respiratory
glutamate decrease stem produced arrest
thiopental produced arrest respiratory
thiopental produced arrest
GABA produced arrest respiratory
GABA produced arrest
Naloxone reversed levels respiratory
Naloxone reversed levels paralysis
glutamate paralysis levels respiratory
glutamate paralysis
GABA paralysis levels respiratory
GABA paralysis
naloxone reverses paralysis respiratory
naloxone reverses paralysis
GABA involves reverses paralysis respiratory
GABA involves reverses paralysis
DA receptors density increases due concentration nicotine develop hyperactivity locomotor
DA receptors density increases due concentration nicotine develop hyperactivity
DA receptor inducing followed nicotine treated develop hyperactivity locomotor
DA receptor inducing followed nicotine treated develop hyperactivity
prostaglandins responses pain
acetic tests plate using evaluated effects administration prostaglandins responses pain
acid tests plate using evaluated effects administration prostaglandins responses pain
pg doses showed effect hyperalgesic
AH blocked blocked effect hyperalgesic
6809 AH blocked blocked effect hyperalgesic
AH blocked hyperalgesia
6809 AH blocked hyperalgesia
Prostaglandin F had effect responses pain
F had effect responses pain
2 alpha F had effect responses pain
alpha F had effect responses pain
heparin products lots number found contaminated derivative elicit response hypotensive
heparin products Using showed produces dose hypotension
glutathione S alpha transferase levels evaluated toxicity Liver
glutathione S alpha transferase levels evaluated toxicity
15 levels measured results steatosis
F levels measured results steatosis
2 t F levels measured results steatosis
t F levels measured results steatosis
IsoP measured results steatosis
15 levels measured IsoP precedes onset necrosis
F levels measured IsoP precedes onset necrosis
2 t F levels measured IsoP precedes onset necrosis
t F levels measured IsoP precedes onset necrosis
IsoP precedes onset necrosis
Topiramate medication becoming more prescribed efficacy treating seizures refractory
Topiramate medication becoming more prescribed efficacy treating seizures
calcium nephrolithiasis
phosphate nephrolithiasis
allopurinol other given described case anemia aplastic
allopurinol other given described case anemia
Loreclezole exerted reducing durations seizure
Hibiscus sinensis extract Effect studied reserpine induced dyskinesia
rosa sinensis extract Effect studied reserpine induced dyskinesia
sinensis extract Effect studied reserpine induced dyskinesia
Hibiscus sinensis had role dyskinesia
rosa sinensis had role dyskinesia
sinensis had role dyskinesia
Ketanserin alfentanil induced rigidity muscle
Ketanserin alfentanil induced rigidity
serotonin antagonist type attenuated produced rigidity muscle
serotonin antagonist type attenuated produced rigidity
ketanserin pretreatment attenuated produced rigidity muscle
ketanserin pretreatment attenuated produced rigidity
Chlordiazepoxide failed influence rigidity
ketanserin received animals motionless absence rigidity
serotonin antagonists useful Pretreatment induced rigidity
serotonin antagonists useful Pretreatment induced necessary assess interaction CNS cardiovascular
serotonin antagonists useful Pretreatment induced necessary assess interaction CNS and
serotonin antagonists useful Pretreatment induced necessary assess interaction CNS depression respiratory
serotonin antagonists useful Pretreatment induced necessary assess interaction CNS depression
epinephrine induced ischemia Mechanisms induced ischemia
epinephrine role examined patients disease coronary
epinephrine role examined patients disease artery
epinephrine role examined patients disease
epinephrine infusion compared signs ischemia
oxygen consumption increasing signs ischemia
epinephrine produced depression angina
epinephrine produced depression
epinephrine volume product rate induced characterized ischemia
epinephrine produced ischemia
caffeine lead stroke
pindolol propranolol inhibiting arrhythmia
propranolol inhibiting arrhythmia
deoxycholic acid hydroxylation sulfation cholestasis
acid hydroxylation sulfation cholestasis
potassium Diuretics disease hypertensive
potassium Diuretics arrhythmias
potassium Diuretics disease coronary
potassium Diuretics disease
potassium changes alter tendency arrhythmias cardiac
potassium changes alter tendency arrhythmias
potassium known hypertension
potassium conserving known hypertension
amiloride conserving known hypertension
potassium known disease coronary
potassium known disease artery
potassium known disease
potassium conserving known disease coronary
potassium conserving known disease artery
potassium conserving known disease
chlorthalidone losing known disease coronary
chlorthalidone losing known disease artery
chlorthalidone losing known disease
amiloride conserving known disease coronary
amiloride conserving known disease artery
amiloride conserving known disease
chlorthalidone losing known hypertension
amiloride treatment associated frequency beats ventricular
amiloride treatment associated frequency beats ectopic
amiloride treatment associated frequency beats
potassium increase patients disease ischaemic
potassium increase patients disease heart
potassium increase patients disease
potassium concentrations avoided falls increase patients disease ischaemic
potassium concentrations avoided falls increase patients disease heart
potassium concentrations avoided falls increase patients disease
N safety butyl deoxynojirimycin zidovudine patients HIV
N safety butyl deoxynojirimycin infection 1
N safety butyl deoxynojirimycin infection
butyl deoxynojirimycin zidovudine patients HIV
butyl deoxynojirimycin infection 1
butyl deoxynojirimycin infection
deoxynojirimycin zidovudine patients HIV
deoxynojirimycin infection 1
deoxynojirimycin infection
SC deoxynojirimycin zidovudine patients HIV
SC deoxynojirimycin infection 1
SC deoxynojirimycin infection
48334 SC deoxynojirimycin zidovudine patients HIV
48334 SC deoxynojirimycin infection 1
48334 SC deoxynojirimycin infection
zidovudine patients HIV
zidovudine deoxynojirimycin infection 1
zidovudine deoxynojirimycin infection
SC level concentration virus immunodeficiency
48334 steady SC level concentration virus immunodeficiency
creatine levels lupus systemic
creatine levels lupus
creatine levels diagnosis erythematosus
chloroquine woman year induced myopathy
cyclophosphamide azathioprine undergone suffering erythematosus involvement renal
cyclophosphamide azathioprine undergone suffering erythematosus involvement
azathioprine undergone suffering erythematosus systemic
azathioprine undergone suffering erythematosus lupus
azathioprine undergone suffering erythematosus
azathioprine undergone suffering erythematosus SLE
azathioprine undergone suffering erythematosus involvement renal
azathioprine undergone suffering erythematosus involvement
cyclophosphamide azathioprine undergone suffering erythematosus systemic
cyclophosphamide azathioprine undergone suffering erythematosus lupus
cyclophosphamide azathioprine undergone suffering erythematosus
cyclophosphamide azathioprine undergone suffering erythematosus SLE
chloroquine therapy started arthralgia
CQ therapy started arthralgia
steroids treated suspected Myositis
chloroquine induced myopathy
aniracetam learning impaired
aniracetam learning
aniracetam learning and
aniracetam learning memory
Ro aniracetam learning impaired
Ro aniracetam learning
Ro aniracetam learning and
Ro aniracetam learning memory
13 Ro aniracetam learning impaired
13 Ro aniracetam learning
13 Ro aniracetam learning and
13 Ro aniracetam learning memory
5057 Ro aniracetam learning impaired
5057 Ro aniracetam learning
5057 Ro aniracetam learning and
5057 Ro aniracetam learning memory
aniracetam effect studied forms functions impaired
aniracetam effect studied forms functions cognitive
aniracetam effect studied forms functions
Ro effect studied forms functions impaired
Ro effect studied forms functions cognitive
Ro effect studied forms functions
13 Ro effect studied forms functions impaired
13 Ro effect studied forms functions cognitive
13 Ro effect studied forms functions
5057 Ro effect studied forms functions impaired
5057 Ro effect studied forms functions cognitive
5057 Ro effect studied forms functions
1 5057 Ro effect studied forms functions impaired
1 5057 Ro effect studied forms functions cognitive
1 5057 Ro effect studied forms functions
anisoyl pyrrolidinone 1 5057 Ro effect studied forms functions impaired
anisoyl pyrrolidinone 1 5057 Ro effect studied forms functions cognitive
anisoyl pyrrolidinone 1 5057 Ro effect studied forms functions
2 pyrrolidinone 1 5057 Ro effect studied forms functions impaired
2 pyrrolidinone 1 5057 Ro effect studied forms functions cognitive
2 pyrrolidinone 1 5057 Ro effect studied forms functions
pyrrolidinone 1 5057 Ro effect studied forms functions impaired
pyrrolidinone 1 5057 Ro effect studied forms functions cognitive
pyrrolidinone 1 5057 Ro effect studied forms functions
chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions impaired
chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions cognitive
chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions
cycloheximide chloramphenicol induced task deficit retrieval response rats exposed sublethal short amnesia
cycloheximide chloramphenicol induced task deficit retrieval response protection amnesia
cycloheximide induced task deficit h late administered prevention applied reversal incapacity learn response rats exposed sublethal short amnesia
cycloheximide induced task deficit h late administered prevention applied reversal incapacity learn response protection amnesia
chloramphenicol induced task deficit retrieval response rats exposed sublethal hypercapnia
chloramphenicol induced task deficit retrieval response learn incapacity reversal applied prevention induced electroshock hypercapnia
scopolamine prevention rats sublethal exposed rats response learn incapacity reversal prevention effects produced studied forms functions impaired
scopolamine prevention rats sublethal exposed rats response learn incapacity reversal prevention effects produced studied forms functions cognitive
scopolamine prevention rats sublethal exposed rats response learn incapacity reversal prevention effects produced studied forms functions
aniracetam effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
aniracetam effect studied produced effects prevention reversal incapacity learn response protection amnesia
Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
13 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
13 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
anisoyl pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
2 pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
1 5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
anisoyl pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
2 pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
aniracetam effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
aniracetam effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
13 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
13 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
anisoyl pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
2 pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
1 5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
anisoyl pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
2 pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
cycloheximide chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions impaired
cycloheximide chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions cognitive
cycloheximide chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions
cycloheximide induced task deficit h late administered prevention applied reversal prevention effects produced studied forms functions impaired
cycloheximide induced task deficit h late administered prevention applied reversal prevention effects produced studied forms functions cognitive
cycloheximide induced task deficit h late administered prevention applied reversal prevention effects produced studied forms functions
cycloheximide chloramphenicol induced task deficit retrieval response rats exposed sublethal hypercapnia
cycloheximide chloramphenicol induced task deficit retrieval response learn incapacity reversal applied prevention induced electroshock hypercapnia
cycloheximide induced task deficit h late administered prevention applied reversal incapacity learn response rats exposed sublethal hypercapnia
cycloheximide induced task deficit h late administered prevention induced electroshock hypercapnia
scopolamine prevention rats sublethal hypercapnia
scopolamine prevention rats sublethal exposed rats response learn incapacity reversal applied prevention induced electroshock hypercapnia
chloramphenicol induced task deficit retrieval response rats exposed sublethal short amnesia
chloramphenicol induced task deficit retrieval response protection amnesia
aniracetam doses seen improvements functions impaired
aniracetam doses seen improvements functions cognitive
aniracetam doses seen improvements functions
fluconazole had cardiomyopathy
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had cardiomyopathy
fluconazole had disease coronary
fluconazole had disease artery
fluconazole had disease
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had disease coronary
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had disease artery
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had disease
fluconazole commencing days developed abscess isolated glabrata woman failure congestive
fluconazole commencing days developed abscess isolated glabrata woman failure heart
fluconazole commencing days developed abscess isolated glabrata woman failure
fluconazole initiation association was abnormalities woman failure congestive
fluconazole initiation association was abnormalities woman failure heart
fluconazole initiation association was abnormalities woman failure
fluconazole discontinued resolved continued nonsustained tachycardia ventricular
fluconazole discontinued resolved continued nonsustained tachycardia
fluconazole discontinued resolved continued nonsustained tachycardia NSVT
fluconazole use relationship indicates resolved continued nonsustained tachycardia ventricular
fluconazole use relationship indicates resolved continued nonsustained tachycardia
fluconazole use relationship indicates resolved continued nonsustained tachycardia NSVT
fluconazole discontinued resolved continued have contractions premature
fluconazole discontinued resolved continued have contractions ventricular
fluconazole discontinued resolved continued have contractions
fluconazole use relationship indicates resolved continued have contractions premature
fluconazole use relationship indicates resolved continued have contractions ventricular
fluconazole use relationship indicates resolved continued have contractions
potassium currents activating depression
fluconazole suggests was etiology explain TDP disappearance NSVT
fluconazole suggests contractions premature
fluconazole suggests contractions ventricular
fluconazole suggests contractions
fluconazole suggests was etiology explain prolongation QT
fluconazole suggests was etiology explain prolongation
fluconazole cause prolongation
fluconazole cause prolongation interval of
fluconazole cause prolongation interval the
fluconazole cause prolongation interval QT
fluconazole cause prolongation interval
fluconazole administered patients risk arrhythmias ventricular
fluconazole administered patients risk arrhythmias
olanzapine treatment introduction developed disorder psychotic
olanzapine treatment introduction developed disorder
lindane Effect s influence lindane induced neurotoxicity
lindane induced neurotoxicity
phenobarbital increased pretreatment produce incidence convulsions
phenobarbital increased incidence convulsions
3 methylcholanthrene pretreatment produce incidence convulsions
methylcholanthrene pretreatment produce incidence convulsions
3 methylcholanthrene pretreatment produce pretreatment increased incidence convulsions
methylcholanthrene pretreatment produce pretreatment increased incidence convulsions
MC methylcholanthrene pretreatment produce incidence convulsions
MC methylcholanthrene pretreatment produce pretreatment increased incidence convulsions
ethanol B P inducer phenobarbital increased pretreatment produce incidence convulsions
ethanol B P inducer phenobarbital increased incidence convulsions
cobalt incidence convulsions
chloride incidence convulsions
cobalt incidence blocked lindane metabolism P increased involved toxicity
chloride incidence blocked lindane metabolism P increased involved toxicity
lindane metabolism P increased involved toxicity
lindane treated animals increased involved toxicity
lindane se indicating lindane treated animals increased involved toxicity
ethanol PB P formed metabolites lindane treated animals increased P metabolism lindane blocked incidence convulsions
ethanol PB P formed metabolites lindane treated animals increased involved toxicity
PTU associated Syndrome Turner
PTU associated Syndrome
PTU associated Syndrome disease Graves
PTU associated Syndrome disease Graves '
PTU associated Syndrome disease
carbamazepine inhibits development seizures
carbamazepine treatment seizures
CBZ treatment seizures
CBZ administration methods evaluated evaluated effects treatment seizures
CBZ inhibited development seizures
CBZ inhibited had effect seizures
CBZ decreased injected incidence seizure
CBZ had effect lidocaine induced seizures
CBZ injection i effect development seizures
CBZ effects suggest stage development seizure
CBZ effects suggest underlie development seizures
sevoflurane induction undergoing arrest child palsy cerebral
sevoflurane induction undergoing arrest child palsy
clonidine undergoing arrest child palsy cerebral
clonidine undergoing arrest child palsy
sevoflurane induction undergoing arrest Cardiac
sevoflurane induction undergoing arrest
baclofen pump placement presented restlessness receiving present case 5 child palsy disorder seizure
baclofen pump placement presented restlessness receiving present case 5 child palsy disorder
clonidine receiving restlessness
baclofen pump placement presented restlessness receiving present case 5 child palsy cerebral
baclofen pump placement presented restlessness receiving present case 5 child palsy
baclofen pump placement presented restlessness
clonidine receiving present case 5 child palsy cerebral
clonidine receiving present case 5 child palsy
clonidine receiving present case 5 child palsy disorder seizure
clonidine receiving present case 5 child palsy disorder
clonidine doses administered reduce anxiety
Heparin BACKGROUND presents thromboemboli arterial
Heparin BACKGROUND presents thromboemboli arterial or
Heparin BACKGROUND presents thromboemboli arterial venous
Heparin BACKGROUND presents thromboemboli
heparin exposure presents thromboemboli arterial
heparin exposure presents thromboemboli arterial or
heparin exposure presents thromboemboli arterial venous
heparin exposure presents thromboemboli
heparin became complications thromboembolic
heparin results Platelet onset thromboembolism
heparin exposure included return complications thromboembolic
heparin thrombocytopenia initiated returns thromboembolism
heparin returns thromboembolism
amlodipine pill started report female hypertension
benazapril report female hypertension
angiotensin converting enzyme angioedema intestinal
angiotensin converting enzyme angioedema
angiotensin blocker enzyme angioedema intestinal
angiotensin blocker enzyme angioedema
prednisone exposure developed lethargy
prednisone exposure developed lethargy polydipsia
prednisone exposure developed lethargy somnolence
prednisone exposure developed lethargy polyuria
prednisone exposure developed lethargy polyphagia
lactate level ketosis
lactate level ketosis present present acidosis lactic
lactate level ketosis present present acidosis
bupropion use associated failure liver
bupropion use associated failure
carbimazole bupropion use associated failure liver
carbimazole bupropion use associated failure
propranolol carbimazole treated man history hyperthyroidism
carbimazole treated man history hyperthyroidism
azelastine treatment rhinitis spring
azelastine treatment rhinitis allergic
azelastine treatment rhinitis
chlorpheniramine azelastine treatment rhinitis spring
chlorpheniramine azelastine treatment rhinitis allergic
chlorpheniramine azelastine treatment rhinitis
Azelastine compared study efficacy safety treatment rhinitis spring
Azelastine compared study efficacy safety treatment rhinitis allergic
Azelastine compared study efficacy safety treatment rhinitis
chlorpheniramine maleate compared study efficacy safety treatment rhinitis spring
chlorpheniramine maleate compared study efficacy safety treatment rhinitis allergic
chlorpheniramine maleate compared study efficacy safety treatment rhinitis
maleate compared study efficacy safety treatment rhinitis spring
maleate compared study efficacy safety treatment rhinitis allergic
maleate compared study efficacy safety treatment rhinitis
Azelastine appears medication rhinitis seasonal
Azelastine appears medication rhinitis allergic
Azelastine appears medication rhinitis
Dopamine plays role control seizures epileptic
Dopamine plays role control seizures
DA Dopamine plays role control seizures epileptic
DA Dopamine plays role control seizures
DA receptors role known occurrence epilepsy
pilocarpine treated analyze occurrence seizures neurotoxicity
acetylcholine glutamate induced seizures
glutamate induced seizures
morphine treated Hyperalgesia patients cancer
morphine doses treated disease stages patients cancer
potassium loss administration patients hypertension
potassium loss hypokalaemia
sodium restriction influence loss administration patients hypertension
sodium restriction influence loss hypokalaemia
chlorthalidone administration patients hypertension
potassium loss investigate performed hypertension
potassium loss hypokalaemia
potassium loss investigate performed hypertension shown hypokalaemia
D Tiopronin due nephritis
Penicillamine D Tiopronin due nephritis
D Tiopronin due nephritis dermatitis
Penicillamine D Tiopronin due nephritis dermatitis
D Tiopronin due due dermatitis
Penicillamine D Tiopronin due due dermatitis
gold thiosulphate due dermatitis due due nephritis
thiosulphate due dermatitis due due nephritis
thiosulphate due dermatitis due due nephritis dermatitis
thiosulphate due dermatitis
Tiopronin group observed patients RA
N effects synthase investigated lidocaine convulsions
nitro effects synthase investigated lidocaine convulsions
L nitro effects synthase investigated lidocaine convulsions
arginine nitro effects synthase investigated lidocaine convulsions
methyl ester effects synthase investigated lidocaine convulsions
ester effects synthase investigated lidocaine convulsions
L ester effects synthase investigated lidocaine convulsions
NAME L ester effects synthase investigated lidocaine convulsions
nitric oxide ester effects synthase investigated lidocaine convulsions
oxide ester effects synthase investigated lidocaine convulsions
NO effects synthase investigated lidocaine convulsions
NO precursor arginine investigated lidocaine convulsions
L inhibitor synthase investigated lidocaine convulsions
arginine investigated lidocaine convulsions
L decreased incidence lidocaine convulsions
NAME decreased incidence lidocaine convulsions
diazepam NAME decreased incidence lidocaine convulsions
L induced convulsions
arginine treatment L induced convulsions
NO mediator convulsions
tamoxifen cancer breast
tamoxifen cancer
Tamoxifen agent cancer breast
Tamoxifen agent cancer
Tamoxifen agent associated development cancer endometrial
Tamoxifen agent associated development cancer
tamoxifen trial randomised have cancer breast
tamoxifen trial randomised have cancer
tamoxifen placebo frequency breast
tamoxifen placebo frequency cancer
tamoxifen receiving women cancer breast
tamoxifen receiving women cancer
tamoxifen receiving women cancer reduction is found cases cancer breast
tamoxifen receiving women cancer reduction is found cases cancer
tamoxifen allocated women case found is reduction cancer breast
tamoxifen allocated women case found is reduction cancer
tamoxifen allocated women case found cases cancer breast
tamoxifen allocated women case found cases cancer
tamoxifen effects apparent has cohort women risk cancer breast
tamoxifen effects apparent has cohort women risk cancer
L patients parkinsonian
dopa overactivation patients parkinsonian
L patients parkinsonian
dopa medication execution task supplementary groups patients parkinsonian
L one medication execution task supplementary groups patients parkinsonian
dopa execution task supplementary groups patients parkinsonian
L movement hyperkinetic
dopa L movement hyperkinetic
thiamine transketolase studied fibroblasts patient developed encephalopathy Wernicke
thiamine transketolase studied fibroblasts patient developed encephalopathy Wernicke '
thiamine transketolase studied fibroblasts patient developed encephalopathy s
thiamine transketolase studied fibroblasts patient developed encephalopathy
thiamine transketolase studied fibroblasts patient diabetic
tolazamide treated encephalopathy developed patient fibroblasts studied delineate transketolase syndrome Km reported Wernicke
tolazamide treated encephalopathy developed patient fibroblasts studied delineate transketolase syndrome Korsakoff
tolazamide treated encephalopathy developed patient fibroblasts studied delineate transketolase syndrome
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient diabetic
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient diabetic
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient diabetic
tolazamide treated encephalopathy developed patient diabetic
thiamine transketolase studied delineate transketolase syndrome Km reported Wernicke
thiamine transketolase studied delineate transketolase syndrome Korsakoff
thiamine transketolase studied delineate transketolase syndrome
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke '
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy s
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke '
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy s
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke '
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy s
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy
thiamine pyrophosphate -RSB- Km reported Wernicke
thiamine pyrophosphate -RSB- Km syndrome Korsakoff
thiamine pyrophosphate -RSB- Km syndrome
pyrophosphate -RSB- Km reported Wernicke
pyrophosphate -RSB- Km syndrome Korsakoff
pyrophosphate -RSB- Km syndrome
TPP -RSB- Km reported Wernicke
TPP -RSB- Km syndrome Korsakoff
TPP -RSB- Km syndrome
TPP Km determined mentioned patient kindreds diabetic
TPP Km determined mentioned history encephalopathy Wernicke
TPP Km determined mentioned history encephalopathy Wernicke '
TPP Km determined mentioned history encephalopathy s
TPP Km determined mentioned history encephalopathy
tolazamide patient syndrome similarity Wernicke
tolazamide patient syndrome Korsakoff
tolazamide patient syndrome
cocaine exposed prenatally dysgenesis Brainstem
cocaine exposed prenatally dysgenesis
serotonin nerves involved effect hypotensive
serotonin cells methyldopa neurons microinjection elicits response hypotensive
methyldopa microinjection caused hypertensive
serotonin group area caused hypotension
serotonin abolished caused hypotension
5 neurotoxin serotonin abolished caused hypotension
7 neurotoxin serotonin abolished caused hypotension
dihydroxytryptamine injected caused hypotension
5 dihydroxytryptamine injected caused hypotension
7 5 dihydroxytryptamine injected caused hypotension
DHT 5 dihydroxytryptamine injected caused hypotension
5 neurotoxin serotonin abolished caused hypertensive stroke
7 neurotoxin serotonin abolished caused hypertensive stroke
dihydroxytryptamine injected caused hypertensive stroke
5 dihydroxytryptamine injected caused hypertensive stroke
7 5 dihydroxytryptamine injected caused hypertensive stroke
DHT 5 dihydroxytryptamine injected caused hypertensive stroke
serotonin group area caused hypertensive
serotonin abolished caused hypertensive
5 neurotoxin serotonin abolished caused hypertensive
7 neurotoxin serotonin abolished caused hypertensive
dihydroxytryptamine injected caused hypertensive
5 dihydroxytryptamine injected caused hypertensive
7 5 dihydroxytryptamine injected caused hypertensive
DHT 5 dihydroxytryptamine injected caused hypertensive
serotonin group area caused hypertensive stroke
serotonin abolished caused hypertensive stroke
methyldopa microinjection caused hypertensive stroke
serotonin projections lesion produce 5 injection affect hypotension
5 injection affect hypotension
7 5 injection affect hypotension
DHT produce 5 injection affect hypotension
serotonin contribute cells mediate hypotension
serotonin contribute action hypotensive
Lamotrigine associated myoclonus epilepsies idiopathic
Lamotrigine associated myoclonus epilepsies generalized
Lamotrigine associated myoclonus epilepsies
lamotrigine exacerbation treated patients epilepsies idiopathic
lamotrigine exacerbation treated patients epilepsies generalized
lamotrigine exacerbation treated patients epilepsies
lamotrigine exacerbation treated patients IGE
LTG exacerbation treated patients epilepsies idiopathic
LTG exacerbation treated patients epilepsies generalized
LTG exacerbation treated patients epilepsies
LTG exacerbation treated patients IGE
Coenzyme treatment ameliorates nephrotoxicity
Q treatment ameliorates nephrotoxicity
10 treatment ameliorates nephrotoxicity
cisplatin nephrotoxicity
coenzyme Q effect investigated injury acute
coenzyme Q effect investigated injury renal
coenzyme Q effect investigated injury
Q effect investigated injury acute
Q effect investigated injury renal
Q effect investigated injury
10 Q effect investigated injury acute
10 Q effect investigated injury renal
10 Q effect investigated injury
nitric oxide alpha elevations factor necrosis
oxide alpha elevations factor necrosis
superoxide activity level mechanisms deficits decreased elevations factor tumor
Coenzyme deficits decreased elevations factor necrosis
Q deficits decreased elevations factor necrosis
10 deficits decreased elevations factor necrosis
cisplatin administration resulted tissue attenuated alpha elevations factor necrosis
reduced level mechanisms deficits decreased elevations factor tumor
glutathione level mechanisms deficits decreased elevations factor tumor
platinum concentration oxide alpha elevations factor necrosis
selenium ions reductions attenuated alpha elevations factor necrosis
zinc selenium ions reductions attenuated alpha elevations factor necrosis
nitric oxide alpha elevations factor tumor
oxide alpha elevations factor tumor
superoxide activity level mechanisms deficits decreased elevations factor necrosis
Coenzyme deficits decreased elevations factor tumor
Q deficits decreased elevations factor tumor
10 deficits decreased elevations factor tumor
cisplatin administration resulted tissue attenuated alpha elevations factor tumor
reduced level mechanisms deficits decreased elevations factor necrosis
glutathione level mechanisms deficits decreased elevations factor necrosis
platinum concentration oxide alpha elevations factor tumor
selenium ions reductions attenuated alpha elevations factor tumor
zinc selenium ions reductions attenuated alpha elevations factor tumor
coenzyme treatment ameliorated damage renal
coenzyme treatment ameliorated damage tissue
coenzyme treatment ameliorated damage
Q treatment ameliorated damage renal
Q treatment ameliorated damage tissue
Q treatment ameliorated damage
10 treatment ameliorated damage renal
10 treatment ameliorated damage tissue
10 treatment ameliorated damage
cisplatin mediated damage renal
cisplatin mediated damage tissue
cisplatin mediated damage
coenzyme Q represents protect nephrotoxicity
Q represents protect nephrotoxicity
10 Q represents protect nephrotoxicity
cisplatin nephrotoxicity
paracetamol Induction tumours bladder
paracetamol Induction tumours bladder and
paracetamol Induction tumours bladder liver
paracetamol Induction tumours
paracetamol developed bladder epithelium Papillomas
paracetamol % treated developed hyperplasia epithelium coincident presence calculi bladder
paracetamol % treated developed hyperplasia epithelium coincident presence calculi
paracetamol feeding arose yield tumours
kainate receptor prodrugs antagonists models pain
formalin reversal models pain
formalin reversal models induced hyperalgesia thermal
formalin reversal models induced hyperalgesia
formalin reversal models induced hyperalgesia mechanical
formalin reversal models induced hyperalgesia
carrageenan licking models pain
capsaicin hyperalgesia induced models pain
carboplatin paclitaxel chemotherapy glioblastoma
paclitaxel chemotherapy glioblastoma
carboplatin paclitaxel application effects feasibility examined recurrences glioblastoma
paclitaxel application effects feasibility examined recurrences glioblastoma
carboplatin paclitaxel phases application resection re underwent total patients recurrence multiforme glioblastoma
paclitaxel phases application resection re underwent total patients recurrence multiforme glioblastoma
tolterodine treatment changes women bladder overactive
tolterodine treatment changes women bladder
tolterodine treatment study bladder overactive
tolterodine treatment study bladder
tolterodine treatment study bladder OAB
Tolterodine tolerated improved OAB
ISO response shows phase hypertrophic
serotonin stimulation HT 1 causes syndrome consists shivering muscle
serotonin stimulation HT 1 causes syndrome consists shivering rigidity
serotonin excess syndrome consists shivering muscle
serotonin excess syndrome consists shivering rigidity
serotonin stimulation HT 1 causes syndrome consists shivering rigidity confusion
serotonin excess syndrome consists shivering rigidity confusion
serotonin stimulation HT 1 causes syndrome consists shivering rigidity salivation
serotonin excess syndrome consists shivering rigidity salivation
serotonin stimulation HT 1 causes syndrome consists shivering rigidity hyperthermia
serotonin excess syndrome consists shivering rigidity hyperthermia
serotonin stimulation HT 1 causes syndrome consists shivering rigidity agitation
serotonin excess syndrome consists shivering rigidity agitation
tranylcypromine depression
venlafaxine y male taking tranylcypromine depression
diazepam i mg F 120 pressure v were remained rigidity muscle
diazepam i mg F 120 pressure v were remained rigidity
22 suppresses inducing dogs failure renal
22 suppresses inducing dogs failure
oxacalcitriol suppresses inducing dogs failure renal
oxacalcitriol suppresses inducing dogs failure
22 suppresses inducing turnover low
22 suppresses inducing turnover bone
22 suppresses inducing turnover
oxacalcitriol suppresses inducing turnover low
oxacalcitriol suppresses inducing turnover bone
oxacalcitriol suppresses inducing turnover
22 suppresses hyperparathyroidism secondary
22 suppresses hyperparathyroidism
oxacalcitriol suppresses hyperparathyroidism secondary
oxacalcitriol suppresses hyperparathyroidism
Calcitriol therapy suppresses patients failure renal
Calcitriol therapy suppresses patients failure
OCT effects determine states function normal impaired
OCT effects determine states function renal
OCT effects determine states function
OCT decreased induction insufficiency renal
OCT decreased induction insufficiency
OCT stabilized long standing hyperparathyroidism secondary
OCT stabilized long standing hyperparathyroidism
OCT reversed formation osteoid woven
OCT reversed formation osteoid
OCT reversed formation osteoid fibrosis
OCT prevent insufficiency renal
OCT prevent insufficiency
OCT prevent use induce turnover low
OCT prevent use induce turnover bone
OCT prevent use induce turnover
OCT prevent use induce increase risk disease adynamic
OCT prevent use induce increase risk disease bone
OCT prevent use induce increase risk disease
OCT prevent use management hyperparathyroidism secondary
OCT prevent use management hyperparathyroidism
Ciprofloxacin induced nephritis anemia autoimmune
Ciprofloxacin induced nephritis anemia hemolytic
Ciprofloxacin induced nephritis anemia
ciprofloxacin case nephritis anemia autoimmune
ciprofloxacin case nephritis anemia hemolytic
ciprofloxacin case nephritis anemia
steroid therapy drug stopping improved anemia Hemolytic
steroid therapy drug stopping improved anemia
trihexyphenidyl relationship examine measures reflecting sedation confusion
trihexyphenidyl relationship investigate examine measures reflecting sedation confusion
cholesteryl esters that remained decreased pre stage nephrotic
esters that remained decreased pre stage nephrotic
fatty acids level stage nephrotic
acids level stage nephrotic
triacylglycerol decreased pre stage nephrotic
oral therapy complications Thromboembolic
contraceptive therapy complications Thromboembolic
Cisapride prescribed treatment disorders gastrointestinal
Cisapride prescribed treatment disorders motility
Cisapride prescribed treatment disorders
diltiazem agent has hypertension
cisapride taking woman year diltiazem agent has hypertension
diltiazem year woman taking cisapride disorder gastroesophageal
diltiazem year woman taking cisapride disorder reflux
diltiazem year woman taking cisapride disorder
cisapride disorder gastroesophageal
cisapride disorder reflux
cisapride disorder
mitomycin C induced study dependency cardiotoxicity
C induced study dependency cardiotoxicity
mitomycin suggested cardiotoxic
C suggested cardiotoxic
MMC C suggested cardiotoxic
doxorubicin given combined cardiotoxic
MMC dose cardiotoxicity
doxorubicin treated patients 2 dose cardiotoxicity
lithium treatment hypothyroidism important development insipidus nephrogenic
lithium treatment hypothyroidism important development insipidus diabetes
lithium treatment hypothyroidism important development insipidus
gentamicin nephrotoxicity prevent glycosuria
Phlorizin prevent glycosuria
Phlorizin prevent nephrotoxicity
gentamicin nephrotoxicity
streptozotocin rats have diuresis glycosuria
gentamicin resistance responsible suggested have diuresis glycosuria
gentamicin resistance responsible suggested have rats streptozotocin mellitus diabetes
gentamicin resistance responsible suggested have rats streptozotocin mellitus
gentamicin resistance responsible suggested have rats streptozotocin DM
streptozotocin rats have suggested failure acute
streptozotocin rats have suggested failure renal
streptozotocin rats have suggested failure
streptozotocin rats have suggested failure ARF
glucose reabsorption blockage induced studied protection nephrotoxicity
glucose reabsorption blockage induced rats diabetic
phlorizin reabsorption blockage induced rats diabetic
P phlorizin reabsorption blockage induced rats diabetic
phlorizin reabsorption blockage induced studied protection nephrotoxicity
P phlorizin reabsorption blockage induced studied protection nephrotoxicity
gentamicin nephrotoxicity
gentamicin nephrotoxicity protection studied induced rats diabetic
P animals that similar rats glycosuria
P animals that similar rats DM
P alone Group received P IV gentamicin DM
P IV gentamicin DM
P + P IV gentamicin DM
gentamicin + P IV gentamicin DM
gentamicin III P IV gentamicin DM
gentamicin DM
gentamicin doses Nephrotoxic
P induced glycosuria evidence dysfunction -RSB- tubular
P induced glycosuria evidence dysfunction -RSB- necrosis
P induced glycosuria
P induced glycosuria evidence dysfunction renal
P induced glycosuria evidence dysfunction
P prevent gentamicin ARF 1 0 001 necrosis tubular
P prevent gentamicin ARF 1 0 001 necrosis
P less 9 001 necrosis tubular
P less 9 001 necrosis
P prevent gentamicin ARF
P less 9 001 0 1 ARF
gentamicin ARF 1 0 001 necrosis tubular
gentamicin ARF 1 0 001 necrosis
P % decrease those different ABSTRACT + 701 day necrosis tubular
P % decrease those different ABSTRACT + 701 day necrosis
ethambutol toxicity
Pemoline choreoathetosis
amphetamines different used treatment disorder attention
amphetamines different used treatment disorder deficit
amphetamines different used treatment disorder
oxazolidine derivative different used treatment disorder attention
oxazolidine derivative different used treatment disorder deficit
oxazolidine derivative different used treatment disorder
Pemoline derivative different used treatment disorder attention
Pemoline derivative different used treatment disorder deficit
Pemoline derivative different used treatment disorder
Pemoline associated literature cause disorders movement
Pemoline associated literature cause disorders
pemoline experienced choreoathetosis
methylphenidate treated disorder attention
methylphenidate treated disorder deficit
methylphenidate treated disorder
benzodiazepines decontamination received attempt control movements choreoathetoid
Pemoline associated reported disorder movement
Pemoline associated reported disorder
pemoline overdose presenting patients considered possibility movements choreoathetoid
vasopressin secretion thirst have showed remained thirsty polyuric
vasopressin secretion thirst have showed evidence insipidus nephrogenic
vasopressin secretion thirst have showed evidence insipidus diabetes
vasopressin secretion thirst have showed evidence insipidus
rifampin proteinuria treated tuberculosis
rifampin treated patients tuberculosis
sodium retention edema
sodium retention accompanied syndrome Nephrotic
sodium retention accompanied syndrome
sodium excretion proteinuria ascites
sodium excretion proteinuria hypoalbuminemia
sodium excretion proteinuria
sodium retention associated syndrome nephrotic
sodium retention associated syndrome
sulphasalazine treatment restarting glomerulonephritis
sulphasalazine treatment restarting developed eyes abnormalities urinary
sulphasalazine treatment restarting developed eyes abnormalities
sulphasalazine treatment restarting developed woman colitis ulcerative
sulphasalazine treatment restarting developed woman colitis
sulphasalazine treatment restarting developed eyes eosinophilia
sulphasalazine treatment restarting developed eyes red
sulphasalazine treatment restarting developed eyes
steroid therapy rose increased initiated resulted fever pain chest
steroid therapy rose increased initiated resulted fever pain
steroid therapy rose increased initiated resulted fever
steroid therapy rose increased initiated resulted fever eyes red
steroid therapy rose increased initiated resulted fever eyes
steroid therapy rose increased initiated resulted fever effusions pleural
steroid therapy rose increased initiated resulted fever effusions
steroid therapy rose increased initiated remained effusion pleural
steroid therapy rose increased initiated remained effusion
sulphasalazine treatment cessation resulted fever pain chest
sulphasalazine treatment cessation resulted fever pain
sulphasalazine treatment cessation resulted fever eyes red
sulphasalazine treatment cessation resulted fever eyes
steroid therapy disappeared effusion pleural
steroid therapy disappeared effusion
sulphasalazine induce PR ANCA glomerulonephritis
prostaglandins factor urine patients bladder overactive
prostaglandins factor urine patients bladder
PGs NGF investigated women OAB
PG NGF correlations parameters patients OAB
PGI different OAB
2 PGI different OAB
PGI alpha correlate parameters patients OAB
2 PGI alpha correlate parameters patients OAB
PGs NGF have roles development symptoms OAB
cyclophosphamide secondary myocarditis haemorrhagic
cyclophosphamide secondary myocarditis
cyclophosphamide therapy complication myocarditis Haemorrhagic
cyclophosphamide therapy complication myocarditis
Iron accumulation considered involved pathogenesis disease Parkinson
Iron accumulation considered involved pathogenesis disease Parkinson '
Iron accumulation considered involved pathogenesis disease s
Iron accumulation considered involved pathogenesis disease
tyrosine immunohistochemistry used study demonstrate detection study degeneration
tyrosine immunohistochemistry used study demonstrate detection study degeneration neurons of
tyrosine immunohistochemistry used study demonstrate detection study degeneration neurons dopaminergic
tyrosine immunohistochemistry used study demonstrate detection study degeneration neurons
iron overload relationship demonstrate detection study degeneration
iron overload relationship demonstrate detection study degeneration neurons of
iron overload relationship demonstrate detection study degeneration neurons dopaminergic
iron overload relationship demonstrate detection study degeneration neurons
iron staining immunohistochemistry used study demonstrate detection study degeneration
iron staining immunohistochemistry used study demonstrate detection study degeneration neurons of
iron staining immunohistochemistry used study demonstrate detection study degeneration neurons dopaminergic
iron staining immunohistochemistry used study demonstrate detection study degeneration neurons
iron content detection study degeneration
iron content detection study degeneration neurons of
iron content detection study degeneration neurons dopaminergic
iron content detection study degeneration neurons
iron level increase SN causes degeneration
iron level increase SN causes degeneration neurons of
iron level increase SN causes degeneration neurons dopaminergic
iron level increase SN causes degeneration neurons
iron causes degeneration
iron causes degeneration neurons of
iron causes degeneration neurons dopaminergic
iron causes degeneration neurons
methylphenidate started depression year man treatment
methylphenidate started depression year resistant
methylphenidate started depression
methylphenidate started depression disease Alzheimer
methylphenidate started depression disease Alzheimer '
methylphenidate started depression disease s
methylphenidate started depression disease
fluvoxamine replaced diminished ensued obsessive
fluvoxamine replaced diminished ensued behavior compulsive
fluvoxamine replaced diminished ensued behavior
lithium resistant polyuria
lithium development required Cyclooxygenase induced polyuria
lithium induced polyuria
prostaglandin synthase induced polyuria
E synthase induced polyuria
lithium resistant / induced concentrating polyuria
PGE mPGES 1 / induced concentrating polyuria
2 PGE mPGES 1 / induced concentrating polyuria
lithium PGE 1 mPGES induced expression polyuria
PGE 1 mPGES induced expression polyuria
2 PGE 1 mPGES induced expression polyuria
everolimus prophylaxis Graft
everolimus prophylaxis versus
everolimus prophylaxis host
everolimus prophylaxis disease
tacrolimus everolimus prophylaxis Graft
tacrolimus everolimus prophylaxis versus
tacrolimus everolimus prophylaxis host
tacrolimus everolimus prophylaxis disease
methotrexate inhibitor prophylaxis graft
methotrexate inhibitor prophylaxis disease versus
methotrexate inhibitor prophylaxis disease host
methotrexate inhibitor prophylaxis disease
methotrexate inhibitor prophylaxis disease GVHD
everolimus combination report undergoing patients syndrome leukemia acute
everolimus combination report undergoing patients syndrome leukemia myeloid
everolimus combination report undergoing patients syndrome leukemia
everolimus combination report undergoing patients syndrome AML
tacrolimus everolimus combination report undergoing patients syndrome myelodysplastic
tacrolimus everolimus combination report undergoing patients syndrome
tacrolimus everolimus combination report undergoing patients syndrome MDS
tacrolimus everolimus combination report undergoing patients syndrome leukemia acute
tacrolimus everolimus combination report undergoing patients syndrome leukemia myeloid
tacrolimus everolimus combination report undergoing patients syndrome leukemia
tacrolimus everolimus combination report undergoing patients syndrome AML
everolimus combination report undergoing patients syndrome myelodysplastic
everolimus combination report undergoing patients syndrome
everolimus combination report undergoing patients syndrome MDS
Pravastatin associated myopathy
pravastatin hypercholesterolemia
pravastatin discontinuation resolved myopathy
simvastatin lovastatin associated myopathy
simvastatin lovastatin associated represent pravastatin myopathy
lovastatin associated myopathy
lovastatin associated represent pravastatin myopathy
pravastatin represent associated myopathy
pravastatin myopathy
PCPA exposure decreased activity irritability
PCPA exposure decreased had effect behavior aggression
5 central speculated prone exhibit behavior aggressive
5 central speculated prone exhibit behavior
HT prone exhibit behavior aggressive
HT prone exhibit behavior
angiotensin failure heart
angiotensin failure
angiotensin failure patients function decreased
angiotensin failure patients function renal
angiotensin failure patients function
angiotensin failure patients function converting therapy results studies dysfunction left
angiotensin failure patients function converting therapy results studies dysfunction ventricular
angiotensin failure patients function converting therapy results studies dysfunction
angiotensin reduces patients failure congestive
angiotensin reduces patients failure heart
angiotensin reduces patients failure
angiotensin reduces patients failure CHF
angiotensin reduces cause function decreased
angiotensin reduces cause function renal
angiotensin reduces cause function
angiotensin prescribed function patients CHF
angiotensin prescribed function quantify predictors reduction
angiotensin prescribed function in
angiotensin prescribed function renal
angiotensin prescribed function
enalapril trial controlled data Studies Dysfunction Left
enalapril trial controlled data Studies Dysfunction Ventricular
enalapril trial controlled data Studies Dysfunction
enalapril trial controlled treatment CHF
creatinine > rise defined function Decreased
creatinine > rise defined function renal
creatinine > rise defined function
diuretic antiplatelet hypertension diabetes
diuretic antiplatelet hypertension
creatinine age pressure history hypertension diabetes
creatinine age pressure history hypertension
diuretic therapy age diabetes
enalapril groups placebo associated age diabetes
enalapril had placebo patients diabetes
Enalapril use caused risk function patients CHF
enalapril group reduced associated Diabetes
enalapril group reduced associated risk impairment patients CHF
NIK 247 drug treatment disease Alzheimer
NIK 247 drug treatment disease Alzheimer '
NIK 247 drug treatment disease s
NIK 247 drug treatment disease
- 247 drug treatment disease Alzheimer
- 247 drug treatment disease Alzheimer '
- 247 drug treatment disease s
- 247 drug treatment disease
247 drug treatment disease Alzheimer
247 drug treatment disease Alzheimer '
247 drug treatment disease s
247 drug treatment disease
adenosine studies suggest suggests effective states hypersensitivity
adenosine formulation volunteers studies suggests effective states hypersensitivity
adenosine studies suggest effective treatment pain acute
adenosine studies suggest effective treatment pain acute and
adenosine studies suggest effective treatment pain acute chronic
adenosine studies suggest effective treatment pain
adenosine formulation volunteers studies suggests suggest effective treatment pain acute
adenosine formulation volunteers studies suggests suggest effective treatment pain acute and
adenosine formulation volunteers studies suggests suggest effective treatment pain acute chronic
adenosine formulation volunteers studies suggests suggest effective treatment pain
adenosine formulation efficacy screen using stimulation hypersensitivity
capsaicin stimulation hypersensitivity
adenosine trial doses 25 2 mg blind studied obtained analysis ratings pain
adenosine trial placebo blind studied obtained analysis ratings pain
adenosine trial doses 25 2 mg blind studied obtained stimuli hyperalgesia mechanical
adenosine trial doses 25 2 mg blind studied obtained stimuli hyperalgesia
adenosine trial doses 25 2 mg blind studied obtained stimuli hyperalgesia allodynia
adenosine trial placebo blind studied obtained stimuli hyperalgesia mechanical
adenosine trial placebo blind studied obtained stimuli hyperalgesia
adenosine trial placebo blind studied obtained stimuli hyperalgesia allodynia
capsaicin injection determined obtained analysis ratings pain
Adenosine produced report pain
Adenosine produced reduced hyperalgesia mechanical
Adenosine produced reduced hyperalgesia
Adenosine produced reduced hyperalgesia allodynia
capsaicin injection reduced produced report pain
adenosine hypersensitivity
capsaicin injection reflect presumed adenosine hypersensitivity
adenosine residence due observed pain neuropathic
adenosine residence due observed pain
penicillin discharges epileptic
penicillin discharges stimulation Effects model epilepsy
penicillin activity epileptic
penicillin activity model epilepsy
penicillin suppressed DBS RESULTS induced independent activity epileptic
doxorubicin both T survivors tumors bone
doxorubicin both T survivors tumors
Rosen treated tumors bone
Rosen treated tumors
' Rosen treated tumors bone
' Rosen treated tumors
s T survivors tumors bone
s T survivors tumors
T survivors tumors bone
T survivors tumors
5 T survivors tumors bone
5 T survivors tumors
or T survivors tumors bone
or T survivors tumors
T protocol T survivors tumors bone
T protocol T survivors tumors
10 protocol T survivors tumors bone
10 protocol T survivors tumors
protocol T survivors tumors bone
protocol T survivors tumors
doxorubicin induced cardiotoxicity
methotrexate accident cerebrovascular
methotrexate accident
methotrexate accident leukaemia
pilocarpine tropicamide administration points size MEASURES impairment
pilocarpine tropicamide administration points size MEASURES impairment recall in
pilocarpine tropicamide administration points size MEASURES impairment recall word
pilocarpine tropicamide administration points size MEASURES impairment recall
tropicamide administration points size MEASURES impairment
tropicamide administration points size MEASURES impairment recall in
tropicamide administration points size MEASURES impairment recall word
tropicamide administration points size MEASURES impairment recall
amiodarone therapy tachycardia fibrillation ventricular
amiodarone therapy tachycardia fibrillation
amiodarone therapy Long efficacy toxicity
amiodarone therapy tachycardia ventricular
amiodarone therapy tachycardia
Amiodarone administered sustained tachycardia ventricular
Amiodarone administered sustained tachycardia
Amiodarone administered sustained tachycardia VT
Amiodarone administered sustained tachycardia arrest cardiac
Amiodarone administered sustained tachycardia arrest
amiodarone continued had recurrence VT fibrillation ventricular
amiodarone continued had recurrence VT fibrillation
amiodarone continued had recurrence VT VF
amiodarone continued had recurrence VT
amiodarone managed had recurrence VT
amiodarone large effective VT VF
amiodarone large effective causes toxicity
amiodarone large effective VT
amiodarone managed % patients VT VF
amiodarone managed % patients VT
Calcium toxicity
carbonate toxicity
calcium corrected hypercalcemia
calcium corrected hypercalcemia presented patients report review literature milk
calcium corrected hypercalcemia presented patients report review literature syndrome alkali
calcium corrected hypercalcemia presented patients report review literature syndrome
1 peptide RESULTS patients had insufficiency alkalosis metabolic
1 peptide RESULTS patients had insufficiency alkalosis
25 RESULTS patients had insufficiency alkalosis metabolic
25 RESULTS patients had insufficiency alkalosis
dihydroxyvitamin D RESULTS patients had insufficiency alkalosis metabolic
dihydroxyvitamin D RESULTS patients had insufficiency alkalosis
D RESULTS patients had insufficiency alkalosis metabolic
D RESULTS patients had insufficiency alkalosis
1 peptide RESULTS patients had insufficiency acute
1 peptide RESULTS patients had insufficiency renal
1 peptide RESULTS patients had insufficiency
25 RESULTS patients had insufficiency acute
25 RESULTS patients had insufficiency renal
25 RESULTS patients had insufficiency
dihydroxyvitamin D RESULTS patients had insufficiency acute
dihydroxyvitamin D RESULTS patients had insufficiency renal
dihydroxyvitamin D RESULTS patients had insufficiency
D RESULTS patients had insufficiency acute
D RESULTS patients had insufficiency renal
D RESULTS patients had insufficiency
calcium concentrations patients received intravenously caused hypocalcemia
Pamidronate treatment associated cases hypercalcemia
sirolimus administration psoriasis
rapamycin sirolimus administration psoriasis
sirolimus administration toxicity
rapamycin sirolimus administration toxicity
sirolimus treatment syndrome developed psoriasis
sirolimus specimen OBSERVATIONS induced leak syndrome 3 fold sirolimus treated psoriasis
sirolimus treated psoriasis
dexamethasone spontaneous exhibit tended psoriasis
sirolimus presence apoptosis Activated patients psoriasis
sirolimus effects include fever
sirolimus effects include fever anemia
midazolam group % occurred Pain
diazepam group patients % occurred Pain
alcohol use needle time Smoking had effect incidence complications venous
alcohol use needle time Smoking had effect incidence complications
alcohol use needle time Smoking pain
nitric oxide type study 1 arteritis
oxide type study 1 arteritis
theophylline fenoldopam induced arteritis 1 study type oxide factor tumor
nitric oxide factor tumor
oxide factor tumor
fenoldopam induced arteritis 1 study type oxide factor tumor
nitric synthase type expressions examined Arteritis
oxide synthase type expressions examined Arteritis
theophylline vasodilators induced Arteritis examined expressions type synthase factor tumor
nitric synthase factor tumor
oxide synthase factor tumor
fenoldopam vasodilators induced Arteritis examined expressions type synthase factor tumor
oxygen species production accompanied failure renal
oxygen species production accompanied failure
oxygen species production accompanied failure causes one Diabetic
oxygen species production accompanied failure causes one nephropathy
streptozotocin induced damage renal
streptozotocin induced damage
crocin L constituents Effects model disease Alzheimer
crocin L constituents Effects model disease Alzheimer '
crocin L constituents Effects model disease s
crocin L constituents Effects model disease
crocins disease Alzheimer
crocins disease Alzheimer '
crocins disease s
crocins disease
crocin attenuated impairment learning
crocin attenuated impairment learning and
crocin attenuated impairment learning memory
crocin attenuated impairment
STZ attenuated impairment learning
STZ attenuated impairment learning and
STZ attenuated impairment learning memory
STZ attenuated impairment
crocin effectiveness demonstrate antagonizing deficits cognitive
crocin effectiveness demonstrate antagonizing deficits
crocin effectiveness demonstrate disease potential treatment diseases neurodegenerative
crocin effectiveness demonstrate disease potential treatment diseases
STZ caused deficits antagonizing demonstrate disease potential treatment diseases neurodegenerative
STZ caused deficits antagonizing demonstrate disease potential treatment diseases
crocin effectiveness demonstrate disease potential treatment diseases Alzheimer
crocin effectiveness demonstrate disease potential treatment diseases Alzheimer '
crocin effectiveness demonstrate disease s
crocin effectiveness demonstrate disease
bethanechol stimulation prevented rats diabetic
ATP stimulation prevented rats diabetic
bethanechol stimulation reversed rats diabetic
ATP stimulation reversed rats diabetic
cocaine use Fatal provide mechanisms toxicity
cocaine toxicity
cocaine registry compared victims overdose
cocaine overdose
benzoylecgonine cocaine concentrations had EDDs
cocaine use disrupts precipitate agitation
cocaine use coupled disrupts precipitate agitation
epsilon associated thrombosis sinus sagittal
epsilon associated thrombosis sinus sagittal and
epsilon associated thrombosis sinus sagittal left
epsilon associated thrombosis sinus transverse
epsilon associated thrombosis sinus
epsilon associated thrombosis
aminocaproic therapy year woman developed thrombosis sinus sagittal
aminocaproic therapy year woman developed thrombosis sinus sagittal and
aminocaproic therapy year woman developed thrombosis sinus sagittal left
aminocaproic therapy year woman developed thrombosis sinus transverse
aminocaproic therapy year woman developed thrombosis sinus
aminocaproic therapy year woman developed thrombosis
acid therapy year woman developed thrombosis sinus sagittal
acid therapy year woman developed thrombosis sinus sagittal and
acid therapy year woman developed thrombosis sinus sagittal left
acid therapy year woman developed thrombosis sinus transverse
acid therapy year woman developed thrombosis sinus
acid therapy year woman developed thrombosis
epsilon associated thrombosis developed woman year therapy menorrhagia
aminocaproic therapy menorrhagia
acid therapy menorrhagia
epsilon treatment reported described thrombosis cerebral
epsilon treatment reported described thrombosis sinus
epsilon treatment reported described thrombosis
aminocaproic acid treatment reported described thrombosis cerebral
aminocaproic acid treatment reported described thrombosis sinus
aminocaproic acid treatment reported described thrombosis
acid treatment reported described thrombosis cerebral
acid treatment reported described thrombosis sinus
acid treatment reported described thrombosis
epsilon treatment reported risk disease thromboembolic
epsilon treatment reported risk disease
aminocaproic acid treatment reported risk disease thromboembolic
aminocaproic acid treatment reported risk disease
acid treatment reported risk disease thromboembolic
acid treatment reported risk disease
desipramine administration induced linking alteration sensitivity convulsions
norepinephrine function induced linking alteration sensitivity convulsions
norepinephrine transporter Alterations function sensitization seizures
desipramine administration increased incidence appearance induced convulsions
desipramine administration increased incidence appearance induced convulsions
desipramine lidocaine administration reversed changes activity convulsive
desipramine administration induced activity convulsive
desipramine administration induced NET regulation relevant sensitization convulsions
desipramine relevant sensitization convulsions
Desipramine have sensitization seizures
ACTH N stimulated axons cause long depression
ACTH N stimulated axons cause long depression synapses resulted duration disorder movement
ACTH N stimulated axons cause long depression synapses resulted duration disorder
lidocaine reduce succinylcholine induced myalgia postoperative
lidocaine reduce succinylcholine induced myalgia
lidocaine pretreatment effect determine undertaken undergoing myalgia
succinylcholine reduction determine undertaken undergoing myalgia
lidocaine proven agent reduction myalgia postoperative
lidocaine proven agent reduction myalgia
steroid developed discontinued induced pressure elevated
steroid developed discontinued induced pressure intraocular
steroid developed discontinued induced pressure
steroid induced seem rise IOP
steroid induced seem rise
L rats Reversal coma
dopa Reversal coma
ammonia coma
Ammonia coma
L dopa prevented coma
- dopa prevented coma
dopa prevented coma
ammonium injection prevented coma
salt injection prevented coma
dopamine infusion prevent coma
dopamine raise sufficient dopamine infusion prevent coma
ammonia coma
ammonia concentrations blood affect prevent coma
L effect eliminated prevented dopa ammonia coma
dopa ammonia coma
ammonia coma
ammonia coma
L coma
dopa reduction prevention coma
dopamine effect accounted reduction prevention coma
ammonia reduction prevention coma
ammonia coma
L receiving patients encephalopathic
dopa L receiving patients encephalopathic
lignocaine dose ranged mg caused neurotoxicity
lignocaine neurotoxicity
cyclophosphamide cytotoxicity restores reduction anemia
cyclophosphamide cytotoxicity
cyclophosphamide cytotoxicity tumors
cyclophosphamide cytotoxicity treatment examine impact prevention anemia
cyclophosphamide cytotoxicity
cyclophosphamide cytotoxicity treatment examine tumors
carboplatin treatment days implanted tumors
carboplatin treatment days implanted tumors DS sarcoma
carboplatin influenced rate tumor
cyclophosphamide dose treated tumors
cyclophosphamide dose treated observed delay regrowth tumors
oxygen supply result increases reduces anemia
oxygen supply result increases correction anemia
cyclophosphamide cytotoxicity reduces anemia
cyclophosphamide cytotoxicity reduces increases correction anemia
cyclophosphamide cytotoxicity
cyclophosphamide tumors
cyclophosphamide cytotoxicity reduces increases result supply tissue tumor
oxygen supply result increases reduces cytotoxicity cyclophosphamide tumors
oxygen supply tissue tumor
oxygen supply result increases reduces cytotoxicity
ribavirin disease adenovirus
ribavirin disease
Ribavirin licensed form treatment infection syncytial respiratory
Ribavirin licensed form treatment infection syncytial
Ribavirin licensed form treatment infection virus
Ribavirin licensed form treatment infection
Ribavirin licensed treat C hepatitis
Ribavirin licensed treat C
ribavirin treatment choice infection
ribavirin treatment choice infection viruses with
ribavirin treatment choice infection viruses hemorrhagic
ribavirin treatment choice infection viruses fever
ribavirin treatment choice infection viruses
ribavirin effect anemia
cidofovir use limited effects nephrotoxicity
cidofovir infection adenovirus
cidofovir infection
ribavirin therapy disease adenovirus
ribavirin therapy disease
ribavirin disease adenovirus
ribavirin disease
ribavirin effective unlikely benefit begun course infection
ribavirin effective disease adenovirus
ribavirin effective disease
ribavirin treated disease adenovirus
ribavirin treated disease
ribavirin trial children required seriousness prevalence disease adenovirus
ribavirin trial children required seriousness prevalence disease
hexamethonium atropine administration reduced induced catalepsy
atropine administration reduced induced catalepsy
mecamylamine atropine administration reduced induced catalepsy
naloxone atropine administration reduced induced catalepsy
hexamethonium atropine injection induced catalepsy
atropine injection induced catalepsy
naloxone atropine injection induced catalepsy
testosterone rats Production cancer prostate
testosterone rats Production cancer
N treatments most tumor
nitroso treatments most tumor
N treatments most tumor
methylurea treatments most tumor
testosterone methylurea treatments most tumor
propionate CAS testosterone methylurea treatments most tumor
TP CAS testosterone methylurea treatments most tumor
TP acted agent tumor
Dexmedetomidine prevents opiate rigidity muscle
Dexmedetomidine prevents opiate rigidity
dexmedetomidine highly capable inducing flaccidity muscle
dexmedetomidine highly capable inducing flaccidity
D highly capable inducing flaccidity muscle
D highly capable inducing flaccidity
MED D highly capable inducing flaccidity muscle
MED D highly capable inducing flaccidity
D MED treatment prevents rigidity muscle
D MED treatment prevents rigidity
- MED treatment prevents rigidity muscle
- MED treatment prevents rigidity
MED treatment prevents rigidity muscle
MED treatment prevents rigidity
D induced rigidity muscle
D induced rigidity
MED D induced rigidity muscle
MED D induced rigidity
D akinetic
MED animals akinetic
D akinetic lacked response startle
MED animals akinetic lacked response startle
Apomorphine therapy disease Parkinson
Apomorphine therapy disease Parkinson '
Apomorphine therapy disease s
Apomorphine therapy disease
Apomorphine used treat symptoms disease Parkinson
Apomorphine used treat symptoms disease Parkinson '
Apomorphine used treat symptoms disease s
Apomorphine used treat symptoms disease
apomorphine administration fluctuating disease Parkinson
apomorphine administration fluctuating disease Parkinson '
apomorphine administration fluctuating disease s
apomorphine administration fluctuating disease
apomorphine infusions associated reductions preexisting levodopa dyskinesias
apomorphine treatment effects related play complications sedation psychiatric
apomorphine treatment fluctuating disease Parkinson
apomorphine treatment fluctuating disease Parkinson '
apomorphine treatment fluctuating disease s
apomorphine treatment fluctuating disease
etoposide containing man factors disease coronary
etoposide containing man factors disease heart
etoposide containing man factors disease
tobramycin netilmicin efficacy toxicity
netilmicin efficacy toxicity
tobramycin sulfate sulfate efficacy compared sodium patients infections
sulfate sulfate efficacy compared sodium patients infections
netilmicin sulfate efficacy compared sodium patients infections
sulfate efficacy compared sodium patients infections
piperacillin sodium patients infections
sodium patients infections
aminoglycoside severe ototoxicity
sodium nitroprusside cent 8 flow increased fenoldopam induced + hypotension
sodium nitroprusside cent 8 flow hypotension
dopamine agonist causes preserves kidney hypotension
N C markers toxicity cardiovascular
N C markers toxicity
terminal brain sensitive C markers toxicity cardiovascular
terminal brain sensitive C markers toxicity
pro brain sensitive C markers toxicity cardiovascular
pro brain sensitive C markers toxicity
brain sensitive C markers toxicity cardiovascular
brain sensitive C markers toxicity
natriuretic peptide brain sensitive C markers toxicity cardiovascular
natriuretic peptide brain sensitive C markers toxicity
peptide brain sensitive C markers toxicity cardiovascular
peptide brain sensitive C markers toxicity
NT peptide brain sensitive C markers toxicity cardiovascular
NT peptide brain sensitive C markers toxicity
proBNP NT peptide brain sensitive C markers toxicity cardiovascular
proBNP NT peptide brain sensitive C markers toxicity
glutamate mRNA Loss containing induced seizures
glutamic mRNA determine used vulnerable seizure
acid mRNA determine used vulnerable seizure
glutamic mRNA determine used vulnerable seizure induced model seizures
acid mRNA determine used vulnerable seizure induced model seizures
cresyl staining methods neuronal
cresyl staining methods degeneration
violet staining methods neuronal
violet staining methods degeneration
cresyl staining studies suggested related loss neuronal
cresyl staining studies suggested related loss
violet staining studies suggested related loss neuronal
violet staining studies suggested related loss
cibenzoline concentrations arrhythmias ventricular
cibenzoline concentrations arrhythmias
cibenzoline effects examined Using two induced arrhythmias ventricular
cibenzoline effects examined Using two induced arrhythmias
cibenzoline effects examined determined concentration model arrhythmia
Cibenzoline suppressed arrhythmias
Cibenzoline suppressed arrhythmias concentrations arrhythmias
cibenzoline had found active given dogs arrhythmia
cibenzoline had hypotensive
cibenzoline had hypotensive effects depressive
estrogen development receptor factor induced mediate tumors pituitary
estrogen development receptor factor induced mediate tumors
estrogen mediate tumors pituitary
estrogen mediate tumors
estrogen development receptor factor initiated angiogenesis tumor
estrogen mediate induced factor initiated angiogenesis tumor
Estrogens associated types cancers
Estrogens induce angiogenesis tumor
estrogen carcinogenesis
estrogen carcinogenesis unknown details induction tumor
estrogen role elucidate regulation angiogenesis tumor
E pituitary expression associated potential tumor
2 pituitary expression associated potential tumor
estrogen induced angiogenesis tumor
pregnenolone sulphate effects amnesic
sulphate effects amnesic
Steroid structure determine anti effects amnesic
PREGS able reverse ligands amnesic
GABA NMDAR effects amnesic
PREGS effects enhancing tested task using model amnesia
PREGS ability demonstrated scopolamine amnesia
levodopa disability reduces stage disease Parkinson
levodopa disability reduces stage disease Parkinson '
levodopa disability reduces stage disease s
levodopa disability reduces stage disease
mannitol gliomas
mannitol lower elevated ICP tumor brain
mannitol lower elevated ICP tumor
mannitol reduce edema brain
mannitol reduce edema
mannitol passage research patients brain
mannitol passage research patients tumor
Mannitol administered had glioma malignant
Mannitol administered had glioma
Mannitol administered had glioma metastases
Mannitol administered had glioma meningioma
mannitol concentrations higher patients glioma
mannitol concentrations higher patients meningioma metastases
mannitol concentrations higher patients meningioma
mannitol leak BBB gliomas
mannitol leak reversing edema
corticosteroids doses treated patients occur myopathy
steroid showed reduction
steroid showed reduction intake of
steroid showed reduction intake food
steroid showed reduction intake
M longer was similar tensions tetanic
steroid groups prolonged was similar tensions tetanic
steroid groups IIa showed revealed absence necrosis
steroid groups IIa atrophy
steroid groups IIa atrophy
T showed revealed absence necrosis
steroids induced respiratory types steroids induced atrophy
steroids induced atrophy
steroid caused conclude contractile treatment doses steroids induced respiratory types steroids induced atrophy
steroids doses treatment contractile conclude caused necrosis
steroids types respiratory induced steroids doses treatment contractile conclude caused necrosis
steroid caused necrosis
steroids doses treatment contractile conclude caused atrophy
steroids types respiratory induced steroids doses treatment contractile conclude caused atrophy
steroid caused conclude caused atrophy
NMDA receptors mediated neurotransmission modulate haloperidol induced catalepsy
amino acid influence mechanisms IC catalepsy
acid influence mechanisms IC catalepsy
dopamine haloperidol induced catalepsy
glutamate antagonists microinjections challenged catalepsy
MK antagonists microinjections challenged catalepsy
801 MK antagonists microinjections challenged catalepsy
NMDA antagonists microinjections challenged catalepsy
NMDA N 0 mmol 0 15 801 MK antagonists microinjections challenged catalepsy
N 0 mmol 0 15 801 MK antagonists microinjections challenged catalepsy
methyl 0 15 801 MK antagonists microinjections challenged catalepsy
d 0 15 801 MK antagonists microinjections challenged catalepsy
aspartate NMDA d 0 15 801 MK antagonists microinjections challenged catalepsy
NMDA d 0 15 801 MK antagonists microinjections challenged catalepsy
AP 0 mmol 0 15 801 MK antagonists microinjections challenged catalepsy
7 AP 0 mmol 0 15 801 MK antagonists microinjections challenged catalepsy
MK microinjection showed attenuated catalepsy
801 previous attenuated catalepsy
AP 7 801 previous attenuated catalepsy
7 801 previous attenuated catalepsy
glutamate induced catalepsy
acetazolamide induced confusion reaction patients impairment renal
acetazolamide induced confusion reaction patients impairment
acetazolamide induced confusion
azithromycin beginning treatment pharyngitis
methylprednisolone dexamethasone Corticosteroids agents mentioned associated development hiccups
dexamethasone Corticosteroids agents mentioned associated development hiccups
midazolam benzodiazepines Corticosteroids agents mentioned associated development hiccups
benzodiazepines Corticosteroids agents mentioned associated development hiccups
macrolide antimicrobials related reported hiccups
macrolides reaction reports possible absence explanation hiccups
macrolide antimicrobials reported associated hiccups
S correlates psychosis
ketamine psychosis
N D aspartate implicated pathophysiology schizophrenia
methyl D aspartate implicated pathophysiology schizophrenia
D aspartate implicated pathophysiology schizophrenia
aspartate implicated pathophysiology schizophrenia
NMDA aspartate implicated pathophysiology schizophrenia
NMDA ketamine non dose leads psychopathological similar those observed schizophrenia
ketamine non dose leads psychopathological similar those observed schizophrenia
ketamine exacerbates supporting hypothesis dysfunction glutamatergic
ketamine exacerbates supporting hypothesis dysfunction
ketamine exacerbates patients schizophrenia
Ketamine induces similar those observed patients schizophrenia
NMDA dysfunction pathophysiology schizophrenia
glycine antagonist 7 5 decreased haloperidol rigidity muscle
glycine antagonist 7 5 decreased haloperidol rigidity
5 decreased haloperidol rigidity muscle
5 decreased haloperidol rigidity
7 5 decreased haloperidol rigidity muscle
7 5 decreased haloperidol rigidity
dichlorokynurenic acid 7 5 decreased haloperidol rigidity muscle
dichlorokynurenic acid 7 5 decreased haloperidol rigidity
acid 7 5 decreased haloperidol rigidity muscle
acid 7 5 decreased haloperidol rigidity
5 acid 7 5 decreased haloperidol rigidity muscle
5 acid 7 5 decreased haloperidol rigidity
7 5 acid 7 5 decreased haloperidol rigidity muscle
7 5 acid 7 5 decreased haloperidol rigidity
DCKA 5 acid 7 5 decreased haloperidol rigidity muscle
DCKA 5 acid 7 5 decreased haloperidol rigidity
Valsartan antagonist treatment hypertension
angiotensin antagonist treatment hypertension
II antagonist treatment hypertension
amlodipine efficacy study Valsartan antagonist treatment hypertension
valsartan receive allocated outpatients hypertension
amlodipine valsartan receive allocated outpatients hypertension
valsartan amlodipine treatment hypertension
amlodipine treatment hypertension
levofloxacin treatment sinusitis
levofloxacin efficacy evaluate treating sinusitis
levofloxacin mg treatment sinusitis
cAMP aggregation platelet
cAMP aggregation
ifosfamide induced cystitis hemorrhagic
ifosfamide induced cystitis
mesna administration subcutaneous prevent ifosfamide induced cystitis hemorrhagic
mesna administration subcutaneous prevent ifosfamide induced cystitis
ifosfamide toxicity cystitis Hemorrhagic
ifosfamide toxicity cystitis
mesna administering prevented toxicity
ifosfamide toxicity
mesna administering prevented toxicity cystitis Hemorrhagic
mesna administering prevented toxicity cystitis
mesna concentrations risk emesis
mesna taking patient emesis
ifosfamide experiences mesna taking patient emesis
fluorouracil underwent cancer colorectal
fluorouracil underwent cancer
catecholamines levels contributed development ABS
catecholamines neuropeptides caused diagnosis cancer
prazosin antagonized rigidity muscular
prazosin antagonized rigidity
iodixanol osmolar study comparing effects nephrotoxic
creatinine concentrations involved diabetes
iodixanol used patients high develop likely CONCLUSIONS Nephropathy
isoproterenol demand hypotension
oxygen supply mismatch vs unknown damage myocardial
oxygen supply mismatch vs unknown damage
oxygen supply mismatch vs unknown demand hypotension hyperactivity myocardial
oxygen supply mismatch vs unknown demand hypotension hyperactivity
oxygen supply mismatch vs unknown demand hypotension
vincristine treated Lymphoma patients Non
vincristine treated Lymphoma Hodgkin
vincristine treated Lymphoma Hodgkin '
vincristine treated Lymphoma s
vincristine treated Lymphoma
vincristine effects evaluate investigated patients Non
vincristine effects evaluate investigated patients Lymphoma Hodgkin
vincristine effects evaluate investigated patients Lymphoma Hodgkin '
vincristine effects evaluate investigated patients Lymphoma s
vincristine effects evaluate investigated patients Lymphoma
vincristine dose reversible signs neuropathy
vincristine neuropathy
fluocinolone implants treated pressure patients uveitis
acetonide implants treated pressure patients uveitis
fluocinolone implant treated uveitis
acetonide implant treated uveitis
FA implant treated uveitis
diatrizoate fibrillation Ventricular
diatrizoate fibrillation
Renografin toxicity
76 % Renografin toxicity
% Renografin toxicity
Hypaque that compared toxicity
76 % Hypaque that compared toxicity
% Hypaque that compared toxicity
Renografin occurred suggesting contribute toxicity
Renografin occurred fibrillation Ventricular
Renografin occurred fibrillation
carteolol hydrochloride effect induced catalepsy
hydrochloride effect induced catalepsy
propranolol those studied effects carteolol beta induced catalepsy
biperiden propranolol those studied effects carteolol beta induced catalepsy
carteolol beta induced catalepsy
propranolol Carteolol inhibited haloperidol induced catalepsy
biperiden propranolol Carteolol inhibited haloperidol induced catalepsy
Carteolol inhibited haloperidol induced catalepsy
dopamine receptor evoke stimulating signs stereotypy hyperlocomotion
Carteolol evoke stimulating signs stereotypy hyperlocomotion
haloperidol induced adrenoceptor expected effective treatment akathisia
carteolol improves haloperidol induced catalepsy
dopamine activity due induced induced adrenoceptor expected effective treatment akathisia
carteolol improves haloperidol induced adrenoceptor expected effective treatment akathisia
dopamine activity due induced induced catalepsy
corticosterone effects related Dose induced neuropathy
organophosphorus related Dose induced neuropathy
corticosterone concentrations induced neuropathy
TOTP % hr 24 Neurotoxic
organophosphorous compounds chickens measured values % hr 24 Neurotoxic
DFP TOTP % hr 24 Neurotoxic
tris administration shown protect effects hepatotoxic
salt administration shown protect effects hepatotoxic
CS administration shown protect effects hepatotoxic
cholesteryl administration shown protect effects hepatotoxic
hemisuccinate administration shown protect effects hepatotoxic
carbon tetrachloride adriamycin non toxicity
tetrachloride adriamycin non toxicity
gamma form non toxicity
cholesteryloxybutyric acid gamma form non toxicity
acid gamma form non toxicity
adriamycin non toxicity
CS cytoprotection mechanism understanding further examined abilities non toxicity
CS abilities non toxicity
CS form non toxicity
tris salt form non toxicity
salt form non toxicity
CSE salt form non toxicity
galactosamine chloroform toxicity
chloroform toxicity
acetaminophen salt form non toxicity
CS dose resulted protection effects hepatotoxic
adriamycin administration effect pretreatment pretreatment dose resulted protection effects hepatotoxic
CHCl CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
3 CHCl CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
acetaminophen CHCl CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
4 CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
galactosamine CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
CS dose pretreatment pretreatment effect cardiotoxic
CS protection mechanism appear dependent reactive intermediate light protection observed hepatotoxicity
edaravone effect vestibulotoxicity
edaravone induced vestibulotoxicity
Edaravone has used treat infarction cerebral
Edaravone has used treat infarction
edaravone suppresses streptomycin induced vestibulotoxicity
misoprostol effect induced dysfunction renal
misoprostol effect induced dysfunction
misoprostol Addition minimize affecting control pain
misoprostol Addition minimize impairment renal
misoprostol Addition minimize impairment
ketoconazole gentamicin administration aggravate toxicity
gentamicin administration aggravate toxicity
amphothericin B gentamicin administration potential nephrotoxic
B gentamicin administration potential nephrotoxic
CSA administration aggravate toxicity
CSA toxicity
amphothericin B gentamicin administration aggravate toxicity
B gentamicin administration aggravate toxicity
ketoconazole gentamicin administration potential nephrotoxic
gentamicin administration potential nephrotoxic
Gentamicin increased nephrotoxicity
Tiapride movements involuntary
Tiapride movements
metoclopramide related derivative Tiapride induced disease Parkinson idiopathic
metoclopramide related derivative Tiapride induced disease Parkinson
metoclopramide related derivative Tiapride induced disease Parkinson '
metoclopramide related derivative Tiapride induced disease s
metoclopramide related derivative Tiapride induced disease
Tiapride induced movements involuntary
Tiapride induced movements
metoclopramide related derivative Tiapride induced movements involuntary
metoclopramide related derivative Tiapride induced movements
levodopa Tiapride induced disease Parkinson idiopathic
levodopa Tiapride induced disease Parkinson
levodopa Tiapride induced disease Parkinson '
levodopa Tiapride induced disease s
levodopa Tiapride induced disease
benzamide derivative Tiapride induced movements involuntary
benzamide derivative Tiapride induced movements
Tiapride induced disease Parkinson idiopathic
Tiapride induced disease Parkinson
Tiapride induced disease Parkinson '
Tiapride induced disease s
Tiapride induced disease
benzamide derivative Tiapride induced disease Parkinson idiopathic
benzamide derivative Tiapride induced disease Parkinson
benzamide derivative Tiapride induced disease Parkinson '
benzamide derivative Tiapride induced disease s
benzamide derivative Tiapride induced disease
Tiapride had effect period dystonia
levodopa effect period dystonia
dopamine receptors group overstimulation caused levodopa dyskinesias
ASA administered strains Dawley Sprague results compare test confounds toxicity gastrointestinal
ASA administered strains Dawley Sprague results compare test confounds toxicity
ASA malformations detection confounds toxicity gastrointestinal
ASA malformations detection confounds toxicity
ASA induces focused suggested induce defects defects midline
ASA induces focused suggested induce defects defects
ASA induces focused suggested induce defects defects MDs
ASA induces focused suggested induce defects defects rats MDs
benzodiazepine lorazepam controlled Akathisia
lorazepam controlled Akathisia
oxygen saturations range % mean associated incidence bradycardia
sulindac difluoromethylornithine trial audiograms prevention adenomas colorectal
sulindac difluoromethylornithine trial audiograms prevention adenomas
difluoromethylornithine trial audiograms prevention adenomas colorectal
difluoromethylornithine trial audiograms prevention adenomas
difluoromethylornithine months treatment assessed recurrence polyps adenomatous
difluoromethylornithine months treatment assessed recurrence polyps
DFMO difluoromethylornithine months treatment assessed recurrence polyps adenomatous
DFMO difluoromethylornithine months treatment assessed recurrence polyps
sulindac assessed recurrence polyps adenomatous
sulindac assessed recurrence polyps
DFMO treatment toxicity
DFMO treatment toxicity loss hearing
DFMO treatment toxicity loss
DFMO subjects proportion difference group experienced loss hearing
DFMO subjects proportion difference group experienced loss
alcohol use interval men interval suffer fever hay
alcohol use interval men interval suffer fever
alcohol use interval men interval suffer fever asthma
ibuprofen agents use age history gout
ibuprofen agents use age preexisting disease renal
ibuprofen agents use age preexisting disease
ibuprofen agents use age history stones kidney
ibuprofen agents use age history stones
KF administration ameliorated responses cataleptic
17837 KF administration ameliorated responses cataleptic
adenosine administration agonist manner induced responses cataleptic
KF 17837 reduced catalepsy
17837 reduced catalepsy
KF 17837 drug treatment parkinsonism
17837 drug treatment parkinsonism
Serotonin gene psychosis
serotonin receptor targeted HT amphetamine induced hyperactivity
5 serotonin receptor targeted HT amphetamine induced hyperactivity
HT 5 serotonin receptor targeted HT amphetamine induced hyperactivity
5 use corrected rats induced hyperactivity
HT amphetamine induced hyperactivity
olanzapine clozapine such targeted HT amphetamine induced hyperactivity
d targeted HT amphetamine induced hyperactivity
amphetamine induced hyperactivity
clozapine such targeted HT amphetamine induced hyperactivity
5 altered suggests considered reflect symptoms schizophrenia
HT receptors involved considered reflect symptoms schizophrenia
5 altered suggests considered involved pathophysiology disorders psychotic
5 altered suggests considered involved pathophysiology disorders
HT receptors involved pathophysiology disorders psychotic
HT receptors involved pathophysiology disorders
methamphetamine symptoms similar those schizophrenia paranoid
methamphetamine symptoms similar those schizophrenia type
methamphetamine symptoms similar those schizophrenia
METH methamphetamine symptoms similar those schizophrenia paranoid
METH methamphetamine symptoms similar those schizophrenia type
METH methamphetamine symptoms similar those schizophrenia
5 induced psychosis
HT gene 5 induced psychosis
ketamine Injections produced depression
dopamine receptors induce catalepsy
dopamine antagonists induced catalepsy
dopamine antagonists induced catalepsy tested determined subtypes involved catalepsy
dopamine subtypes determined tested catalepsy
dopamine subtypes involved catalepsy
Dopamine fluphenazine sulpiride induced catalepsy
SKF 38393 D decreased catalepsy
38393 D decreased catalepsy
quinpirole decreased catalepsy
SKF Combination cause catalepsy
38393 SKF Combination cause catalepsy
quinpirole Combination cause catalepsy
dopamine antagonists induced catalepsy
isoflurane exposure Acute hepatitis cholestatic
isoflurane exposure Acute hepatitis
isoflurane exposure hepatitis cholestatic
isoflurane exposure hepatitis
dipyrone analgesia
Isoflurane cause hepatitis cholestatic
Isoflurane cause hepatitis
metoprolol Effect glucagon induced ischemia myocardial
metoprolol Effect glucagon induced ischemia
metoprolol metoprolol Effect glucagon induced ischemia myocardial
metoprolol metoprolol Effect glucagon induced ischemia
metoprolol attenuates evidence ischemia myocardial
metoprolol attenuates evidence ischemia
epinephrine mepivacaine seen addition damage muscle
epinephrine mepivacaine seen addition damage
lithium toxicity regurgitation Tricuspid
lithium toxicity regurgitation valve
lithium toxicity regurgitation
carbonate toxicity regurgitation Tricuspid
carbonate toxicity regurgitation valve
carbonate toxicity regurgitation
lithium toxicity
carbonate toxicity
lithium level newborn regurgitation failure congestive
lithium level newborn regurgitation failure heart
lithium level newborn regurgitation failure
lithium level newborn regurgitation tricuspid
lithium level newborn regurgitation
lithium level newborn regurgitation flutter atrial
lithium level newborn regurgitation flutter
lithium compounds exposed infants described disease cardiac
lithium compounds exposed infants described disease
lithium compounds exposed infants described patient manifest regurgitation tricuspid
lithium compounds exposed infants described patient manifest regurgitation
lithium compounds exposed infants described patient manifest regurgitation flutter atrial
lithium compounds exposed infants described patient manifest regurgitation flutter
Lithium carbonate factor incidence disease congenital
Lithium carbonate factor incidence disease heart
Lithium carbonate factor incidence disease
carbonate factor incidence disease congenital
carbonate factor incidence disease heart
carbonate factor incidence disease
thallium correlation severity stenosis coronary
thallium correlation severity stenosis
dipyridamole had 12 dogs stenosis coronary
dipyridamole had 12 dogs stenosis
Thallium induced hyperemia
valdecoxib placebo events patients arthritis
valdecoxib placebo events thrombotic
valdecoxib data arthritis rheumatoid
valdecoxib data arthritis
valdecoxib data inhibitor patients osteoarthritis
diclofenac bid NSAID valdecoxib data osteoarthritis
naproxen bid bid NSAID valdecoxib trials rheumatoid
naproxen bid bid NSAID valdecoxib trials arthritis
valdecoxib trials rheumatoid
valdecoxib trials arthritis
ibuprofen tid bid NSAID valdecoxib analyzing determined incidence events thrombotic
ibuprofen tid bid NSAID valdecoxib analyzing determined incidence cardiac thrombotic
ibuprofen tid bid NSAID valdecoxib trials rheumatoid
ibuprofen tid bid NSAID valdecoxib trials arthritis
diclofenac bid NSAID valdecoxib trials rheumatoid
diclofenac bid NSAID valdecoxib trials arthritis
valdecoxib data osteoarthritis
ibuprofen tid bid NSAID valdecoxib data osteoarthritis
naproxen bid bid NSAID valdecoxib data osteoarthritis
valdecoxib analyzing determined incidence events thrombotic
valdecoxib analyzing determined incidence cardiac thrombotic
naproxen bid bid NSAID valdecoxib analyzing determined incidence events thrombotic
naproxen bid bid NSAID valdecoxib analyzing determined incidence cardiac thrombotic
diclofenac bid NSAID valdecoxib analyzing determined incidence events thrombotic
diclofenac bid NSAID valdecoxib analyzing determined incidence cardiac thrombotic
valdecoxib similar Crude incidences events thrombotic
valdecoxib dose similar risk events thrombotic
valdecoxib aspirin nonusers higher risk Thrombotic
valdecoxib doses therapeutic treatment associated incidence events patients rheumatoid
valdecoxib doses therapeutic treatment associated incidence events patients arthritis
valdecoxib doses therapeutic treatment associated incidence events osteoarthritis
valdecoxib doses therapeutic treatment associated incidence events thrombotic
bromocriptine received inhibition
bromocriptine received inhibition lactation of
bromocriptine received inhibition lactation
bromocriptine received seen patients history psychiatric
Bromocriptine associated psychosis patients receiving drug disease Parkinson
Bromocriptine associated psychosis patients receiving drug disease Parkinson '
Bromocriptine associated psychosis patients receiving drug disease s
Bromocriptine associated psychosis patients receiving drug disease
nitric oxide levels gene headache patients tension
nitric oxide levels gene type
nitric oxide levels gene type headache
oxide levels gene headache patients tension
oxide levels gene type
oxide levels gene type headache
nitric oxide induced headache headaches primary
nitric oxide induced headache headaches
oxide induced headache headaches primary
oxide induced headache headaches
NO oxide induced headache headaches primary
NO oxide induced headache headaches
NO donor glyceryl trinitrate induced patients tension
NO donor glyceryl trinitrate induced headache headache type
NO donor glyceryl trinitrate induced headache headache
glyceryl trinitrate induced patients tension
glyceryl trinitrate induced headache headache type
glyceryl trinitrate induced headache headache
trinitrate induced patients tension
trinitrate induced headache headache type
trinitrate induced headache headache
GTN trinitrate induced patients tension
GTN trinitrate induced headache headache type
GTN trinitrate induced headache headache
Levodopa induced dystonia palsy progressive
Levodopa induced dystonia palsy supranuclear
Levodopa induced dystonia palsy
Levodopa induced reported disease atrophy multiple
Levodopa induced reported disease atrophy system
Levodopa induced reported disease atrophy
Levodopa induced reported disease Parkinson
Levodopa induced reported disease Parkinson '
Levodopa induced reported disease s
Levodopa induced reported disease
Levodopa induced reported dyskinesias
levodopa case describe dystonia patient PSP
levodopa case describe highlight importance recognizing complication management PSP
levodopa case describe dystonia Oromandibular
levodopa case describe dystonia
levodopa case describe dystonia OMD
VPA treatment tonic
VPA convulsions clonic
VPA convulsions
VPA administration consider result combination factors weakness
VPA administration consider result combination factors weakness system of
VPA administration consider result combination factors weakness system the
VPA administration consider result combination factors weakness system central
VPA administration consider result combination factors weakness system nervous
VPA administration consider result combination factors weakness system
furosemide effect nephropathy
furosemide efficacy determine fluids prevention nephropathy
creatinine rise pretreated function Renal
creatinine rise pretreated function
creatinine rise pretreated function deteriorated significantly
creatinine rise pretreated function deteriorated
furosemide associated failure Renal
furosemide associated failure
furosemide associated loss weight
furosemide associated loss
Furosemide deleterious prevention nephropathy
amphetamine cocaine use stroke hemorrhagic ischemic
cocaine use stroke hemorrhagic ischemic
Pyrazinamide have effects disorders toxicity hyperuricemia
Pyrazinamide have effects disorders hepatic
Pyrazinamide have effects disorders toxicity
lovastatin Efficacy women hypercholesterolemia
lovastatin efficacy evaluate women hypercholesterolemia
creatine elevations symptoms defined rare Myopathy
Lovastatin effective therapy hypercholesterolemia
dopamine agonist use 86929 study levodopa parkinsonian
A agonist use 86929 study levodopa parkinsonian
86929 study levodopa parkinsonian
levodopa parkinsonian
dopamine agonists utility treatment disease Parkinson
dopamine agonists utility treatment disease Parkinson '
dopamine agonists utility treatment disease s
dopamine agonists utility treatment disease
dopamine agonists utility treatment disease PD
DA agonists utility treatment disease Parkinson
DA agonists utility treatment disease Parkinson '
DA agonists utility treatment disease s
DA agonists utility treatment disease
DA agonists utility treatment disease PD
A 0 doses evaluate induced dyskinesias
86929 -LSB- A 0 doses evaluate induced dyskinesias
A 0 doses evaluate locomotor effects dyskinetic
86929 -LSB- A 0 doses evaluate locomotor effects dyskinetic
-LSB- A 0 doses evaluate induced dyskinesias
-RSB- A 0 doses evaluate induced dyskinesias
-LSB- 5 aR A 0 doses evaluate induced dyskinesias
5 aR A 0 doses evaluate induced dyskinesias
aR A 0 doses evaluate induced dyskinesias
11 -RSB- aR A 0 doses evaluate induced dyskinesias
bS -RSB- aR A 0 doses evaluate induced dyskinesias
-RSB- aR A 0 doses evaluate induced dyskinesias
4 b A 0 doses evaluate induced dyskinesias
5 b A 0 doses evaluate induced dyskinesias
5 b A 0 doses evaluate induced dyskinesias
a b A 0 doses evaluate induced dyskinesias
6 b A 0 doses evaluate induced dyskinesias
7 b A 0 doses evaluate induced dyskinesias
11 b A 0 doses evaluate induced dyskinesias
b A 0 doses evaluate induced dyskinesias
hexahydro A 0 doses evaluate induced dyskinesias
2 A 0 doses evaluate induced dyskinesias
propyl A 0 doses evaluate induced dyskinesias
3 A 0 doses evaluate induced dyskinesias
thia A 0 doses evaluate induced dyskinesias
5 A 0 doses evaluate induced dyskinesias
+ azacyclopent A 0 doses evaluate induced dyskinesias
++ azacyclopent A 0 doses evaluate induced dyskinesias
azacyclopent A 0 doses evaluate induced dyskinesias
1 A 0 doses evaluate induced dyskinesias
ena -LSB- 1 A 0 doses evaluate induced dyskinesias
-LSB- 1 A 0 doses evaluate induced dyskinesias
c 1 A 0 doses evaluate induced dyskinesias
-RSB- phenathrene 1 A 0 doses evaluate induced dyskinesias
phenathrene 1 A 0 doses evaluate induced dyskinesias
9 A 0 doses evaluate induced dyskinesias
10 A 0 doses evaluate induced dyskinesias
diol A 0 doses evaluate induced dyskinesias
-LSB- A 0 doses evaluate locomotor effects dyskinetic
-RSB- A 0 doses evaluate locomotor effects dyskinetic
-LSB- 5 aR A 0 doses evaluate locomotor effects dyskinetic
5 aR A 0 doses evaluate locomotor effects dyskinetic
aR A 0 doses evaluate locomotor effects dyskinetic
11 -RSB- aR A 0 doses evaluate locomotor effects dyskinetic
bS -RSB- aR A 0 doses evaluate locomotor effects dyskinetic
-RSB- aR A 0 doses evaluate locomotor effects dyskinetic
4 b A 0 doses evaluate locomotor effects dyskinetic
5 b A 0 doses evaluate locomotor effects dyskinetic
5 b A 0 doses evaluate locomotor effects dyskinetic
a b A 0 doses evaluate locomotor effects dyskinetic
6 b A 0 doses evaluate locomotor effects dyskinetic
7 b A 0 doses evaluate locomotor effects dyskinetic
11 b A 0 doses evaluate locomotor effects dyskinetic
b A 0 doses evaluate locomotor effects dyskinetic
hexahydro A 0 doses evaluate locomotor effects dyskinetic
2 A 0 doses evaluate locomotor effects dyskinetic
propyl A 0 doses evaluate locomotor effects dyskinetic
3 A 0 doses evaluate locomotor effects dyskinetic
thia A 0 doses evaluate locomotor effects dyskinetic
5 A 0 doses evaluate locomotor effects dyskinetic
+ azacyclopent A 0 doses evaluate locomotor effects dyskinetic
++ azacyclopent A 0 doses evaluate locomotor effects dyskinetic
azacyclopent A 0 doses evaluate locomotor effects dyskinetic
1 A 0 doses evaluate locomotor effects dyskinetic
ena -LSB- 1 A 0 doses evaluate locomotor effects dyskinetic
-LSB- 1 A 0 doses evaluate locomotor effects dyskinetic
c 1 A 0 doses evaluate locomotor effects dyskinetic
-RSB- phenathrene 1 A 0 doses evaluate locomotor effects dyskinetic
phenathrene 1 A 0 doses evaluate locomotor effects dyskinetic
9 A 0 doses evaluate locomotor effects dyskinetic
10 A 0 doses evaluate locomotor effects dyskinetic
diol A 0 doses evaluate locomotor effects dyskinetic
1 study dose conducted methyl exposed monkeys primed induced dyskinesias
methyl exposed monkeys primed induced dyskinesias
4 methyl exposed monkeys primed induced dyskinesias
phenyl - 4 methyl exposed monkeys primed induced dyskinesias
- 4 methyl exposed monkeys primed induced dyskinesias
1 - 4 methyl exposed monkeys primed induced dyskinesias
2 - 4 methyl exposed monkeys primed induced dyskinesias
3 - 4 methyl exposed monkeys primed induced dyskinesias
6 - 4 methyl exposed monkeys primed induced dyskinesias
tetrahydropyridine - 4 methyl exposed monkeys primed induced dyskinesias
1 study dose conducted methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
phenyl - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
- 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
1 - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
2 - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
3 - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
6 - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
tetrahydropyridine - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
MPTP tetrahydropyridine - 4 methyl exposed monkeys primed induced dyskinesias
MPTP tetrahydropyridine - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
DA D doses evaluate induced dyskinesias
DA D doses evaluate locomotor effects dyskinetic
LY levodopa induced parkinsonism
171555 efficacious alleviating MPTP induced parkinsonism
LY with efficacious alleviating MPTP induced parkinsonism
171555 86929 efficacious alleviating MPTP induced parkinsonism
A administration 86929 efficacious induced dyskinesias
86929 efficacious induced dyskinesias
MPTP alleviating efficacious induced dyskinesias
A administration 86929 efficacious alleviating MPTP induced parkinsonism
86929 efficacious alleviating MPTP induced parkinsonism
LY levodopa induced MPTP alleviating efficacious induced dyskinesias
171555 efficacious induced dyskinesias
LY with efficacious induced dyskinesias
171555 86929 efficacious induced dyskinesias
levodopa induced parkinsonism
levodopa reproduce likely efficacious alleviating MPTP induced parkinsonism
levodopa challenge 171555 86929 efficacious alleviating MPTP induced parkinsonism
A efficacy duration 86929 agents tools PD
86929 agents tools PD
DA agents tools PD
fluoxetine exposure induces hypertension fetal
fluoxetine exposure induces hypertension pulmonary
fluoxetine exposure induces hypertension
fluoxetine exposure resulted hypertension fetal
fluoxetine exposure resulted hypertension pulmonary
fluoxetine exposure resulted hypertension
acetaminophen NSAID g starting diagnosis SAH aneurysmal
acetaminophen g starting diagnosis SAH aneurysmal
ketoprofen receive randomized Patients hemorrhage aneurysmal
ketoprofen receive randomized Patients hemorrhage subarachnoid
ketoprofen receive randomized Patients hemorrhage
ketoprofen receive randomized Patients SAH
ketoprofen NSAID g starting diagnosis SAH
ketoprofen ketoprofen receive randomized Patients hemorrhage aneurysmal
ketoprofen ketoprofen receive randomized Patients hemorrhage subarachnoid
ketoprofen ketoprofen receive randomized Patients hemorrhage
ketoprofen ketoprofen receive randomized Patients SAH
ketoprofen ketoprofen NSAID g starting diagnosis SAH
acetaminophen NSAID ketoprofen receive randomized Patients hemorrhage aneurysmal
acetaminophen NSAID ketoprofen receive randomized Patients hemorrhage subarachnoid
acetaminophen NSAID ketoprofen receive randomized Patients hemorrhage
acetaminophen NSAID ketoprofen receive randomized Patients SAH
acetaminophen NSAID g starting diagnosis SAH
acetaminophen g NSAID ketoprofen receive randomized Patients hemorrhage aneurysmal
acetaminophen g NSAID ketoprofen receive randomized Patients hemorrhage subarachnoid
acetaminophen g NSAID ketoprofen receive randomized Patients hemorrhage
acetaminophen g NSAID ketoprofen receive randomized Patients SAH
acetaminophen g starting diagnosis SAH
ketoprofen NSAID g starting diagnosis SAH aneurysmal
ketoprofen ketoprofen NSAID g starting diagnosis SAH aneurysmal
adenosine diphosphate microM induced aggregation platelet
adenosine diphosphate microM induced aggregation
diphosphate microM induced aggregation platelet
diphosphate microM induced aggregation
acetaminophen group increased aggregation platelet
acetaminophen group increased aggregation
acetaminophen group increased results platelet
acetaminophen group increased results aggregation
Ketoprofen platelet function patients SAH
acetaminophen impaired Ketoprofen platelet function patients SAH
ketoprofen used surgery aneurysms artery
ketoprofen used surgery aneurysms
ketoprofen used pose hemorrhage
dopamine blockade result thought syndrome Neuroleptic
dopamine blockade result thought syndrome malignant
dopamine blockade result thought syndrome
risperidone impart frequency symptoms extrapyramidal
risperidone impart frequency symptoms
Quinidine responsible hepatitis
cytosine treatment patient leukemia acute
cytosine treatment patient leukemia myeloid
cytosine treatment patient leukemia
arabinoside treatment patient leukemia acute
arabinoside treatment patient leukemia myeloid
arabinoside treatment patient leukemia
cytosine arabinoside high toxicity
arabinoside high toxicity
cytosine arabinoside high toxicity recognized reported toxicity
arabinoside high toxicity recognized reported toxicity
cytosine arabinoside toxicity reported recognized toxicity
arabinoside toxicity reported recognized toxicity
cytosine arabinoside toxicity
arabinoside toxicity
cytosine arabinoside high course resulted complained numbness
arabinoside high course resulted complained numbness
methylprednisolone responded worsened development graft
methylprednisolone responded worsened versus
methylprednisolone responded worsened worsened disease -
methylprednisolone responded worsened worsened disease host
methylprednisolone responded worsened worsened disease
methylprednisolone responded worsened resolving neuropathy
Sorafenib induced due infarction myocardial
Sorafenib induced due infarction
nicorandil Addition reduced maintained status stable
nicorandil Addition reduced maintained status angina
acetaminophen overdose
fenfluramine users disease valvular
fenfluramine users disease heart
fenfluramine users disease
dexfenfluramine fenfluramine users disease valvular
dexfenfluramine fenfluramine users disease heart
dexfenfluramine fenfluramine users disease
fenfluramine users % had disease valvular
fenfluramine users % had disease
dexfenfluramine fenfluramine users % had disease valvular
dexfenfluramine fenfluramine users % had disease
fenfluramine users abnormalities valvular
fenfluramine users abnormalities
dexfenfluramine fenfluramine users abnormalities valvular
dexfenfluramine fenfluramine users abnormalities
phentermine developed disease valvular
phentermine developed disease heart
phentermine developed disease
fenfluramine receiving patients RESULTS phentermine developed disease valvular
fenfluramine receiving patients RESULTS phentermine developed disease heart
fenfluramine receiving patients RESULTS phentermine developed disease
D treated cirrhosis primary
D treated cirrhosis biliary
D treated cirrhosis
penicillamine case cirrhosis primary
penicillamine case cirrhosis biliary
penicillamine case cirrhosis
D used diseases rheumatologic
D used diseases
penicillamine D used diseases rheumatologic
penicillamine D used diseases
D used limits toxicity
penicillamine D used limits toxicity
D complications one develop dermatomyositis
penicillamine Polymyositis develop dermatomyositis
D receiving developed cirrhosis primary
D receiving developed cirrhosis biliary
D receiving developed cirrhosis
penicillamine therapy D receiving developed cirrhosis primary
penicillamine therapy D receiving developed cirrhosis biliary
penicillamine therapy D receiving developed cirrhosis
D dermatomyositis
penicillamine therapy followed D dermatomyositis
atenolol resolved arrhythmia
atenolol week stopping disappeared arrhythmia
salbutamol agonist beta known induce tachycardia
atenolol blocker beta relieve swallowing originating reflexes trigger beta known induce tachycardia
imipenem therapy activity Seizure
imipenem cilastatin doses receiving developed patients history accident cerebral
imipenem cilastatin doses receiving developed patients history accident vascular
imipenem cilastatin doses receiving developed patients history accident
/ cilastatin doses receiving developed patients history accident cerebral
/ cilastatin doses receiving developed patients history accident vascular
/ cilastatin doses receiving developed patients history accident
cilastatin doses receiving developed patients history accident cerebral
cilastatin doses receiving developed patients history accident vascular
cilastatin doses receiving developed patients history accident
imipenem cilastatin doses receiving developed patients history accident CVA
/ cilastatin doses receiving developed patients history accident CVA
cilastatin doses receiving developed patients history accident CVA
imipenem cilastatin doses receiving developed patients history trauma head
imipenem cilastatin doses receiving developed patients history trauma
/ cilastatin doses receiving developed patients history trauma head
/ cilastatin doses receiving developed patients history trauma
cilastatin doses receiving developed patients history trauma head
cilastatin doses receiving developed patients history trauma
imipenem cilastatin doses receiving developed patients history trauma evidence disease renal
imipenem cilastatin doses receiving developed patients history trauma evidence disease
/ cilastatin doses receiving developed patients history trauma evidence disease renal
/ cilastatin doses receiving developed patients history trauma evidence disease
cilastatin doses receiving developed patients history trauma evidence disease renal
cilastatin doses receiving developed patients history trauma evidence disease
phenytoin doses controlled seizures
beta doses received antibiotics evidence activity seizure
lactam antibiotics evidence activity seizure
steroids using seen tumors liver
steroids using seen tumors
digoxin group patients capacity selected patients rheumatic
digoxin group patients capacity selected patients heart
digoxin group patients capacity selected patients disease
lithium therapy secondary developed attacks syncopal
lithium therapy secondary developed attacks
lithium levels remained attacks syncopal
lithium levels remained attacks
Vancomycin curative % patients infection
aminoglycoside receiving patients confined nephrotoxicity
aminoglycoside receiving patients confined nephrotoxicity ototoxicity
vancomycin aminoglycoside receiving patients confined nephrotoxicity
aminoglycoside receiving patients confined occurred Thrombophlebitis
vancomycin constitutes infections
6 man leukemia acute
6 man leukemia lymphocytic
6 man leukemia
thioguanine year man leukemia acute
thioguanine year man leukemia lymphocytic
thioguanine year man leukemia
Unfractionated sodium BACKGROUND used prevent thrombosis
heparin sodium BACKGROUND used prevent thrombosis
sodium BACKGROUND used prevent thrombosis
UFH sodium BACKGROUND used prevent thrombosis
low sodium BACKGROUND used prevent thrombosis
molecular heparin used prevent thrombosis
weight heparin used prevent thrombosis
heparin used prevent thrombosis
heparin induced negative test platelet
heparin induced negative test aggregation
dobutamine infusion managed admitted patient known have cardiomyopathy hypertrophic
dobutamine infusion managed admitted patient known have cardiomyopathy
dobutamine infusion managed admitted failure biventricular
dobutamine infusion managed admitted failure
propofol infusion continued available detect hyperthermia malignant
propofol infusion continued available detect hyperthermia
butylated hydroxyanisole induced rats carcinogenesis acetate effect carcinogenic
hydroxyanisole induced rats carcinogenesis acetate effect carcinogenic
retinyl acetate carcinogenesis forestomach
retinyl acetate carcinogenesis
acetate carcinogenesis forestomach
acetate carcinogenesis
retinyl acetate effect carcinogenic
acetate effect carcinogenic
retinyl acetate effect hydroxyanisole tumorigenesis forestomach
retinyl acetate effect hydroxyanisole tumorigenesis
acetate effect hydroxyanisole tumorigenesis forestomach
acetate effect hydroxyanisole tumorigenesis
RA effect hydroxyanisole tumorigenesis forestomach
RA effect hydroxyanisole tumorigenesis
RA % animals observed BHA given groups increased incidence papilloma squamous
RA % animals observed BHA given groups increased incidence papilloma cell
RA % animals observed BHA given groups increased incidence papilloma
RA given group increased incidence papilloma squamous
RA given group increased incidence papilloma cell
RA given group increased incidence papilloma
BHA given groups increased incidence papilloma squamous
BHA given groups increased incidence papilloma cell
BHA given groups increased incidence papilloma
BHA given groups increased incidence papilloma carcinoma
BHA given groups increased % 9 rats carcinoma
BHA given groups increased % 3 20 rat carcinoma
RA % animals observed BHA given groups increased incidence tumors forestomach
RA % animals observed BHA given groups increased incidence tumors
RA given group increased incidence tumors forestomach
RA given group increased incidence tumors
RA % animals observed BHA given groups increased incidence papilloma carcinoma
RA % animals observed BHA given groups increased % 9 rats carcinoma
RA % animals observed BHA given groups increased % 3 20 rat carcinoma
RA given group increased incidence papilloma carcinoma
RA given group increased % 9 rats carcinoma
RA given group increased % 3 20 rat carcinoma
BHA given rats showed dose induced hyperplasia epithelial
BHA given rats showed dose induced hyperplasia
BHA development enhancing dependent dose induced hyperplasia epithelial
BHA development enhancing dependent dose induced hyperplasia
RA co showed dose induced hyperplasia epithelial
RA co showed dose induced hyperplasia
RA 0 rats rat % administration induced Tumors papillomas
RA co % administration induced Tumors papillomas
RA 0 rats rat % administration induced Tumors
RA co % administration induced Tumors
RA acted indicate forestomach
RA acted indicate forestomach carcinogenesis
crack abusers endorsing CIP
cocaine abusers endorsing CIP
crack abusers endorsing CIP group denied CIP
cocaine abusers endorsing CIP group denied CIP
crack addicts group CIP
crack addicts group denied CIP
crack abusers group distinguish able Measures oscillation pupillary
crack abusers group distinguish able Measures oscillation
cocaine abusers group distinguish able Measures oscillation pupillary
cocaine abusers group distinguish able Measures oscillation
crack addicts group CIP endorsing abusers group distinguish able Measures oscillation pupillary
crack addicts group CIP endorsing abusers group distinguish able Measures oscillation
Amiodarone represents drug cardioversion recent fibrillation atrial
Amiodarone represents drug cardioversion recent fibrillation
Amiodarone represents drug cardioversion recent AF
amiodarone loading initiation experienced fibrillation atrial
amiodarone loading initiation experienced fibrillation
salicylates association lack disappearing syndrome Reye
salicylates association lack disappearing syndrome
Penicillamine induced arthritis rheumatoid
Penicillamine induced arthritis
D months presented arthritis rheumatoid
D months presented arthritis
penicillamine treatment woman arthritis rheumatoid
penicillamine treatment woman arthritis
D course case emphasizes need sediment proteinuria
penicillamine treatment emphasizes need sediment proteinuria
hepatitis antigen stick assess examined globulin Hepatitis
hepatitis antigen stick assess examined globulin B
B antigen stick assess examined globulin Hepatitis
B antigen stick assess examined globulin B
surface antigen stick assess examined globulin Hepatitis
surface antigen stick assess examined globulin B
antigen stick assess examined globulin Hepatitis
antigen stick assess examined globulin B
hepatitis antigen stick assess preventing hepatitis type
hepatitis antigen stick assess preventing hepatitis B
hepatitis antigen stick assess preventing hepatitis
B antigen stick assess preventing hepatitis type
B antigen stick assess preventing hepatitis B
B antigen stick assess preventing hepatitis
surface antigen stick assess preventing hepatitis type
surface antigen stick assess preventing hepatitis B
surface antigen stick assess preventing hepatitis
antigen stick assess preventing hepatitis type
antigen stick assess preventing hepatitis B
antigen stick assess preventing hepatitis
HBsAG antigen stick assess examined globulin Hepatitis
HBsAG antigen stick assess examined globulin B
HBsAG antigen stick assess preventing hepatitis type
HBsAG antigen stick assess preventing hepatitis B
HBsAG antigen stick assess preventing hepatitis
Nimodipine prevents impairment hypotension
Nimodipine prevents impairment memory
Nimodipine prevents impairment
nimodipine administered tested preserve hypotension
NIMO nimodipine administered tested preserve hypotension
NIMO saline injected those showed Mice subjected hypotensive
NIMO attenuated caused improve absence hypotension
NIMO effect attributable hypotension
calcium homeostasis preservation attributable hypotension
gamma synthesis attributed induced tachycardia bradycardia
aminobutyric acid gamma synthesis attributed induced tachycardia bradycardia
acid gamma synthesis attributed induced tachycardia bradycardia
GABA gamma synthesis attributed induced tachycardia bradycardia
gamma synthesis attributed induced doses hypotension
aminobutyric acid gamma synthesis attributed induced doses hypotension
acid gamma synthesis attributed induced doses hypotension
GABA gamma synthesis attributed induced doses hypotension
gamma synthesis attributed induced tachycardia
aminobutyric acid gamma synthesis attributed induced tachycardia
acid gamma synthesis attributed induced tachycardia
GABA gamma synthesis attributed induced tachycardia
isoniazid hypotension doses induced tachycardia
urethane chloralose anaesthetised rats determined induced enhancement isoniazid bradycardia
chloralose anaesthetised rats determined induced enhancement isoniazid bradycardia
hexamethonium increased increased bradycardia
propranolol increased bradycardia
clonidine increased bradycardia
atenolol propranolol increased bradycardia
labetalol propranolol increased bradycardia
pindolol propranolol increased bradycardia
carbachol hexamethonium increased increased bradycardia
Valproic acid given patients epileptic
acid given patients epileptic
VPA acid given patients epileptic
angiotensin proteins altered rats syndrome nephrotic
angiotensin proteins altered rats syndrome
angiotensin proteins altered rats syndrome NS
tobramicyn regimen effect evaluate concentrations toxicity
creatinine observed evidence nephrotoxicity
Doxorubicin cardiomyopathy Wilms
Doxorubicin cardiomyopathy Wilms tumor
anthracycline cardiomyopathy
anthracycline cardiomyopathy experienced bed tumor
anthracycline cardiomyopathy experienced children tumor Wilms
anthracycline cardiomyopathy experienced children tumor
doxorubicin bed tumor
doxorubicin bed experienced children tumor Wilms
doxorubicin bed experienced children tumor
doxorubicin interaction fact include fields tumor Wilms
doxorubicin interaction fact include fields tumor
doxorubicin dosage restricted tumor Wilms
doxorubicin dosage restricted tumor
lithium sex duration respect had relative disease thyroid
lithium sex duration respect had relative disease
lithium therapy receiving disorder bipolar
lithium therapy receiving disorder
lithium therapy years hypothyroidism onset accelerated patients having first relatives affected illness thyroid
lithium therapy years hypothyroidism onset accelerated patients having first relatives affected illness
lithium therapy onset years hypothyroidism onset accelerated patients having first relatives affected illness thyroid
lithium therapy onset years hypothyroidism onset accelerated patients having first relatives affected illness
lithium therapy factor illness thyroid
lithium therapy factor illness
lithium therapy factor hypothyroidism hypercalcemia
Doxorubicin cardiomyopathy induced attenuated inflammation
doxorubicin use limited effects cardiotoxic
DOX doxorubicin use limited effects cardiotoxic
anthracycline doxorubicin use limited effects cardiotoxic
DOX cardiomyopathy development elucidate studied B mice investigating inflammation
DOX induction investigating inflammation
DOX mice showed dysfunction cardiac
DOX mice showed dysfunction
DOX mice improved dysfunction cardiac
DOX mice improved dysfunction
DOX mice improved dysfunction cardiac
DOX mice improved dysfunction
ephedrine study placebo induced dysfunction sexual
ephedrine study placebo induced dysfunction
ephedrine has effects dysfunction sexual
ephedrine has effects dysfunction
ephedrine effects study cross controlled measures women sexually
ephedrine effects study cross controlled measures women dysfunctional
Pilocarpine age seizures
Pilocarpine induced resulted loss seizures
Pilocarpine induced resulted had loss seizures
baclofen muscimol drugs jerks myoclonic
baclofen muscimol drugs jerks
benzodiazepines drugs jerks myoclonic
benzodiazepines drugs jerks
clonazepam found blocking jerks myoclonic
clonazepam found blocking jerks
diazepam potent found blocking jerks myoclonic
diazepam potent found blocking jerks
benzodiazepines found blocking jerks myoclonic
benzodiazepines found blocking jerks
5 fact found beneficial management myoclonus
HTP found beneficial management myoclonus
5 fact found seems myoclonus
HTP found seems myoclonus
benzodiazepines HTP found beneficial management myoclonus
benzodiazepines HTP found seems myoclonus
MK value myoclonus
212 value myoclonus
baclofen value myoclonus
phenytoin administration safe child hypothermic
phenytoin administered part surgery prophylaxis seizure
atropine refractory developed bradycardia
adrenaline atropine refractory developed bradycardia
phenytoin hypothermia
phenytoin presence hypothermia
doxorubicin induced cardiotoxicity
fat diet sensitive doxorubicin induced cardiotoxicity
doxorubicin sensitive rats obese
doxorubicin chemotherapy limited life threatening cardiotoxicity
Adriamycin doxorubicin chemotherapy limited life threatening cardiotoxicity
doxorubicin induced cardiotoxicity
doxorubicin sensitizes rats diet feeding intervention induced cardiotoxicity
fat diet feeding intervention induced cardiotoxicity
doxorubicin sensitizes rats diet induces obesity
doxorubicin dose administered day regimen led absence toxicity renal
doxorubicin dose administered day regimen led absence toxicity renal or
doxorubicin dose administered day regimen led absence toxicity renal hepatic
doxorubicin dose administered day regimen led absence toxicity
doxorubicin dose administered day regimen led cardiotoxicity
doxorubicin dose administered day regimen led cardiotoxicity mortality rats obese
doxorubicin dose administered day regimen led cardiotoxicity mortality rats OB
doxorubicinol doxorubicin accumulation change fed revealed OB
Doxorubicin studies revealed OB
doxorubicin accumulation change fed revealed OB
ATP levels drop leading stress revealed sensitized rats OB
ATP levels drop leading upregulation uncoupling proteins downregulation proliferators oxidation min min heart OB
ATP ratio accompanied levels drop leading stress revealed sensitized rats OB
ATP ratio accompanied levels drop leading upregulation uncoupling proteins downregulation proliferators oxidation min min heart OB
doxorubicin administration ratio accompanied levels drop leading stress revealed sensitized rats OB
doxorubicin administration ratio accompanied levels drop leading upregulation uncoupling proteins downregulation proliferators oxidation min min heart OB
AMP decreased oxidation proliferators downregulation proteins uncoupling upregulation leading stress revealed sensitized rats OB
AMP decreased oxidation min min heart OB
ADP ratio accompanied levels drop leading stress revealed sensitized rats OB
ADP ratio accompanied levels drop leading upregulation uncoupling proteins downregulation proliferators oxidation min min heart OB
ATP generation downregulating induced HFD induced sensitized rats obese
doxorubicin sensitized induced HFD induced cardiotoxicity
doxorubicin sensitized rats obese
ATP generation downregulating induced cardiotoxicity
testosterone concentration increased affected hyperprolactinemia
risperidone started occurred fractures
Diazepam remains ketamine buffers decreases duration hallucinations
haloperidol potentiation induced hyperactivity
apomorphine prevention catalepsy
steroids protect acid seizures epilepticus status
steroids protect acid seizures epilepticus
steroids protect acid seizures
deoxycorticosterone progesterone metabolites seizures
3 alpha progesterone metabolites seizures
alpha progesterone metabolites seizures
hydroxy pregnane alpha progesterone metabolites seizures
pregnane alpha progesterone metabolites seizures
21 pregnane alpha progesterone metabolites seizures
diol 21 pregnane alpha progesterone metabolites seizures
20 diol 21 pregnane alpha progesterone metabolites seizures
ones 21 pregnane alpha progesterone metabolites seizures
progesterone metabolites seizures
3 alpha progesterone metabolites seizures
alpha progesterone metabolites seizures
hydroxy pregnane alpha progesterone metabolites seizures
pregnane alpha progesterone metabolites seizures
20 pregnane alpha progesterone metabolites seizures
ones 20 pregnane alpha progesterone metabolites seizures
N metabolites seizures
methyl metabolites seizures
D methyl metabolites seizures
aspartate metabolites seizures
NMDA aspartate metabolites seizures
Steroids induced seizures epilepticus status
Steroids induced seizures epilepticus
Steroids induced seizures
benzodiazepine clonazepam potent protecting seizures
benzodiazepine clonazepam potent had values TD divided protection seizure
clonazepam potent had values indicating have toxicity
clonazepam values indicating have toxicity
benzodiazepine clonazepam potent had values indicating have toxicity
steroids potent had values indicating have toxicity
steroids had values indicating have toxicity
steroids have toxicity
steroids potent protecting seizures
steroids potent had values TD divided protection seizure
steroids had potent protecting seizures
steroids had values TD divided protection seizure
steroids have indicating values had potent protecting seizures
steroids have indicating values TD divided protection seizure
clonazepam potent protecting seizures
clonazepam potent had values TD divided protection seizure
clonazepam values had potent protecting seizures
clonazepam values TD divided protection seizure
pilocarpine seizures protecting potent had values indicating have toxicity
Steroids produced onset seizures
Steroids produced protect seizures
steroid dose administered However obtained seizures epilepticus status
steroid dose administered However obtained seizures epilepticus
steroid dose administered However obtained seizures
steroids caused protect seizures
NMDA delay dose induced caused protect seizures
NMDA seizures
steroids effective protecting acid seizures epilepticus status
steroids effective protecting acid seizures epilepticus
steroids effective utility treatment forms epilepticus status
steroids effective utility treatment forms epilepticus
steroids effective protecting acid seizures
heparin therapy thrombophlebitis
oxacillin treated man year developed failure lesions purpuric
oxacillin treated man year developed failure lesions
oxacillin week bacteremia Staphylococcus
oxacillin week bacteremia aureus
oxacillin week bacteremia
cyanoacrylate doxorubicin toxicity renal
cyanoacrylate doxorubicin toxicity
doxorubicin toxicity renal
doxorubicin toxicity
adriamycin doxorubicin toxicity renal
adriamycin doxorubicin toxicity
doxorubicin nanoparticle explored rats glomerulonephritis
doxorubicin nanoparticle explored toxicity renal
doxorubicin nanoparticle explored toxicity
DX died given rats rats glomerulonephritis
DX killed toxicity renal
DX killed toxicity
naloxazone Pretreatment blocked morphine analgesia catalepsy
morphine analgesia
naloxazone Pretreatment blocked morphine analgesia
naloxazone Pretreatment blocked morphine analgesia hypothermia
naloxazone attenuated bradycardia
morphine bradycardia induced hypotension depression respiratory
morphine bradycardia induced hypotension depression
morphine induced hypotension depression respiratory
morphine induced hypotension depression
naloxazone attenuated bradycardia induced hypotension
naloxazone attenuated bradycardia induced hypotension depression respiratory
naloxazone attenuated bradycardia induced hypotension depression
methylprednisolone dose reviews mechanisms death sudden
methylprednisolone dose reviews mechanisms death
IVMP methylprednisolone dose reviews mechanisms death sudden
IVMP methylprednisolone dose reviews mechanisms death
Amiodarone proved treatment tachyarrhythmias
amiodarone treatment due hepatitis patient cholestatic
amiodarone treatment due hepatitis
amiodarone hepatotoxicity review given presented hepatitis patient cholestatic
amiodarone hepatotoxicity review given presented hepatitis
amiodarone treatment due injury exists concluded alterations hepatitis alcoholic
amiodarone treatment due injury exists concluded alterations hepatitis
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis cholestatic
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis
apomorphine infusion induced state dyskinetic
apomorphine infusion induced state modification result investigated Using area group patients disease Parkinson
apomorphine infusion induced state modification result investigated Using area group patients disease
azidothymidine erythropoietin colonies Sensitivity treated mice immunodeficient
AZT due determine BM used model AIDS
AZT due determine BM infection
AZT due determine BM leukaemia
phenylhydrazine compared observed degree anaemia
PHZ phenylhydrazine compared observed degree anaemia
PHZ AZT treated degrees anaemia
AZT observed anaemia degree inappropriate reticulocytosis
amisulpride unmasked Pheochromocytoma
tiapride amisulpride unmasked Pheochromocytoma
amisulpride treated patient describe unmasking pheochromocytoma
tiapride amisulpride treated patient describe unmasking pheochromocytoma
nicardipine recovered discontinued CASE man headache
verapamil treatment nicardipine recovered discontinued CASE man hypertension
verapamil treatment nicardipine recovered discontinued CASE man headache
nicardipine recovered discontinued CASE man hypertension
verapamil treatment nicardipine recovered discontinued CASE man headache vomiting
nicardipine recovered discontinued CASE man headache vomiting
benzamide drugs use associated symptoms pheochromocytoma
amisulpride crisis patient pheochromocytoma
tiapride amisulpride crisis patient pheochromocytoma
barbiturate melatonin effects narcosis
barbiturate narcosis
barbiturate narcosis
barbiturate mechanism specific seems action melatonin narcosis
pegylated alpha patient chronic
pegylated alpha patient hepatitis
pegylated alpha patient C
interferon alpha patient chronic
interferon alpha patient hepatitis
interferon alpha patient C
alpha patient chronic
alpha patient hepatitis
alpha patient C
2 b case parasitosis patient chronic
2 b case parasitosis patient hepatitis
2 b case parasitosis patient C
b case parasitosis patient chronic
b case parasitosis patient hepatitis
b case parasitosis patient C
ribavirin treatment b case parasitosis patient chronic
ribavirin treatment b case parasitosis patient hepatitis
ribavirin treatment b case parasitosis patient C
ribavirin interferon treatment patients chronic
ribavirin interferon treatment patients hepatitis
ribavirin interferon treatment patients C
MPTP dyskinesias
L drugs Effect dopa dyskinesias
dopa dyskinesias
L tested see modified movements dyskinetic
DOPA tested see modified movements dyskinetic
dopamine neurotransmitters acting agents series tested see modified movements dyskinetic
clonidine reduced cost return symptomatology parkinsonian
methysergide clonidine reduced movements dyskinetic
5 methysergide clonidine reduced movements dyskinetic
MDOT clonidine reduced movements dyskinetic
physostigmine clonidine reduced movements dyskinetic
MK MDOT clonidine reduced cost return symptomatology parkinsonian
801 clonidine reduced cost return symptomatology parkinsonian
propranolol MDOT clonidine reduced movements dyskinetic
methysergide clonidine reduced cost return symptomatology parkinsonian
propranolol MDOT clonidine reduced cost return symptomatology parkinsonian
5 methysergide clonidine reduced cost return symptomatology parkinsonian
MDOT clonidine reduced cost return symptomatology parkinsonian
clonidine reduced movements dyskinetic
physostigmine clonidine reduced cost return symptomatology parkinsonian
MK MDOT clonidine reduced movements dyskinetic
801 clonidine reduced movements dyskinetic
yohimbine reduced movements dyskinetic
meperidine yohimbine reduced movements dyskinetic
Baclofen useful monkey form dyskinesia
Baclofen useful monkey form dystonic
Atropine converted movements dystonic
Atropine converted chorea
3 shown known lesions neurotoxic
3 shown known lesions
4 3 shown known lesions neurotoxic
4 3 shown known lesions
methylenedioxymethamphetamine 4 3 shown known lesions neurotoxic
methylenedioxymethamphetamine 4 3 shown known lesions
MDMA methylenedioxymethamphetamine 4 3 shown known lesions neurotoxic
MDMA methylenedioxymethamphetamine 4 3 shown known lesions
ecstasy MDMA methylenedioxymethamphetamine 4 3 shown known lesions neurotoxic
ecstasy MDMA methylenedioxymethamphetamine 4 3 shown known lesions
MDMA HT consequences long lesions neurotoxic
MDMA HT consequences long lesions
serotonin neurons damage shown known lesions neurotoxic
serotonin neurons damage shown known lesions
5 neurons damage shown known lesions neurotoxic
5 neurons damage shown known lesions
HT 5 neurons damage shown known lesions neurotoxic
HT 5 neurons damage shown known lesions
5 HT consequences long lesions neurotoxic
5 HT consequences long lesions
HT consequences long lesions neurotoxic
HT consequences long lesions
5 functions known lesions neurotoxic
5 functions known lesions
HT involved 5 functions known lesions neurotoxic
HT involved 5 functions known lesions
testosterone fat effects carcinogenesis
testosterone implanted rats developed interval % developed tumors
testosterone implanted rats developed interval % included tumors
5 toxicity Cardiac
5 toxicity
fluorouracil toxicity Cardiac
fluorouracil toxicity
5 presented metastasis
fluorouracil administration metastasis
5 administration metastasis
FU 5 administration metastasis
5 presented metastasis patient carcinoma colon
5 presented metastasis patient carcinoma
fluorouracil administration metastasis patient carcinoma colon
fluorouracil administration metastasis patient carcinoma
5 administration metastasis patient carcinoma colon
5 administration metastasis patient carcinoma
FU 5 administration metastasis patient carcinoma colon
FU 5 administration metastasis patient carcinoma
nifedipine resolved pain chest
nifedipine resolved pain
nifedipine resolved similar observed angina Prinzmetal
nifedipine resolved similar observed angina Prinzmetal '
nifedipine resolved similar observed angina s
nifedipine resolved similar observed angina
calcium antagonists used cause due cardiotoxicity
calcium antagonists used cause suggest cardiotoxicity
calcium antagonists used cause spasm coronary
calcium antagonists used cause spasm
5 due cause spasm coronary
5 due cause spasm
FU cause spasm coronary
FU cause spasm
5 prevention used cause spasm coronary
5 prevention used cause spasm
FU cardiotoxicity suggest cause spasm coronary
FU cardiotoxicity suggest cause spasm
5 due cardiotoxicity
FU cause due cardiotoxicity
5 due cause suggest cardiotoxicity
FU cause suggest cardiotoxicity
5 prevention used cause due cardiotoxicity
FU cardiotoxicity suggest cause due cardiotoxicity
5 prevention used cause suggest cardiotoxicity
FU cardiotoxicity
paroxetine treatment day exhibited tremors
paroxetine treatment day exhibited retardation rigidity muscle
paroxetine treatment day exhibited retardation rigidity
paroxetine treatment day exhibited retardation psychomotor
paroxetine treatment day exhibited retardation
alprazolam paroxetine treatment day exhibited tremors
alprazolam paroxetine treatment day exhibited retardation rigidity muscle
alprazolam paroxetine treatment day exhibited retardation rigidity
alprazolam paroxetine treatment day exhibited retardation psychomotor
alprazolam paroxetine treatment day exhibited retardation
penicillamine therapy effects patient arthritis rheumatoid
penicillamine therapy effects patient arthritis
penicillamine therapy complications recorded patients arthritis rheumatoid
penicillamine therapy complications recorded patients arthritis
penicillamine treated arthritis reported serpiginosa perforans resembled lesion skin
penicillamine treated arthritis reported serpiginosa perforans resembled lesion
penicillamine treated arthritis rheumatoid
penicillamine treated arthritis
penicillamine treated arthritis reported serpiginosa perforans elastosis
penicillamine treated arthritis reported serpiginosa perforans
penicillamine treated arthritis reported serpiginosa
penicillamine treated arthritis reported effect patients disease Wilson
penicillamine treated arthritis reported effect patients disease Wilson '
penicillamine treated arthritis reported effect patients disease s
penicillamine treated arthritis reported effect patients disease
chloramphenicol beginning undergoing extraction cataract
chloramphenicol treatment report reported cases hypoplasia bone
chloramphenicol treatment report reported cases hypoplasia marrow
chloramphenicol treatment report reported cases hypoplasia
chloramphenicol associated toxicity ocular
chloramphenicol associated toxicity
ifosfamide Hallucinations induced neurotoxicity
ifosfamide effect symptom neurotoxicity
ifosfamide hallucinations occur signs neurotoxicity
haloperidol neuroleptics becomes agitation
prostaglandin synthetase Effect inhibitors induced convulsions
prostaglandins induction seizure
prostaglandins induction effects inhibitors convulsions
PGs prostaglandins induction seizure
PGs prostaglandins induction effects inhibitors convulsions
PGs involved fluorthyl induced convulsions
PGs involved fluorthyl convulsions
azidothymidine induced impairment activity immunodeficiency
Benzylacyclouridine reverses azidothymidine induced suppression marrow
Benzylacyclouridine reverses azidothymidine induced suppression
Benzylacyclouridine reverses azidothymidine induced impairment activity immunodeficiency
azidothymidine vitro inhibition concentrations cells impairment activity immunodeficiency
AZT azidothymidine vitro inhibition concentrations cells impairment activity immunodeficiency
uridine concentrations cells impairment activity immunodeficiency
Urd uridine concentrations cells impairment activity immunodeficiency
benzylacyclouridine ability effect AZT induced anemia
BAU ability effect AZT induced anemia
benzylacyclouridine ability effect AZT induced anemia leukopenia
BAU ability effect AZT induced anemia leukopenia
AZT effect ability assessed toxicities
benzylacyclouridine ability assessed toxicities
BAU ability assessed toxicities
Urd administration associated toxicities
Urd administration associated toxicities assessed ability effect AZT induced anemia leukopenia
Urd administration associated toxicities assessed ability effect AZT induced anemia
Urd catabolism inhibits toxicity
Urd concentration increases inhibits toxicity
Urd manner toxicity
BAU reversed rendered anemic
BAU reversed induced anemia
BAU reversed rendered anemic leukopenic
BAU reversed induced anemia leukopenia
BAU reversed rendered mice increased improved megaloblastosis
AZT administration rendered mice increased improved megaloblastosis
AZT administration water drinking days reversed rendered mice increased improved megaloblastosis
AZT induced reversed rendered mice increased improved megaloblastosis
BAU reduced AZT induced toxicity marrow
BAU reduced AZT induced toxicity
levodopa overflow dyskinesias disease Parkinson
levodopa overflow dyskinesias disease Parkinson '
levodopa overflow dyskinesias disease s
levodopa overflow dyskinesias disease
levodopa therapy complications assessed coordination hand disease Parkinson
levodopa therapy complications assessed coordination hand disease Parkinson '
levodopa therapy complications assessed coordination hand disease s
levodopa therapy complications assessed coordination hand disease
levodopa complications assessed coordination hand disease Parkinson
levodopa complications assessed coordination hand disease Parkinson '
levodopa complications assessed coordination hand disease s
levodopa complications assessed coordination hand disease
levodopa with studied groups patients Parkinson
levodopa with studied groups patients Parkinson '
levodopa with studied groups patients s
levodopa with studied groups patients disease
levodopa with LID + Parkinson
levodopa with LID + Parkinson '
levodopa with LID + s
levodopa with LID + disease
levodopa dyskinesias disease Parkinson
levodopa dyskinesias disease Parkinson '
levodopa dyskinesias disease s
levodopa dyskinesias disease
levodopa assessed lift score Scale Parkinson
levodopa assessed lift score Scale Parkinson '
levodopa assessed lift score Scale s
levodopa assessed lift score Scale Disease
levodopa increased LID Parkinson
levodopa increased LID Parkinson '
levodopa increased LID s
levodopa increased LID disease
mangiferin Role infarction myocardial
mangiferin Role infarction
creatine phosphokinase isoenzymes dehydrogenase activity determined heart caused damage myocardial
creatine phosphokinase isoenzymes dehydrogenase activity determined heart caused damage
uric level activity determined heart caused damage myocardial
uric level activity determined heart caused damage
acid level activity determined heart caused damage myocardial
acid level activity determined heart caused damage
lactate dehydrogenase activity determined heart caused damage myocardial
lactate dehydrogenase activity determined heart caused damage
iron capacity activity determined heart caused damage myocardial
iron capacity activity determined heart caused damage
ISPH injection caused damage myocardial
ISPH injection caused damage
triphenyl chloride test used assay myocardium ischemic
triphenyl chloride test used assay myocardium
tetrazolium chloride test used assay myocardium ischemic
tetrazolium chloride test used assay myocardium
chloride test used assay myocardium ischemic
chloride test used assay myocardium
TTC chloride test used assay myocardium ischemic
TTC chloride test used assay myocardium
mangiferin role analyzed chloride test used assay myocardium ischemic
mangiferin role analyzed chloride test used assay myocardium
Vitamin C dismutase enzymes altered rats MI
C dismutase enzymes altered rats MI
glutathione peroxidase dismutase enzymes altered rats MI
glutathione transferase dismutase enzymes altered rats MI
glutathione activities transferase dismutase enzymes altered rats MI
glutathione levels dismutase enzymes altered rats MI
Vitamin E dismutase enzymes altered rats MI
E dismutase enzymes altered rats MI
superoxide dismutase enzymes altered rats MI
dimethyl sulphoxide ml suspended weight pretreatment given rats MI
sulphoxide ml suspended weight pretreatment given rats MI
mangiferin pretreatment given rats MI
mangiferin administration rose ISPH induced rats MI
mangiferin exerts due MI
ISPH exerts due potential regulated system damage cardiac
ISPH exerts due potential regulated system damage
mangiferin exerts due potential regulated system damage cardiac
mangiferin exerts due potential regulated system damage
CCNU toxicity
lomustine toxicity
1 receiving dogs tumour toxicities haematological
1 receiving dogs tumour toxicities haematological renal
1 receiving dogs tumour toxicities haematological hepatic
1 receiving dogs tumour toxicities haematological and
1 receiving dogs tumour toxicities haematological gastrointestinal
1 receiving dogs tumour toxicities
2 toxicities haematological
2 toxicities haematological renal
2 toxicities haematological hepatic
2 toxicities haematological and
2 toxicities haematological gastrointestinal
2 toxicities
chloroethyl 2 toxicities haematological
chloroethyl 2 toxicities haematological renal
chloroethyl 2 toxicities haematological hepatic
chloroethyl 2 toxicities haematological and
chloroethyl 2 toxicities haematological gastrointestinal
chloroethyl 2 toxicities
3 describe incidence toxicities haematological
3 describe incidence toxicities haematological renal
3 describe incidence toxicities haematological hepatic
3 describe incidence toxicities haematological and
3 describe incidence toxicities haematological gastrointestinal
3 describe incidence toxicities
cyclohexyl nitrosourea 3 describe incidence toxicities haematological
cyclohexyl nitrosourea 3 describe incidence toxicities haematological renal
cyclohexyl nitrosourea 3 describe incidence toxicities haematological hepatic
cyclohexyl nitrosourea 3 describe incidence toxicities haematological and
cyclohexyl nitrosourea 3 describe incidence toxicities haematological gastrointestinal
cyclohexyl nitrosourea 3 describe incidence toxicities
1 nitrosourea 3 describe incidence toxicities haematological
1 nitrosourea 3 describe incidence toxicities haematological renal
1 nitrosourea 3 describe incidence toxicities haematological hepatic
1 nitrosourea 3 describe incidence toxicities haematological and
1 nitrosourea 3 describe incidence toxicities haematological gastrointestinal
1 nitrosourea 3 describe incidence toxicities
nitrosourea 3 describe incidence toxicities haematological
nitrosourea 3 describe incidence toxicities haematological renal
nitrosourea 3 describe incidence toxicities haematological hepatic
nitrosourea 3 describe incidence toxicities haematological and
nitrosourea 3 describe incidence toxicities haematological gastrointestinal
nitrosourea 3 describe incidence toxicities
CCNU nitrosourea 3 describe incidence toxicities haematological
CCNU nitrosourea 3 describe incidence toxicities haematological renal
CCNU nitrosourea 3 describe incidence toxicities haematological hepatic
CCNU nitrosourea 3 describe incidence toxicities haematological and
CCNU nitrosourea 3 describe incidence toxicities haematological gastrointestinal
CCNU nitrosourea 3 describe incidence toxicities
CCNU treated dogs met class toxicity
CCNU used treatment lymphoma
CCNU used treatment lymphoma lymphoma epitheliotropic
CCNU used treatment lymphoma lymphoma
CCNU used treatment lymphoma tumour mast
CCNU used treatment lymphoma tumour cell
CCNU used treatment lymphoma tumour
CCNU used treatment lymphoma tumour brain
CCNU used treatment lymphoma tumour
CCNU used treatment lymphoma tumours histiocytic
CCNU used treatment lymphoma tumours
alanine transaminase toxicity
CCNU CONCLUSIONS common toxicity
quipazine aggressiveness
quipazine aggressiveness induced deprivation REM
quipazine aggressiveness induced deprivation sleep
quipazine aggressiveness induced deprivation
quipazine aggressiveness induced deprivation REMD
apomorphine deprivation REM
apomorphine deprivation sleep
apomorphine deprivation
apomorphine deprivation REMD
apomorphine deprivation induced twitches head
apomorphine deprivation induced twitches
quipazine increased reduced increased induced aggressiveness
quipazine increased reduced increased hr REMD
quipazine increased reduced immediately completing REMD
quipazine hr REMD
apomorphine increased hr REMD
apomorphine increased reduced immediately completing REMD
apomorphine increased reduced increased quipazine hr REMD
apomorphine increased reduced twitches head
apomorphine increased reduced twitches
oestrogen Long increased increase risk cancer breast
oestrogen Long increased increase risk cancer
amine Effects pretreatment catatonia
catecholamines role idolamines catatonia
norepinephrine pretreatment did increased duration catatonia
adriamycin effects Cardiotoxic
anthracycline induced cardiomyopathy
anthracycline found resembled lesions myocardial
anthracycline found resembled lesions
adriamycin cardiotoxin consequence leukemia
daunorubicin sarcoma Kaposi
daunorubicin sarcoma Kaposi '
daunorubicin sarcoma s
daunorubicin sarcoma
daunorubicin efficacy assess treatment AIDS
daunorubicin efficacy assess treatment AIDS related sarcoma Kaposi
daunorubicin efficacy assess treatment AIDS related sarcoma Kaposi '
daunorubicin efficacy assess treatment AIDS related sarcoma s
daunorubicin efficacy assess treatment AIDS related sarcoma
daunorubicin agent treatment sarcoma Kaposi
daunorubicin agent treatment sarcoma Kaposi '
daunorubicin agent treatment sarcoma s
daunorubicin agent treatment sarcoma
Mesna adding precise frequency hematuria
Mesna adding infusate patients hematuria
cyclophosphamide associated cancer urothelial
cyclophosphamide associated cancer
Amisulpride symptoms schizophrenic
risperidone antipsychotics treated disorders Tic
risperidone antipsychotics treated disorders
ziprasidone risperidone antipsychotics treated disorders Tic
ziprasidone risperidone antipsychotics treated disorders
olanzapine risperidone antipsychotics treated disorders Tic
olanzapine risperidone antipsychotics treated disorders
quetiapine occurring show tic
quetiapine occurring like
quetiapine occurring symptoms
clozapine quetiapine occurring show tic
clozapine quetiapine occurring like
clozapine quetiapine occurring symptoms
amisulpride treatment months movements year schizophrenic
amisulpride treatment months movements year schizophrenic developed eye involuntary
amisulpride treatment months movements year schizophrenic developed eye
amisulpride treatment months movements blinking
amisulpride treatment months movements
quetiapine occur suggests tic
quetiapine occur symptoms like
quetiapine occur symptoms
clozapine quetiapine occur suggests tic
clozapine quetiapine occur symptoms like
clozapine quetiapine occur symptoms
acetic acid induced writhing
acid induced writhing
acetic acid paw model edema
acid paw model edema
